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Abstract
The EGFR/ErbB/HER family of kinases contains four homologous receptor tyrosine kinases that are
important regulatory elements in key signaling pathways. To elucidate the atomistic mechanisms of
dimerization-dependent activation in the ErbB family, we have performed molecular dynamics simulations
of the intracellular kinase domains of the four members of the ErbB family (those with known kinase
activity), namely EGFR, ErbB2 (HER2) and ErbB4 (HER4) as well as ErbB3 (HER3), an assumed
pseudokinase, in different molecular contexts: monomer vs. dimer, wildtype vs. mutant. Using
bioinformatics and fluctuation analyses of the molecular dynamics trajectories, we relate sequence
similarities to correspondence of specific bond-interaction networks and collective dynamical modes. We
find that in the active conformation of the ErbB kinases (except ErbB3), key subdomain motions are
coordinated through conserved hydrophilic interactions: activating bond-networks consisting of hydrogen
bonds and salt bridges. The inactive conformations also demonstrate conserved bonding patterns (albeit
less extensive) that sequester key residues and disrupt the activating bond network. Both conformational
states have distinct hydrophobic advantages through context-specific hydrophobic interactions. The
inactive ErbB3 kinase domain also shows coordinated motions similar to the active conformations, in line
with recent evidence that ErbB3 is a weakly active kinase, though the coordination seems to arise from
hydrophobic interactions rather than hydrophilic ones. We show that the functional (activating)
asymmetric kinase dimer interface forces a corresponding change in the hydrophobic and hydrophilic
interactions that characterize the inactivating interaction network, resulting in motion of the αC-helix
through allostery. Several of the clinically identified activating kinase mutations of EGFR act in a similar
fashion to disrupt the inactivating interaction network. Our molecular dynamics study reveals the
asymmetric dimer interface helps progress the ErbB family through the activation pathway using both
hydrophilic and hydrophobic interaction. There is a fundamental difference in the sequence of events in
EGFR activation compared with that described for the Src kinase Hck.
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Abstract
Unveiling the Molecular Mechanisms Regulating the Activation of the ErbB Family
Receptors at Atomic Resolution through Molecular Modeling and Simulations
Andrew Shih
Advisor: Ravi Radhakrishnan

The EGFR/ErbB/HER family of kinases contains four homologous receptor tyrosine
kinases that are important regulatory elements in key signaling pathways. To elucidate
the atomistic mechanisms of dimerization-dependent activation in the ErbB family, we
have performed molecular dynamics simulations of the intracellular kinase domains of
the four members of the ErbB family (those with known kinase activity), namely EGFR,
ErbB2 (HER2) and ErbB4 (HER4) as well as ErbB3 (HER3), an assumed pseudokinase,
in different molecular contexts: monomer vs. dimer, wildtype vs. mutant. Using
bioinformatics and fluctuation analyses of the molecular dynamics trajectories, we relate
sequence similarities to correspondence of specific bond-interaction networks and
collective dynamical modes. We find that in the active conformation of the ErbB kinases
(except ErbB3), key subdomain motions are coordinated through conserved hydrophilic
interactions: activating bond-networks consisting of hydrogen bonds and salt bridges.
The inactive conformations also demonstrate conserved bonding patterns (albeit less
extensive) that sequester key residues and disrupt the activating bond network. Both
conformational states have distinct hydrophobic advantages through context-specific
hydrophobic interactions. The inactive ErbB3 kinase domain also shows coordinated
iii

motions similar to the active conformations, in line with recent evidence that ErbB3 is a
weakly active kinase, though the coordination seems to arise from hydrophobic
interactions rather than hydrophilic ones.

We show that the functional (activating)

asymmetric kinase dimer interface forces a corresponding change in the hydrophobic and
hydrophilic interactions that characterize the inactivating interaction network, resulting in
motion of the αC-helix through allostery. Several of the clinically identified activating
kinase mutations of EGFR act in a similar fashion to disrupt the inactivating interaction
network. Our molecular dynamics study reveals the asymmetric dimer interface helps
progress the ErbB family through the activation pathway using both hydrophilic and
hydrophobic interaction. There is a fundamental difference in the sequence of events in
EGFR activation compared with that described for the Src kinase Hck.
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Chapter 1.) Regulation of ErbB Receptor Tyrosine Kinases

Lung Cancer is the number one cause of death (157,000 in 2010) in America and
accounts for almost as many deaths as the next three cancers (Breast/Prostate
(40,000/32,000 in 2010), Colon (51,000 in 2010) and Pancreas (36,000 in 2010)) in both
genders combined (American Cancer Society). About 85-90% of Lung Cancer cases are
Non-Small Cell Lung Cancers (NSCLCs), and present a poor prognosis in comparison to
breast/prostate and colon cancers. Recent advances in Cancer Therapeutics targeting the
EGFR/ErbB family of Receptor Tyrosine Kinases (RTKs) have shown promise in
providing an alternate therapy for NSCLC patients with efficacy at least equivalent to
chemotherapy in patients harboring mutant forms of EGFR. Here in this chapter we shall
focus our attention upon the ErbB family, and in particular the intracellular kinase
domain; however we will review overall RTK function and regulation as well.

1.1) RTK Structure and Signaling

The ErbB family kinases are a set of four homologous RTKs: EGFR/ErbB1/HER1,
ErbB2/HER2, ErbB3/HER3, ErbB4/HER4. RTKs are single pass transmembrane protein
important in intercellular communication, by translating extracellular signals (ligands)
into activation of specific cell signaling cascades (reviewed in [1, 2]). In humans, there
are currently 58 known RTKs divided into 20 families. RTKs are composed of an
extracellular ligand binding domain, a single transmembrane helix, a juxtamembrane
1

domain, a cytoplasmic kinase domain and a C-terminal tail containing multiple
phosphorylatable tyrosines. Activation of the extracellular domain by ligands triggers
receptor dimerization and trans-phosphorylation of both the cytoplasmic kinase domains
as well as the C-terminal tail. Dimerization and phosphorylation of the kinase domains
activates the kinase domain which then phosphorylates the tyrosines in the C-terminal
tail. The phosphorylated tyrosines serve as a docking site for downstream signaling
molecules containing Src homology domain 2 and/or phosphotyrosine-binding domains
and in turn relay the signal into the cell. The cell signaling pathways RTKs modulate
involve crucial cellular processes such as cell proliferation, differentiation, metabolism,
migration, and apoptosis.

The ErbB signaling network presents a “bow-tie” architecture, where multiple inputs and
outputs are linked through a set of core processes [3]. The ErbB kinases are capable of
binding a variety of ligands resulting in homo and heterodimerization, improving the
flexibility and robustness in the ErbB signaling network by increasing response to
extracellular signaling as well as allowing for cross-talk between ErbB kinase dimers,
compensating for any reduced signaling of an individual ErbB member in a given cell
type. For example, ErbB2 does not currently have a known ligand and ErbB3 is missing
key residues in the active site, greatly reducing its kinase efficacy: a pseudo kinase [4].
However, ErbB2/ErbB3 heterodimers are extremely relevant in the signaling picture as
overexpression is correlated with oncogenic transformation in breast cancers [5, 6].
Extracellular signaling is reduced to the four ErbB family kinases, which is then fed
2

through the core process: a conserved, relatively small collection of biochemical
interactions. The ErbB network then expands again through transcription factors and
positive as well as negative feedback mechanisms, eventually leading to the important
cell signaling pathways of proliferation, differentiation, etc.

1.2) Regulation of RTK signaling duration at the cell surface

Following the phosphorylation of the RTK kinase domains, there are pathways to
modulate the length of time the kinase is active on the cell surface, mainly receptormediated endocytosis and phosphatases. Upon ligand induced activation, RTKs are
internalized which removes the active RTK as well as the ligand from the cell surface
(reviewed in [7-9]). The predominant pathway for endocytosis for RTKs is clathrinmediated endocytosis, where the RTKs are rapidly endocytosed via clathrin-coated pits.
There are also clathrin independent endocytosis pathways for RTK internalization, but
they are not as well understood physiologically. One of the members of the ErbB family,
ErbB4, has an alternate method of internalization by means of proteolytic cleavage [10],
which constitutes a biochemical switch and is involved in proper cardiac and neural
development [11, 12].

Protein Tyrosine Phosphatases (PTPs) are the opposite half of the RTKs, removing the
phosphate group on phosphotyrosines. The balance of the interplay between the RTKs
and PTPs act as a major switch controlling the full activation of RTKs and thereby the
3

cell decision fates [13]. Before RTK activation, PTPs are in constant activity to reduce
any residual phosphorylation from cross-talk and accidental activation. Given significant
ligand, the RTKs inhibit local PTP activity and have enhanced signal propagation [14].
Paradoxically, ligand binding also causes recruitment of PTPs that bind to target RTKs,
dephosphorylates them, stabilizes the inactive form at the cell surface and inhibits further
signaling [15]. The bivalent reaction of PTPs to RTK ligand binding may be from
general non-specific PTP function versus RTK specific PTP function, however this is
beyond the scope of this thesis.

Adding to activation and regulation of RTKs is the role of recently discovered
cytoplasmic proteins cytohesins in EGFR [16] (and the proteins Dok7 in MuSK [17]).
The proteins modulate the activity of the proteins in both a positive and negative fashion
dependent on concentration.

Increased amounts of the proteins activate the RTKs

without any ligand binding events, while lacking the proteins prevents the activation of
the RTKs even with a ligand binding event. It is clear that cytohesins are important in the
scheme of ErbB in dimerization and activation though their specific role in the cell is
unclear: as an extra layer of control, where a level of local concentration is necessary for
activation or as an activator from the cytoplasmic side, where the cell can trigger the
RTK cascade without a ligand binding domain or as a signal propagator, where activation
of a single EGFR molecule causes recruitment of cytohesins to further increase the
activity or if any combination of the three are true.

4

1.3) Regulation, Structure and Auto-inhibition of RTKs

At the protein level, the extracellular domains are locked into an auto-inhibitory state
preventing dimerization and are released with a ligand binding event. The specifics of
how ligand binding facilitates dimerization for each RTK falls in the spectrum of “ligand
mediated” dimerization, where the ligands bridge the two receptors without the receptors
making direct contact, and “receptor mediated” dimerization, where the ligands make no
direct contribution to the dimer interface (all mechanisms are reviewed in [18]). The
ErbB family represents the extreme of “receptor mediated” dimerization [19, 20]. The
ErbB extracellular domain consists of four domains, with auto-inhibitory interaction
between domains II and IV in a tethered conformation (Figure 1.1A) [21-24]. Ligands
for the ErbB family are bivalent and bind to Domains I and III which cause a
conformational change breaking the tethered conformation and exposing a dimerization
arm in domain II allowing the dimerization arm to contact another ErbB RTK molecule.

Each RTK kinase domain is cis-autoinhibited in a characteristic fashion (reviewed in
[18]) with activation mechanisms being unveiled as each RTK is being studied more indepth. In RTK signaling, the intracellular kinase domain catalyzes transfer of the phosphate of ATP to tyrosines on both the RTK itself and in other target substrates
(reviewed in [1]). Regulation of the RTK kinase domain is thought to involve
contributions from several conserved subregions: the catalytic loop (C-loop), the
activation loop (A-loop), the glycine-rich nucleotide binding loop (P-loop), and the C5

helix, which together define the active site in the cleft between the  strand-rich N-lobe
and the helical C-lobe. The catalytic loop residues directly participate in phosphoryl
transfer. The A-loop and the C-helix (Figure 1.1B) modulate the activity of the kinase
domain by regulating accessibility of the active site to binding and coordinating both
ATP and the substrate tyrosine. The ~20 amino acid A-loop in ErbB kinases contains one
phosphorylatable tyrosine (Y845 in EGFR, Y877 in ErbB2, Y850 in ErbB4, note: there
are two numbering schemes for the ErbB family where Y845 is equivalent to Y869). The
C-helix and P-loop must be positioned correctly to coordinate the ATP and the substrate
tyrosine for effective phosphoryl transfer.

Figure 1.1: (A) Activation scheme for the ErbB family. The inactive kinase
(brown N-lobe) is auto-inhibited through the A-loop and αC-helix (Purple).
Introduction of the asymmetric dimer interface rotates the αC-helix to the
active state (orange N-lobe). (B) Enhanced view of the inactive and active
kinase domains (C) Hydrophobic core (cyan) in the inactive and active
conformations (D) C-spine (left yellow spine) and R-spine (right yellow
spine) in the inactive and active conformations.
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In the inactive state there is a small hydrophobic „core‟ formed between the αC-helix and
the A-loop, that helps maintain the kinase in the inactive conformation (Figure 1.1C).
Disruption of this hydrophobic core by single point mutations has been shown to activate
EGFR [25-29]. Recent structural studies have revealed highly conserved hydrophobic
“spines” within active kinases that are considered important in catalysis [30, 31], shown
in Figure 1.1D. The regulatory spine (R-spine) consists of four hydrophobic side chains
(M742, L753, H811, F832 in EGFR) anchored by an aspartic acid in the αF-helix (D872
in EGFR) and coordinates the motion of the N- and C-lobes of the kinase [30]. The
catalytic spine (C-spine) involves eight hydrophobic side-chains (V702, A719, L774,
V819, L820, V821, T879, L883 in EGFR) that help support and coordinate the adenine
ring of ATP in the active state during phosphotransfer [31].

Many of the kinase domains are inhibited through steric hindrances of a protein segment
blocking off the active site and greatly reducing the efficacy of the kinase. Dimerization
puts two kinase domains in close proximity to each other and although the kinase
efficiency is greatly reduced, it is theorized that each kinase still has enough activity to
phosphorylate its dimer partner. Phosphorylation of the protein segment prevents the
protein segment from binding into the active site and allows the kinase to fully function.
For the Ins [32] and FGFR [33] family of kinases, the A-loop serves as the inhibitory
segment, while the juxtamembrane domain serves the same autoinhibitory role as the Aloop in MuSK [34], Flt3 [35], KIT [36] and the Eph [37] family and in the Tie2 [38]
kinase, a segment of the C-terminal tail acts as the auto-inhibitor.
7

The ErbB family has a different method of inactivation as phosphorylation of the A-loop
or any other protein segment does activate the kinase; rather than a steric hindrance of the
active site, there are collective auto-inhibitory interactions preventing the proper
coordination between key loops in the kinase [39, 40]. Activation of the kinase domain is
also achieved through dimerization, though in this case, the dimer interface itself serves
as the activating mechanism. In the ErbB family, the dimer interface is asymmetric
similar to that of the cyclin dependent kinases and cyclin; the C-lobe one kinase, the
“activator”, contacts the N-lobe of the other kinase, the “receiver,” with the asymmetric
dimer contacts causing a conformational change towards the active state through
allosteric methods (Figure 1.1A) [41, 42]. The αC-helix in the inactive ErbB kinase is
rotated out preventing key bonds from forming.

Introduction of the activating

asymmetric dimer interface forces the αC-helix to sample a different conformational
space biasing towards the active state. Furthermore, the juxtamembrane domain in EGFR
serves as latch to facilitate the asymmetric dimer interface between kinase domains [4345].

1.4) Kinase Domain Mutations in Cancer and their Therapeutic Importance

Deregulation and mutation of RTKs have been correlated with cancer almost
immediately after their discovery and purification in the early 1980s.

The v-erbb

oncogene in the avian erythroblastosis virus, that was capable of inducing acute leukemia
8

encoded, was found to encode a constituently active form of the homologous ErbB kinase
protein [46]. With the increased study upon RTKs, the correlation between deregulation
of RTKs and a variety of ailments and particularly in cancer has only grown stronger.
Deregulation of RTKs in cancers can occur at several points: (1) increased ligand
production through enhanced local autocrine activation (2) specific gene translocations to
produce kinase fusions with altered signaling profiles (3) RTK overexpression at the cell
surface (4) mutation of the RTK protein to modulate activity (5) disregulation of
phosphatase and endocytosis mechanisms to increase RTK signal propagation.

Further exploration of pathway (4) above and specifically clinically identified activating
RTK mutations in the intracellular kinase domain have been discovered throughout many
cancers (Table 1.1 a&b). The results from Table 1.1 a&b are curated from Catalog of
Somatic Mutations In Cancer (COSMIC [47]), which has a much more thorough listing
for all the mutations and all cancers.

The oncogenic mutations cluster near the

characteristic aspects of kinase activation (Table 1.1 a&b). In Kit the predominant
clinically identified activating mutations are focused on the juxtamembrane domain and
the A-loop, both of which alter how the juxtamembrane domain serves as a steric
hindrance to the active site. In the FGFR family, the kinase mutations are around the Aloop which serves as its inactivating segment.

EGFR is cis-inhibited through

autoinhibitory bonds centered around the rotation of the αC-helix and is released by the
asymmetric dimer interface.

The activating mutations observed in cancers for

9

Lung
PL:[27, 28]
αC: [27-29, 48]
HC:[27-29, 48]
AD1: [48]
αC:[54]
αCβ4:[55-57]
----

Colon

Skin
αCβ4:[49]
AD1:[49,
50]

Breast

αCβ4:[54]
AL: [59]

---AL:[60]

αC:[51]
αCβ4:[54]
αC:[58]
AL: [59]

JM:[61]
CT:[62]

----

----

----

----

Kit/SCFR

JM:[66]

Flt3/Flk2
VEGFR2/
KDR

---CT:[61]

FGFR1

AL:[62]

----

FGFR2
FGFR3
FGFR4
Met
EphA18,10

------AL:[61]
JM:[61, 88-90]
AL:[61, 62]
CT:[61]
AL:[61]
CT:[61]

EGFR
ErbB2
ErbB4
PDGFRα
CSF1R/F
ms

LTK

Prostate

Leukemia

AL:[52]
αC:[53]
AD1:[53]
-------

-------

----

----

AL:[63]

----

----

CT:[64, 65]

----

---JM:[67-70]
αC:[68, 70]
AL:[68-70]

----

----

----

----

---TM:[80]
AL: [80]

----

JM:[71, 72]
AL:[71-74]
JM:[75-77]
AL:[78, 79]

----

----

----

----

----

---------αC:[91]

---JM:[81]
αC:[81]
AL:[81]
AL:[82-84]
-------

-------------

-------------

---AL:[85-87]
-------

----

----

----

----

----

----

----

----

----

----

----

Table 1.1a: Currently known clinically identified activating cytoplasmic
domain mutations in RTKs classified by kinase sub-domains in each of most
common tumor types. JM: juxtamembrane domain, PL:P-loop, αC: αC-helix,
αC-β4: αC-β4 loop, HC: Hydrophobic Core, AL: A-loop, AD1: Asymmetric
Dimer Interface in ErbB family, AD2: Asymmetric Dimer Interface in Ret,
CT: C-terminal Tail; See also Table 1.1b

EGFR are dominated by two mutations accounting for ~4500 of the 5000 or so total

mutations (Figure 1.2): a point mutation (L834R) within the hydrophobic core as well as
a small in frame deletion at least involving residues 747 to 751, at the tip of the αC-helix.
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Ovary

Kidney

EGFR
ErbB2
ErbB4

αCβ4:[96-98]
----

αC:[92, 93]
-------

PDGFRα
Kit/SCFR
FGFR2

---AL:[102, 103]
AL:[108]

Met

Ret

ALK

---------AL:[109]
αC:[110]

Thyroid
αC:[94]
AL:[94]
AD1:[95]
----------------

----

----

JM [111, 112]
AD2:[113-116]
JM:[116, 117]
AL:[118]

----

----

----

Gastro
Intestinal

Neuro
Blastoma

------αC:[59]

----------

AL:[99-101]
JM:[99-101]
JM:[104-107]
----

----------

----

----

----

----

---AL:[119-122]
αC: [120-122]
JM:[119, 120, 122]

Table 1.1b: Currently known clinically identified activating cytoplasmic
domain mutations in RTKs classified by kinase sub-domains in each of most
common tumor types. JM: juxtamembrane domain, PL:P-loop, αC: αC-helix,
αC-β4: αC-β4 loop, HC: Hydrophobic Core, AL: A-loop, AD1: Asymmetric
Dimer Interface in ErbB family, AD2: Asymmetric Dimer Interface in Ret,
CT: C-terminal Tail

Both of those mutations alter the motion/conformation of the αC-helix thereby causing
activation. The ErbB2 RTK is prevented from forming heterodimers through association
with Hsp90 through the uniquely hydrophobic αC-β4 region [123, 124], which is where
the majority of the activating mutations present (Figure 1.2). ErbB4 is not as well studied
as EGFR and ErbB2; however it has recently come under scrutiny as potential therapeutic
target. However there is debate is to whether constituent activation of ErbB4 functions as
an oncogenic promoter [60] or as protection from oncogenic transformation [125].
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Figure 1.2: Non-unique mutations cataloged in cancer samples for the ErbB
family in catalytically important sub-domains, curated from the COSMIC
database.
The increased kinase activity increases the dependency of tumor upon the RTK, which
becomes “oncogenically addicted [126]” and inhibition of the RTK is a viable route for
cancer therapeutics. EGFR and one of its small molecule tyrosine kinase inhibitors
(TKIs), Gefitinib, is a canonical example of RTKs, cancer and targeted therapeutics. The
initial discovery of Gefitinib in 1994 was met with much excitement as a potential cancer
therapeutic since it would be a low-dose targeted oral cancer therapeutic. In two phase II
clinical trials of Gefitinib for advanced NSCLC patients after progression of the cancer
with chemotherapy, patients overall showed symptom improvement rates around 40%
and a 1-year survival rates of 25-35% [127, 128]. The favorable results from the phase II
trials gained Gefitinib FDA approval in 2003 prior to phase III clinical trials. However,
the phase III clinical trials of Gefitinib versus placebo as a second-line therapy did not
show any statistical significance in survival in the overall population, but there was a
therapeutic benefit to the sub-group of Asian non-smokers [129]. Examination of the
tumors revealed sets of mutations in the EGFR tyrosine kinase domain [27-29]. The subset of the tumors harboring these EGFR mutations are exceptionally sensitive to
12

inhibition through Gefitinib, so much so that Gefitinib has equal to or greater efficacy
than standard chemotherapy treatments in EGFR mutation positive patients [130, 131].
There are several other RTK inhibitors already approved by the FDA and in use in the
clinical settings (Table 1.2).
Name
Bevacizumab
(Avastin)

Target

Company

VEGF

Cetuximab (Erbitux)
Panitumumab
(Vectibix)
Ranibizumab
(Lucentis)
Trastuzumab
(Herceptin)
Pegaptanib
(Macugen)
Dasatinib (Sprycel)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Imatinib (Gleevec)
Lapatinib (Tykerb)
Nilotinib (Tasigna)

EGFR

Genentech
Imclone/BristolMeyers Squib

EGFR

Amgen

VEGF

Genentech

Erb2

Genentech

Class
Monoclonal
antibody
Monoclonal
antibody
Monoclonal
antibody
Monoclonal
antibody
Monoclonal
antibody

VEGF
Src/Bcr-Abl
EGFR
EGFR
Bcr-Abl
EGFR/Erb2
Bcr-Abl
VEGFR1/2/3
PDGFR/c-kit
RAF/VEGFR2/PDGFRB
VEGFR2/PDGFRB
c-kit/FLT3

OSI/Pfizer
Bristol-Meyers Squib
Genentech/OSI
AstraZeneca
Novartis
GSK
Novartis

RNA Aptamer
TKI
TKI
TKI
TKI
TKI
TKI

GlaxoSmithKline
Onyx/Bayer

TKI
TKI

Pfizer

TKI

Pazopanib (Votrient)
Sorafenib (Nexavar)
Sunitinib (Sutent)

Table 1.2: FDA approved RTK inhibitors currently in use.
Given the importance of the ErbB family in cancers, it is important to understand their
activation mechanisms at the molecular level to help design higher specificity
therapeutics. This is especially important in recent light as after sustained use of TKIs
the cancers tend to adapt through resistance mutants, in EGFR the main mutation seen
after extended treatment with Gefitinib is the T766M mutation [132]. Computational
methodologies offer a powerful, quantitative, and complimentary alternative for the study
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of intracellular kinase domains which if utilized correctly can predict resistance
mutations [133, 134]. The scope of this thesis is to examine the molecular mechanisms
of activation for the ErbB family of receptors using computational modeling techniques,
particularly molecular dynamics simulation techniques. Chapter 2 reviews common
computational modeling techniques utilized for exploring atomic protein properties.
Chapter 3 examines the hydrophilic interaction networks in EGFR kinase domain
contrasting the inactive and active conformations as well as how the asymmetric dimer
interface and mutations affect these networks. Chapter 4 extends the interaction network
analysis to the other canonical ErbB kinases, ErbB2 and ErbB4 as well as adding in
analysis of hydrophobic interactions. In chapter 5, we examine the interaction networks
in the pseudokinase ErbB3. Chapter 6 examines future work especially in regards to
umbrella sampling techniques and present preliminary results from targeted molecular
dynamics simulations. Finally, chapter 7 places the atomic level analysis in a multi-scale
model and links them together with cellular signaling network effects.
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Chapter 2.) Computational Methods Related to Reaction Chemistry

2.1) Introduction

This chapter is altered from work presented in a book chapter on simulation techniques
for biomaterials [135]. The acceptance of multiscale simulation techniques has helped
bridge the gap between theory and experiment [136]. Electronic structure (quantum level
or ab initio) simulations can reveal how specific molecules assume stable geometrical
configurations and charge distributions when subject to specific chemical environment.
By examining the charge distributions and structure it is possible to quantify and predict
structural properties as well as chemical reactivity pertaining to the molecule, which are
particularly pertinent when investigating novel materials. Although the quantum
simulations provide a wealth of information regarding structure and reactivity, it is
currently not possible to model much more than a few hundred atoms at most. Molecular
dynamics (MD) simulations based on classical (empirical) force-fields can model
hundred thousands of atoms for nanoseconds and for some systems, up to a microsecond
in time. Since MD simulations can be set up at atomic resolution, they are uniquely
suited to examine thermodynamic and statistical properties of biomolecules and
biomaterials: such properties include (but not limited to) Young‟s modulus, surface
hydration energies, and protein adsorption to different surfaces [137]. Coarse-grained or
mesoscale simulations are used to bridge the gap between the atomistic scale of MD
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simulations and continuum approaches such as elasticity theory or hydrodynamics at the
macroscale (i.e. milliseconds, millimeters and beyond) [136].

2.2) Computational Methods

2.2.1) Molecular Dynamics

Molecular dynamics (MD) simulation techniques are one of the most commonly used to
model systems of biomolecules and biomaterials because they can track individual atoms
and therefore answer questions pertaining to specific material properties [138, 139]. To
perform MD simulations, the starting point is defining the initial coordinates and initial
velocities of the atoms characterizing the model system, for example, the desired
biomolecule plus the biologically relevant environment; i.e. water molecules or other
solvent and/or membranes. The coordinates of the desired biomolecule can usually be
found as structural data (X-ray or NMR) deposited into the protein data bank (PDB)
[140] (www.pdb.org); otherwise it is possible to derive initial geometry and coordinate
data from model building techniques, including homology methods (see section 2.2.2).
This step also typically includes the placement and positioning of the environment of the
molecules (solvation, ionic strength etc.). The initial velocities are typically derived from
the Maxwell-Boltzmann distributions at the desired temperature of the simulation. The
potential of interactions of each of the atoms are calculated using a force field, which
parameterizes the non-bonded and bonded interaction terms of each atom depending on
16

its constituent atom connectivity: bond terms, angle terms, dihedral terms, improper
dihedral terms, non-bonded Lennard-Jones terms, and electrostatic terms. The potential
interactions are summed across all the atoms contained in the system, to compute an
overall potential energy function for the system [141-145]:

Taking the derivative of the potential energy function yields the force, and from
Newton‟s second law, this is equal to mass times acceleration. Although, the process
seems simple, the derivative function results in a set of 3N-coupled 2nd order ordinary
differential equations that must be solved numerically.

The solution consists of a

numerical recipe to advance the positions and the velocities by one time step. This
process is repeated over and over again to generate MD trajectories of constant energy.
Constant temperature dynamics are derived by coupling the system to a thermostat using
well established formulations such as the Langevin dynamics or the Nose-Hoover
methodologies [146]. Application of MD simulations to biomolecules is facilitated by
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several popular choices of force fields such as CHARMM27 [147] (www.charmm.org),
AMBER [148] (www.ambermd.org), and GROMOS [149] (www.gromacs.org), as well
as dynamic simulations packages and visualization/analysis tools such as NAMD [150]
(www.ks.uiuc.edu/Research/namd/) and VMD [151] (www.ks.uiuc.edu/Research/vmd/).

With analysis of molecular dynamics trajectories, it is possible to calculate statistical
properties under a variety of initial and other external conditions [136] such as hydrogen
bond analyses for hydrophilic interactions and solvent accessible surface area for
hydrophobic interactions.

For example, by analyzing the relative positions of the

hydrogen bond donors to the hydrogen bond acceptors with a preset cutoff angle and a
bond length, the hydrogen bonds present in the majority of a given trajectory can be
identified to record permanent stabilizing interactions and differentiate them from
transient interactions [152]. Similarly, using the solvent accessible surface area analysis,
i.e. by mapping a surface area created using a probe sphere of 1.4 Å and accumulating the
statistical data, provides a quantitative metric of hydrophobic stabilization effects.

A popular statistical approach to analyze biomolecular dynamics is principal component
analysis (PCA) [153, 154], which provides us with a framework to project out
independent motions in an MD trajectory and sort them in the order of their dominance
(the strongest motions first). This is achieved by diagonalizing the variance-covariance
matrix of atomic fluctuations along the trajectory. PCA solves the eigenvalue equation:
[ - I] = 0 to project out principal components (PC) or independent modes of atomic
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motion, captured in an MD trajectory and sort them by their variance (in decreasing
order). Here  is a two dimensional variance-covariance matrix of atomic fluctuations
about the trajectory average, with elements σij=(xi−xi)(xj−xj) (i,j =1,…,3N, N being
the total number of atoms with position given by Cartesian coordinates x);.
=(1,2,…,3N) are the 3N independent (uncorrelated) eigenvectors (PC) with
eigenvalues =(I, 2,…,3N) sorted in descending order i.e. 1>2…,3N-7>3N-6. All
global translations/ rotations about the center of mass are removed prior to evaluating 
and the six eigenvalues corresponding to these degrees of freedom are close to zero. The
resulting eigenvectors represent the uncoupled principal components (PCs), (modes
orthogonal to each other) and the eigenvalues reflect their magnitude (strength) in the
trajectory. Generally, the top 10 principal components contain most of the atomic
fluctuations in the MD trajectory (>40-90%); moreover, pair wise correlations between
motions of atoms in an extended region of interest such as the active site of an enzyme
can provide valuable information in relating structure to function through dynamics (or
fluctuations) captured in the MD trajectory [153].

The utility of MD simulations generally depend on the accuracy of the underlying forcefield. Since force-fields are created using empirical energy functions, they are
parameterized and tuned to specific class of molecules; this introduces a constraint on
their transferability to model non-native systems or environments and results must often
be compared to experimental results, not only to verify their accuracy, but also to identify
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where methodological improvements can be made. Thus, there is continued development
of the basic force-field as well as the simulation methodology.

Another important consideration is the ability to perform sufficient sampling of the
combinatorially large number of conformations available to even the simplest of
biomolecules [155, 156]. In this respect, a potential disadvantage of molecular dynamics
calculations is that there is an inherent limitation upon the maximum time step used for
the simulation (≤ 2 fs). Solvated systems of protein monomers typically consist of 40000
atoms, and those of higher order complexes such as dimers or membrane-bound proteins
can be as large as 200,000 to 500,000 atoms. For such system sizes, with current
hardware and software, simulation times extending into the microsecond regime and
beyond is an exceedingly difficult and labor intensive endeavor which requires a
combination of algorithmic enhancements as well as the utilization of high-performance
computing hardware infrastructure. For example, cutoff distances reduce the number of
interactions to be computed without loss of accuracy for short-range interactions but not
for long-range (electrostatic) interactions; to help maintain accuracy, long-range
corrections such as the particle mesh Ewald algorithm [157] along with periodic
boundary conditions are typically implemented. Parallelization techniques enable the
execution of the simulations on supercomputing resources such as 4096 processors of a
networked Linux cluster.

Although a cluster of this size is a big investment, its

accessibility is feasible through the US National Science Foundations‟ TeraGrid Initiative
(founded in 2001) for academic researchers. TeraGrid resources (www.teragrid.org)
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currently include more than a petaflop of computing capability and more than 30
petabytes of online and archival data storage, with rapid access and retrieval over highperformance networks. Capitalizing on advances in hardware architecture, another
approach is the creation of custom hardware for MD simulations, and offers one-two
orders of magnitude enhancement in performance; examples include MDGRAPE-3 [158,
159] and ANTON [160, 161]. Recently, graphical processing unit (GPU) accelerated
computation has come into the forefront to enable massive speed enhancements for easily
parallelizable tasks with early data indicating that GPU accelerated computing may allow
for the power of a supercomputing cluster in a desktop, see examples [162, 163].

2.2.2) Homology Modeling

Protein structure prediction is a fast-growing research field with applications to
biotechnology [164-166]. Current experimental techniques for resolving protein structure
through X-ray crystallography or NMR spectroscopy are laborious and thus can solve
only a small fraction of proteins sequenced by large-scale genome sequencing endeavors.
At present, at least 6,800,000 protein sequences have been deposited in the nonredundant protein sequence database (NR; accessible through the National Center for
Biotechnology Information: ftp://ftp.ncbi.nlm.nih.gov/blast/db/), yet the Protein Data
Bank (PDB; http://www.rcsb.org/pdb/) contains fewer than 50,000 protein structures
[167]. Given this discrepancy, computational modeling of protein structure has proven to
be an invaluable tool for bridging the gap between protein sequence and structure. In
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particular, homology modeling, or prediction of an unknown structure by using a related
protein with a known structure as a template, has been one of the most successful
computational techniques for protein structure prediction [168-171]; see also several
computer

programs

and

web

servers:

(http://www.expasy.ch/swissmod/);

Swiss-Model

CPH

(http://www.cbs.dtu.dk/services/CPHmodels/);

server
models

MODELLER

[172]

(http://salilab.org/modeller/). Homology modeling typically consists of the following
steps: search for homologous protein structures, selection of an appropriate template,
target-template alignment, model construction, and model quality assessment.

The search for homologous or highly related protein structures to be used as the template
for model-building typically involves querying the Protein Data Bank (PDB) with the
target sequence: the target sequence is compared with the sequence of every structure in
the database, and potential templates are identified. In order to select the best template
for comparative modeling, several factors must be considered. First, the higher the
degree of sequence identity between the target and template, the better the quality of the
template. Secondly, the similarity between the environment (i.e., the type of solvent, pH,
presence of ligands) of the template and the environment of the target should be
considered [172]. In addition, the quality of the template structure, which has been
experimentally derived, must be taken into account.

For example, resolution of a

crystallographic structure is an indicator of the structure quality.

Once a template

structure has been selected, a target-template alignment must be performed, which can be
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done by using standard sequence alignment methods [173-175]. However, if the degree
of sequence identity between the target and template is below 40%, user intervention is
required to correct any gaps or misaligned residues generated in the alignment. More
accurate alignments can be generated by incorporating structural information from the
template, and some modeling programs, including MODELLER, utilize a combination of
sequence and structure information in the alignment algorithm.

Once a target-template alignment is created, several algorithms may be used to build a
3D model of the target protein [164, 166]. One commonly employed method is to use
distance geometry to satisfy spatial restraints determined from the target-template
alignment [176-178].

MODELLER, for instance, imposes spatial restraints that are

derived from two sources: homology-derived restraints on the bond distances and angles
in the target structure that are based on its alignment with the template structure, and
stereochemical restraints on bond distance and dihedral angle preferences that are
obtained from a representative set of all known protein structures. The model is then
constructed using molecular dynamics methods to minimize violations of the spatial
restraints.

A reliable homology modeling program should allow for modeling of insertions (i.e.,
loops) during model building. The ab initio loop modeling method involves exploring
multiple conformations for the specified loop region, and each are then scored by an
energy function to identify the most likely loop conformation [179]. Alternatively, a
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database approach may be employed, which involves identification of a main chain
segment that fits the two stem regions of a loop by searching a database of many known
protein structures. A limitation of the database approach is the availability of only a
small number of known protein structures [180], whereas the ab initio approach is more
widely applicable to loop regions bound to ligands or other molecules. Currently, loop
regions of up to 12 residues can be modeled accurately using these techniques, provided
that the loop environment is well-defined [172].

The final step in homology modeling is model quality assessment. Over the past couple
of decades, several techniques have been developed to assess the quality and correctness
of protein structural models. These methods analyze the stereochemical quality of the
model, including bonds, bond angles, dihedral angles, and non-bonded atom-atom
distances.

Several programs, including PROCHECK (www.ebi.ac.uk/thornton-

srv/software/PROCHECK [181]) and (WhatCheck swift.cmbi.ru.nl/gv/whatcheck [182]),
perform this type of analysis. When there is less than approximately 30% sequence
identity between the target and template, external assessment methods must be applied to
determine whether a correct template was used [183]. Thus, several different alignments
for the same template may be tested, in addition to alternative templates. The model can
be further analyzed by computing a residue-by-residue energy profile, where peaks in the
profile represent model errors. However, a potential pitfall of this method is that a
segment of residues may appear to be erroneous, when in fact it is only interacting with
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an erroneously modeled region. Therefore, the use of energy profiles should not be the
only means of model assessment.

Despite the predictive power and utility of homology modeling, several challenges
persist. First, the level of target-template structural conservation and the accuracy of the
alignment are key determinants of the quality of the resulting model. If the targettemplate sequence identity is less than 20%, approximately half of the residues in the
model may be misaligned [184]. This issue can be addressed by modeling based on more
than one template, to integrate the most relevant features from each template. Another
challenge is that homology modeling programs must evolve new techniques to keep pace
with the increasing number of known protein structures.

Pre-computing structural

relationships within the PDB may be helpful in addressing this issue, as many irrelevant
structures may be excluded without the need to align them explicitly [184].

An

additional challenge in comparative modeling is determination of side-chain
conformation. Many side-chain programs are based on rotamer libraries [185], which
contain values for side-chain torsional angles for preferred conformations of specific side
chains. However, as the number of rotamers increases, the issue of sampling all potential
conformations becomes a combinatorial problem. Xiang et al. [186] have recently shown
that the use of a rotamer library based on Cartesian coordinates of known structures,
rather than optimal bond lengths and angles, can successfully predict side-chain
conformation. Thus, local minima for side-chain prediction may be nearly as reliable as
the global minimum, and renders the combinatorial problem less of an issue. Despite
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these present challenges, homology modeling remains a powerful tool for reliable
prediction of protein structure. As the accuracy of the technique increases over the next
several years, comparative modeling will further close the gap between the number of
known sequences and the number of available structures, as well as deepen our
understanding of the relationship between protein structure and function.

2.2.3) Free Energy

The first law of thermodynamics states that natural systems seek a state of minimum free
energy at equilibrium. Thus computation of free energy of a system is important in
comparing the results of simulation and experiment. Several different methods have been
implemented for calculation of the free energy of various biological systems, and here we
will discuss two of the more commonly employed techniques, namely the free energy
perturbation (FEP) method [187] and umbrella sampling [188].

Free Energy Perturbation (FEP): In molecular systems, the free energy problem is
typically presented in terms of computing a free energy difference, ΔF, between two
defined thermodynamic states, for example, a ligand-bound versus unbound molecule.
The free energy difference between the two states is expressed as [189]:

;

,
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where the subscript zero indicates configurational averaging over the ensemble of
configurations representative of the initial state of the system, kB is the Boltzmann
constant, T is the temperature, and v(x) is the potential energy function that depends on
the Cartesian coordinates of the system, [x]. ΔF can also be computed by the reverse
integration:

,

where the subscript one indicates averaging over the ensemble of configurations
representative of the final state of the system. The most straightforward implementation
of the FEP method involves defining the potential energy function for each state and
performing a molecular dynamics simulation for the initial state of the system, hence
calculating the ensemble average. Both forward and backward integrations may be run to
obtain an estimate of the statistical uncertainty in ΔF. This uncertainty arises from
configurations sampled in the ensemble representative of the initial state but not the final
state and vice versa, and is typically small when the initial and final states of the system
are very similar (i.e., the free energy difference between the initial and final states is on
the order of 2kBT, or 1.5 kcal/mol) [190]. However, for systems in which the free energy
difference is significantly larger, a series of intermediate states must be defined and must
differ by no more than 2kBT. The total ΔF can then be computed by summing the ΔFs
between the intermediate states:
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,

where M indicates the number of intermediate states and λ is the coupling parameter, a
continuous parameter that marks the extent of the transition from the initial to the final
state. As λ is varied from 0 (initial state) to 1 (final state), the potential energy function
v(x; λ) passes from v0 to v1.

A limitation of this method is that the end points of the transformation, which correspond
to the creation or elimination of a group of atoms, are subject to VDW clashes that result
in end-point catastrophes [191, 192]. To obtain an accurate estimate of the free energy at
the diverging end points, the number of windows at the beginning and end of the FEP
simulations can be increased to collect data at several points with λ values close to zero
or one. Another challenge is particularly relevant to biological systems, as there are often
multiple ways that a ligand can bind to a receptor [189].

Indeed, some of these

possibilities will result in comparable free energy estimates. However, the current FEP
methodology must improve upon ways to distinguish among the alternative possibilities
and thoroughly sample the possible conformations at a binding site. Despite these
limitations, the FEP method is capable of providing an accurate theoretical estimate of
the free energy of numerous biomolecular systems [193-196].

Umbrella Sampling: This procedure enables the calculation of the potential of mean force
(free energy density) along an a priori chosen set of reaction coordinates or order
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parameters, from which free energy changes can be calculated by numerical integration
(see for example, [197]). For the free energy calculation, the probability distribution P(χi)
is calculated by dividing the range of order parameter χi into several windows. The
histograms for each window are collected by harvesting and binning trajectories in that
window, from which the potential of mean force Λ(χi) is calculated; the potential of mean
force Λi(χi) is given by [198, 199],

Λi( χi) = −kBT ln(P(χi)) + Constant; Then, exp(-F)= exp(-Λi( χi)) dχi

The functions Λi(χi) in different windows are pieced together by matching the constants
such that the Λi function is continuous at the boundaries of the windows. Thus, the
arbitrary constant associated with each window is adjusted to make the Λ function
continuous. The standard deviation in each window of the potential of mean force
calculations is estimated by dividing the set of trajectories in two blocks and collecting
separate histograms. The calculation of the multi-dimensional potential of mean force
(multiple reaction coordinates) using the weighted histogram analysis method (WHAM)
reviewed by Roux [200], which enables an easy and accurate recipe for unbiasing and
combining the results of umbrella sampling calculations, which simplifies considerably,
the task of recombining the various windows of sampling in complex systems and
computing F, see examples [199-203].

2.2.4) Electronic Structure Methods
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Molecular simulations using the empirical force-field approach are rooted in the validity
of classical mechanics. Electronic structure methods [204-206] that relieve this
fundamental assumption are often necessary in force-field development as well as in
understanding chemical reaction pathways and catalytic mechanisms. While electronic
structure methods are computationally rather demanding, recent advances in mixed
quantum mechanics molecular mechanics (QM/MM) methods enable us to combine high
level electronic structure methods with molecular mechanics [207-218]. This multiscale
description of force-fields provides a route to extend the electronic structure methods to
the nanometer scale to enable the study of biomolecular systems. Compared to their
classical counter-parts [142, 219-243], the quantum approaches (such as the empirical
valence bond [207, 208]) and mixed QM/MM approaches are more challenging to apply
in the biochemical context, though several successful demonstrations are available [193,
215, 244-247]. Here, we describe the utility of electronic structure methods in the study
of catalytic reaction mechanisms.

Quantum Mechanics Molecular Mechanics (QM/MM) Simulations: In the QM/MM
simulations, the system is sub-divided into two sub-regions, the quantum mechanical subregion (QM region) where the reactive events take place, and the molecular mechanical
sub-region (which provides the complete environment around the reactive chemistry)
[208, 210]. Since electronic structure methods are limited by the number of atoms they
can handle (typically 50-500), the QM sub-region is restricted to a small number of atoms
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of the total system. For example, in an enzymatic system, the quantum region can consist
of Mg2+ ions, water molecules within 3 Å of the Mg2+ ions, parts of the substrate
molecules and the catalytic amino acid residues (such as aspartic acids). The remaining
protein and solvent molecules are treated classically using the regular classical force-field
(such as CHARMM27).

In QM/MM simulations, wave function optimizations are typically performed in the
quantum (or QM) sub-region of the system using an electronic structure method such as
density functional theory (DFT) [205]. In this step, the electrostatic coupling between the
QM and the MM sub-regions is accounted for: i.e., the charges in the MM sub-region are
allowed to polarize the electronic wave functions in the QM sub-region. The forces in the
quantum sub-region are calculated using DFT on-the-fly assuming that the system moves
on the Born-Oppenheimer surface [210, 248]. That is, we assume a clear timescale of
separation between the electronic and nuclear degrees of freedom and the electronic
degrees of freedom are in their ground state around the instantaneous configurations of
the nuclei. The forces on the classical region are calculated using a classical force-field.
In addition, a mixed Hamiltonian (energy function) accounts for the interaction of the
classical and the quantum sub-regions. For example, since the QM/MM boundary often
cuts across covalent bonds one can use a link atom procedure [213] to satisfy the
valences of broken bonds in the QM sub-region. Also, bonded terms and electrostatic
terms between the atoms of the QM region and those of the classical region are typically
included [211].
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From a practitioner‟s stand-point, QM/MM methods are implemented based on existing
interfaces between the electronic structure and the molecular dynamics programs, one
implementation is between GAMESS-UK (www.cfs.dl.ac.uk [249]) (an ab-initio
electronic structure prediction package) and CHARMM [147]. The model system can
then be subjected to the usual energy minimization and constant temperature
equilibration runs at the desired temperature using the regular integration procedures in
operation for pure MM systems; it is customary to carry out QM/MM dynamics runs
(typically limited to 10-100 ps because of the computationally intensive electronic
structure calculations) using a standard 1 fs time step of integration. The main advantage
of the QM/MM simulations is that one can follow reactive events and dissect reaction
mechanisms in the active site, while considering the explicit coupling to the extended
region. In practice, sufficient experience and care is needed in the choices of the QM subregion and the many alternative choices of system sizes, as well as the link-atom schemes
need to be compared to ensure convergence and accuracy of results [211]. The shorter
length of the dynamics runs in the QM/MM simulations (ps) relative to the MM MD
simulations (ns) implies that sufficiently high resolution structures are usually necessary
for setting up such runs as the simulations only explore a limited conformational space
available to the system. Another challenge is an accurate and reliable representation of
the mixed QM/MM interaction terms [214]. These challenges are currently being
overcome by the suitable design of next generation methods for electronic structure and
molecular mechanics simulations [250, 251].
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2.2.5) Methods for Determining Reaction Paths

Brute-force molecular dynamics simulations of realistic models are restricted to the nanomicrosecond regimes. The development of long-time dynamics and sampling algorithms
is a well appreciated central objective of single molecule biophysics as the prediction of
biologically relevant properties, which occur in the timescale upwards of a microsecond,
has remained a problem. Sampling the complex configurational space of biomolecules is
a challenge, but can be partially overcome via smart sampling techniques [252-255],
umbrella sampling [194, 200], steered and targeted dynamics [229, 256], meta-dynamics
[257, 258], Tsallis statistics [259, 260], adaptive sampling [261], and density of states
Monte Carlo [262, 263]. Path-based methodologies seek to describe transition pathways
connecting two well defined states [224, 264, 265]; practical applications of this ideology
are available through methods such as stochastic path approach [266], nudged elastic
band [267-269], finite temperature string [261], and transition path sampling [270-272],
which each exploit the separation in timescales in activated processes, namely, the
existence of a shorter time scale of relaxation at the kinetic bottle neck or the transition
state (relax), in comparison to a much longer timescale of activation at the transition state
itself (TS). Below, we review the path-based method of transition path sampling and the
related method of Bolas sampling.

33

Transition path sampling (TPS) [270, 271] aims to capture rare events (excursions or
jumps between metastable basins in the free energy landscape) in molecular processes by
essentially performing Monte Carlo sampling of dynamics trajectories; the acceptance or
rejection criteria are determined by selected statistical objectives that characterize the
ensemble of trajectories. In transition path sampling, time reversible MD trajectories in
each transition state region are harvested using the shooting algorithm [272] to connect
two metastable states via a Monte Carlo protocol in trajectory space. Essentially, for a
given dynamics trajectory, the state of the system (i.e., basin A or B) is characterized by
defining a set of order parameters =[1,2,…]. Each trajectory is expressed as a time
series of length . To formally identify a basin, the population operator hA=1 if and only
if a particular molecular configuration associated with a time t of a trajectory belongs to
basin A; otherwise hA=0. The trajectory operator HB=1 if and only if the trajectory visits
basin B in duration , i.e., there is at least one time-slice for which hB=1; otherwise HB=0.
The idea in TPS is to generate many trajectories that connect A to B from one such
existing pathway. This is accomplished by a Metropolis algorithm that generates an
ensemble of trajectories [] according to a path action S[] given by:
S[]=(0)hA(0)HB[], where (0) is the probability of observing the configuration at
t=0 ((0)exp(-E(0)/kBT), in the canonical ensemble). Trajectories are harvested using
the shooting algorithm [272]: a new trajectory * is generated from an existing one  by
perturbing the momenta of atoms at a randomly chosen time t in a symmetric manner
[272], i.e., by conserving detailed balance. The perturbation scheme is symmetric, i.e.,
the probability of generating a new set of momenta from the old set is the same as the
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reverse probability. Moreover, the scheme conserves the equilibrium distribution of
momenta and the total linear momentum (and, if desired, the total angular momentum).
The acceptance probability implied by the above procedure is given by P acc=min(1,
S[*]/S[]). With sufficient sampling in trajectory space, the protocol converges to
yield physically-meaningful trajectories passing through the true transition state (saddle)
region.

Figure 2.1: Convergence analysis in TPS simulations. Left: order parameter
correlation functions transitioning between A2 and AB in a timescale of
mol. Right: decorrelation of transition paths
The convergence of each sampling run is monitored by calculating the autocorrelation
function of the order parameter. The characteristic relaxation time mol associated with the
crossing of each transition state region is given by the time taken for the gradual
transition of the autocorrelation function χi(0)χi(t), where · denotes the average over
the ensemble of generated trajectories. Order parameter autocorrelation functions
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transition from an initial value χi(0)χi(t) ≈ χA2 to a final value χi(0)χi(τ) ≈ χA*χB, to
indicate crossing of the barrier region between two metastable regions A and B over time
τ . The timescale of barrier relaxation τmol is inferred from these correlation functions
graphically. Shown in Figure 2.1 are these functions for four different sampling runs.
The top left panel captures a large subdomain motion while the bottom left panel captures
three residue flips during the closing conformational change [273]. The gradual change in
the order parameters indicates the decorrelation in each TPS run. In addition to the
autocorrelation functions associated with order parameters, an assessment of the quality
of our sampling by checking for the decorrelation of order parameters in path (Monte
Carlo) space is necessary. This is achieved by calculating the function i*(0)i*(n),
where n represents the harvested trajectory number, and i* is the value of the order
parameter evaluated at a particular time-slice at the bottleneck of the transition.

In calculating this correlation function, no shifting with respect to the first trajectory is
done. This removes the trivial decorrelation because of the shifting moves. Figure 2.1
shows such correlation functions; it is evident from Figure 2.1 that on an average, every
10th to 20th trajectory is statistically decorrelated; therefore the 200 to 300 trajectories
that are generated for each TS ensure sufficiently good sampling, see examples [273,
274].

Bolas Sampling for Calculating Free Energies: BOLAS is motivated by the method of
transition path sampling. BOLAS generates an ensemble of molecular dynamics
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trajectories using a Monte Carlo protocol with an appropriate action S based on shooting
perturbations. Below, we define the BOLAS action S and show that using BOLAS, the
free energy as a function of a reaction coordinate or order parameter chosen a priori can
be computed. The BOLAS path action (different from the TPS path action) is:
S[]=(0). The need to use a modified path action for BOLAS stems from our
requirement to compute the unbiased probability distribution of a given order parameter
at equilibrium. In principle, configurations contained within the trajectories harvested by
TPS are also obtained from the shooting algorithm. However, the bias imposed at the
boundaries due to the hA(0) and HB[] in the TPS action prevents the correct estimation
of the equilibrium probability distribution P(). This is because the contribution to P()
comes from six classes of trajectories: trajectories that start in A and visit B in time
interval ; trajectories that start in B and visit A; trajectories that neither originate in A
nor B, but visit both the states in the time interval ; trajectories that visit A and not B;
trajectories that visit B and not A; and trajectories that neither visit A nor B. The TPS
action includes only the first class of trajectories; an action defined by
S[]=(0)HA[]HB[] includes the first three classes of trajectories; the BOLAS action
includes all six classes of trajectories.

Since detailed balance is preserved for the momentum perturbation move of the shooting
algorithm, and the individual molecular dynamics trajectories conserve a stationary
(equilibrium) distribution , the configurations contained within the ensemble of the
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generated trajectories are also distributed according to the equilibrium distribution , (see
derivation in [201]). Thus, from the ensemble of trajectories generated using the BOLAS
action, the equilibrium probability distribution of the order parameter can be calculated
by binning the data from accepted trajectories into histograms of the order parameters. In
our implementation, the desired range of  is divided up in terms of smaller windows and
the BOLAS protocol is used to independently sample the configurations in each of these
windows. This is equivalent to performing an umbrella sampling. The functions in
different windows are then pieced together by using the WHAM algorithm [200]. The
validity and application of BOLAS have been illustrated in several applications of protein
nucleic acid interactions [201, 273, 275].

2.2.6) Effect of Force on Biomolecules

In the single molecule experiments, a force applied can linearly couple to a reaction
coordinate and alter the free energy landscape. If A and B denote the ground and
transition states for a given transition (associated with catalysis or a ligand-binding
event), then according to transition state theory the equilibrium constant for the system to
switch

from

state

A

K eq (0)  exp  G / k BT  ,

to

B

in

the

absence

of

any

external

force

is:

where G is the free energy difference between A and B

[276]. Within the linear response limit, the applied force will shift the ground state
equilibrium position XA(F) and the position of the transition state XB(F) [276]. Thus, the
change in the total (free) energy cost to transition from state A to state B, i.e. W=W(0)38

W(F), under an applied force F acting along X is W(F)=W(0)-0.5kx[XB(F)- XA(F)]2,
which will alter the equilibrium constant, see Figure 2.2 [276]:

K eq (F)  exp  [G  W (F)] / k BT  .

Such a linear response, which assumes a perfect alignment of the applied force and the
reaction coordinate, is assumed in the Bell model for receptor-ligand interactions, as well
as in models of two-state transitions used to interpret single-molecule experiments [276,
277]. However, the force will change X only if a coupling exists between X and the
applied force.

We can explore this coupling by carrying out principal component

analysis, PCA, see section 2.2.1 [154]. The coupling between the applied force and a
coordinate X occurs through the alignment of the force and the PCs and how the PCs
impact the coordinate X. While the former can be quantified by projecting the force
component along the eigenvectors, the latter can be quantified linearly combining the
PCs to describe the motion along X, as we illustrate below [278].
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Figure 2.2: Schematic of the effect of the force on the free energy landscape.

An external force applied to a molecule will displace atoms in a given active site. Let x
= (x1, y1, z1, x2, y2, z2,…,x3N, y3N, z3N) be the 3N dimensional displacement
vector which represents the displacement of the N atoms in the active site due to the
applied force F. We can express this displacement vector in terms of the 3N normalized
PC modes m which form a complete basis as: x = m am

m., with expansion

coefficients am . Under the quasiharmonic approximation and linear response, the
Hamiltonian (energy function) for the system is given by:

H

3N
1 3N
k m (a m m ) 2   F  (a m m ) .

2 m1
m 1
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That is, in the quasiharmonic approximation, for each eigenvector m the spring constant
corresponds to km=kBT/m [154]. At equilibrium we have H/am = 0 for each am which
gives:

am 

F   m | F | cos  m
.

km
km

Here F is a 3N dimensional vector representing the force on the active site fragment and

 m is a generalized angle between F and  m (PCs are normalized):

cos  m 

F  m
|F|

F



i 1.. N
j  x, y , z

i

j

 mij

 ( Fi j ) 2

.

i 1.. N
j  x, y, z

Where Fi j denotes the component of applied force acting on the ith atom of the active site
fragment in the direction j. In the experiments the force is applied by tethering polymer
chains (e.g. DNA) to the ends of the molecule, based on which we can define the applied
force to be:

Fi j  F0 (i)n j

 i  [xT]

Fi j  0

 i  [xT]
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Here F0(i) is the magnitude of force acting on the ith atom ( | F |

NT

 ( F (i))
i 1

0

2

) and [xT]

is a subset of NT atoms subject to the force. The components nj (j=x,y,z) belong to a unit
vector along the applied force direction. We generally assume that [xT] includes only the
heavy atoms and that the region subject to the force is small enough that the same force

F0 (i) | F | / N T acts on all the atoms. Calculations are performed by varying |F| to get
the resultant change in the active site geometry due to the applied force F:
R(F)  R(0)   am m , where, R = (x1,x2….x3N) is the vector representing the geometry
m

of the active site. Here, R(0) is the ground state active site geometry at zero force, for
which X=XA(0), and R(F) is the new active state geometry due to F for which X=XA(F).
The force along X which causes a displacement, XA(F)=XA(F)-XA(0) is:
Fx (F)  k x X A (F) . The spring constants kx can simply be obtained from the

distribution (histogram) of X values Px in MD trajectories by fitting a harmonic function
to the energy of the distribution E(X)=(1/2)kxX2=-kBTln(Px). Since the free energy
surface projected along the reaction coordinate has a maximum at the transition state, the
negative curvature is approximated as kts = -(ts)2, where  is the reduced mass of the
coordinate at the transition state and ts is the passage time in transition state theory,
ts=-kBT/ħ. Assuming that the same force acts on X throughout the system‟s passage
from ground to transition state (the dynamic coupling is unaltered), the displacement of
the transition state value of X, XB(F)=XB(F)-XB(0), is given as:
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X B (F) 

Fx (F)
k
  x X A (F) .
kts
kts

Note that the displacements XA(F) and XB(F) have opposite signs due to
positive/negative curvatures of the free energy for ground/transition states. We employ
the full set of 3N-6 PC modes to calculate the displacements XA(F) and XB(F) and
obtain the ratio Keq(F)/Keq(0)=exp(W(F)/kBT) [278].

2.2.7) Limitations and Caveats

From a structural standpoint, one possible limitation in modeling stems from unresolved
regions in the high-resolution crystal structures. This problem can somewhat be
addressed through homology modeling. Molecular dynamics simulations suffer from
inherent modeling limitations (force-field uncertainties, solvent approximations, limited
sampling, finite size effects, etc.). Some of these issues (e.g., finite size effects) are
difficult to overcome because of constraints posed by computational resources, while
others can be addressed to some degree. It is prudent to test the effect of force-fields on
active site geometry by comparing, for example, different force-fields such as CHARMM
and AMBER. While solvent effects are taken into account by explicitly treating water
molecules, there is in general the problem of determining the protonation states. This can
be dealt with at the mean field level by using Debye-Huckel calculations for titratable
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side chain residues and by Poisson-Boltzmann (MMPBSA) [279] evaluation of the
relative free energies for residues participating in the catalytic reaction. QM/MM
calculations can be used to further assess the relative stabilities of the different
protonation states. The QM/MM methodologies make some approximations as well.
Perhaps the most significant is the choice of the QM/MM boundary. Since the boundary
between the MM and QM regions cuts through covalent bonds, single link atom
procedure satisfies valences of broken bonds. In particular, the electrostatic terms
involving the MM host atoms that connect to the QM region need to be excluded from
the Hamiltonian. The test cases [211] have shown that the double link atom method
yields better numerical accuracy to the other popular approaches using local selfconsistent field (LCSF) formalism and single link atom approach [213]. The study also
notes that single link with partially visible MM atoms yields comparable results with the
double-link procedure. Other benchmark recipes for link atoms such as the pseudobond
method [214] are also available. In order to handle complex chemistry, there is generally
a need employ a high-level electronic structure method such as density functional theory,
with a reliable energy functional and a high-level set of basis functions often allowing for
polarization.

The issue of limited time scales explored in molecular dynamics simulations can be
overcome to an extent by smart-sampling algorithms as discussed in section 2.2.5. Of
course, these long-time algorithms have shortcomings of their own: these include issues
of multiple pathways and choice of order parameters. In general, there is a need to devise
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several assessment tools to monitor the quality of sampling and to control the statistical
error. The limitations of PCA in extracting dominant modes of protein dynamics arise
due to the finite simulation time of the molecular dynamics trajectory [280, 281]. While
principal component analysis is not reliable for describing the slow modes of the system
beyond what is captured in the dynamics trajectory it is based on, it does provide an
approximate description of the slow modes faster than the time scale of the trajectory (t).
The error in the eigenvalue propagates as (ti)-1/2, where i is the frequency of the ith
mode. Despite the methodological approximations and limitations, we vouch for the
notion that the predictions from such simulations can be made to have sufficient accuracy
to make meaningful contact with experimental literature.

2.3) Future Directions

As computational modeling techniques are improving, their applications to increasingly
complex biological systems are being explored. Therefore, a renewed focus on direct
connection with experiments to enable proper validation is critical. One strategic
approach is to compare the results of the models and experiments as well as require
consistency at multiple length and time scales, which can be realized by comparing to a
hierarchy of experiments. For example, structural features can be investigated by means
of a combination of experimental approaches such as FTIR, NMR, EPR spectroscopy,
AFM, SEM, TEM microscopy, X-ray diffraction etc. One can simultaneously employ
thermal (DSC and TG), mechanical (hardness and elastic modulus), and biological
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properties for validation and require the modeling to predict a range of properties. In the
future, the utility of well validated models and simulation is in directing the rational
design and modifications of novel materials. This includes creation of well controlled
surfaces that mimic multiple recognition sites for compatibility with the extracellular
matrix, quantifying the effect of chemical heterogeneity (OH- and PO43- groups
distributed randomly as dangling bonds or the presence of divalent metal ions) in
inducing conformational shifts in biomolecules (such as fibronectin), and the effect of
applied force mediated through protein-ligand interactions in orchestrating and triggering
signaling events in the constituent cells.
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Chapter 3.) Molecular Systems Biology of ErbB1 Signaling: Bridging the Gap
through Multiscale Modeling and High-Performance Computing.

3.1) Introduction

This chapter has been altered from work published in Molecular Biosystems [282]. ErbB
family receptors (named because of their homology to the erythroblastoma viral gene
product, v-erbB and consisting of the epidermal growth factor receptor or
EGFR/ErbB1/HER1, ErbB2/HER2, ErbB3, and ErbB4) signal by activating crucial
pathways [283] in response to activation by ligands such as the epidermal growth factor
(EGF) and other related peptide growth factors. Through ligand-stimulated formation of
various homodimeric and heterodimeric complexes the ErbB receptors are activated
leading to the phosphorylation of multiple tyrosine residues on the C-terminal tail of the
receptors as well as on other substrate proteins. Through specific interactions of the
phospho-tyrosine sites to binding domains, the receptors bind to cytosolic partners that
are responsible for the recruitment and activation of multiple down-stream cascades [3,
284-288]. The activation through the mitogen-activated protein kinase (MAPK) cascades
of the extracellular signal-regulated kinases (ERKs) is functionally linked to
proliferation. The phosphoinositide 3-kinase (PI3K) pathway leads to the activation of the
serine/threonine protein kinase Akt (cellular homologue of the viral oncogene v-Akt)
which is linked to survival. Other significant pathways mediated by ErbB signaling
include activation and nuclear translocation of signal transducers and activators of
47

transcription proteins (STATs) [289] and clathrin mediated endocytosis [290]. Yet, the
molecular context in which ErbB receptors activate and regulate signaling has not been
fully recognized. More specifically, it is of great interest to investigate the molecular
mechanisms that lead to the dis-regulation of ErbB signaling in several pathologies such
as cancer, psoriasis, atherosclerosis, impaired cardiac development, and schizophrenia
[291, 292]. With rapid progress in high-performance computing methods and
infrastructure 1 we advocate that multiscale modeling offers a powerful, quantitative, and
complimentary alternative for the study of functional intracellular modules. We describe
the application of a hierarchical multiscale modeling procedure (summarized in section
3.2: Models and Methods) to signaling in the ErbB family receptors to describe how
point-mutations in the ErbB receptors can profoundly alter signaling characteristics
leading to the onset of oncogenic transformations. Here in this chapter, we only discuss
the atomic level fluctuations governing activation of the EGFR kinase domain, and how
molecular perturbations (mutations and dimerization) affect them.

For how this

molecular model fits into a cellular model see Figure 3.1b&c and section 7.2.

3.2) Models and Methods

1

Our applications multiscale algorithms to ErbB signaling are enabled by high-performance
computing infrastructure. As we transition from tera-flops (flops: floating point operations per
second) computing to peta (1015) flops computing in the near future, we expect that extension of
our molecular and systems modeling to complete cellular pathways will become tractable.
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Figure 3.1: Hierarchical multiscale modeling scheme for ErbB signaling. The
dimer-mediated receptor activation characteristics of ErbB1 receptor tyrosine
kinase is studied using molecular dynamics simulations. The interactions of
substrate tyrosine containing peptides derived from the C-terminal tail with
the ErbB1 kinase are studied using molecular docking simulations. We have
employed a deterministic network-based kinetic modeling scheme to study
ErbB1-mediated signaling, and a hybrid discrete/continuum stochastic
dynamics protocol to study the initiation of ErbB1 receptor internalization.
(a) Atomistic model for ErbB1 dimer employed in the molecular dynamics
and molecular docking calculations. (b) Branched network model for ErbB1mediated signaling in which phosphorylation of the ErbB1 dimer occurs at
either tyrosine Y1068, which can bind GAB-1 or Grb2, or at tyrosine Y1173,
which binds Shc. Phosphorylation of the factors Akt and ERK were used as
indicators of downstream activation. (c) Hybrid stochastic model for ErbB1
internalization. (top) Grids in finite difference scheme for membrane
dynamics and the lattice in the kinetic Monte Carlo scheme for protein
diffusion; (bottom) snapshot of vesicle bud on the membrane in response to a
specific spatial ordering of the curvature-inducing protein, epsin, on the
membrane; inset depicts a stabilized vesicle neck. (d) Flow of information
between different simulation methods.

We provide a brief summary of the hierarchical multiscale modeling scheme we have
employed for describing ErbB signaling (see Figure 3.1: a-d). We model the dimermediated receptor activation characteristics of the ErbB1 receptor tyrosine kinase using
molecular dynamics simulations [293, 294]. Figure 3.1(a) depicts the atomistic model of
the explicitly solvated ErbB1 kinase dimer employed in the molecular dynamics: 10-20
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ns trajectories of fully atomistic, explicitly solvated systems of wildtype and mutant
ErbB1 kinase monomers and dimers are obtained and analyzed for specific stabilizing
interactions such as hydrogen bonds and salt-bridges, see also Figure 3.2 [293, 294]. For
how the cellular model interfaces with the cellular model see section 7.2.

3.3) Rationalizing and Predicting the Effects of Molecular Perturbations on
Receptor Kinase Activation

Small molecule tyrosine kinase inhibitors for ErbB1/2 tyrosine kinase such as gefitinib,
erlotinib, and lapatinib, which are ATP analogues, are of significant interest as cancer
drugs. While the receptor tyrosine kinase inhibition approach has shown promise in some
clinical trials, success has been mixed. In particular, the occurrence of somatic mutations
in the ErbB1 kinase domain (L834R: where the leucine residue in position 834 is
replaced by an arginine, L837Q: leucine at 837 replaced by a glutamine, G685S, del
L723-P729 ins S: deletion of residues 723-729 and an insertion of a serine) as seen in
patients of non-small cell lung cancer2 [295] renders the cell lines harboring such
mutations more sensitive to treatment [295, 296].

2

There are 2 main types of lung cancer and they are treated differently: small cell lung cancer and
non-small cell lung cancer. About 85% to 90% of all lung cancers are of the non-small cell type
with three sub-types. The cells in these sub-types differ in size, shape, and chemical make-up: (1)
squamous cell carcinoma linked to smoking, (2) adenocarcinoma usually found in the outer part
of the lung, and (3) large-cell (undifferentiated) carcinoma exhibiting rapid growth and spreading.
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Figure 3.2: (a, b) Stabilizing network residues in ErbB1 kinase in its active
and inactive conformations. The numbers in (a, b) correspond to the entries in
(c). Compared to inactive, the active state presents a significantly increased
number of stabilizing residues, with approximately the same number of
residues affected by the asymmetric dimerization (marked D and boxed red)
and mutation (marked M and boxed green), so the inactive system is much
more susceptible to a conformational shift triggered by the asymmetric dimer
or mutation. We identify the residues participating in stabilizing bonds that
are also proximal (≤3 Å between heavy atoms) to the dimer interface. Crossreferencing this list with the stabilizing residues provides a list of potential
residues possibly affected by dimerization: entries marked D in (c) and boxed
red in (a,b). (d): Symbols represent trace during dimer molecular dynamics
simulations of wildtype and the two mutants L834R and Del L723-P729 ins S
or del: (top) Root-mean-squared deviation or RMSD of C-helix, and
(bottom) RMSD of the activation loop (or A-loop). Insets depict the relative
positions of the C-helix and the A-loop at the end of the dynamics runs.

In order to determine how such molecular perturbations can shape cellular fates, we
sought to determine how the mutations affect the regulatory mechanisms operational
within the kinase domain of ErbB1, ErBb2, and ErbB4. A recent structural and
biochemical study involving the ErbB1 by Zhang et al. [40] proposed a new dimermediated allosteric activation mechanism of kinase activation according to which ErbB1
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receptor tyrosine kinase dimerizes in an asymmetric head-to-tail configuration. While the
monomer ErbB1 kinase is stable in an inactive conformation which interferes with ATP
binding, in the asymmetric dimer configuration, one ErbB1 kinase domain serves as an
activating protein and activates the other ErbB1 kinase in the dimer, through allosteric
contacts. The kinase-kinase contact at the asymmetric dimer interface allosterically
stabilizes the active conformation. Recently, we hypothesized that an underlying network
of stabilizing hydrogen bonds dominates the relative stabilities of the inactive and active
conformations and governs the kinase activation. We then performed a hydrogen bond
analysis of the molecular dynamics data, focusing on the interactions surrounding the
activation-loop and the C-helix sub-domains in the active and inactive conformations,
and identified this network, see Figure 3.2(a,b). The total number of interactions in the
active state out-numbers those in the inactive state by 27 to 13, which led us to
hypothesize that a particular stimulus such as the asymmetric dimerization preferentially
destabilizes the inactive kinase conformation triggering the conformational change to the
active state.

In order to consider the effect of ErbB1 kinase dimerization on the network of stabilizing
interactions, we identified the protein residues participating in stabilizing bonds that are
also proximal (≤3 Å between heavy atoms) to the residues involved in the formation of
the asymmetric dimer interface, (which are P675, L679, L680, I682, V736, L758, V762
in the kinase undergoing activation). The rationale for the proximity analysis is that the
interactions in the stabilizing network could be compromised due to the molecular level
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reorganization upon kinase dimerization. The proximity analysis suggests that 3 out 13
stabilizing residues in the inactive state may be perturbed or lost upon dimerization (these
are marked with D in Figure 3.2(c)), which suggests a potential molecular relay
mechanism by which the kinase dimerization event activates the kinase domain. Indeed,
when we performed 20 ns molecular dynamics simulations of an ErbB1 kinase dimer
system (shown in Figure 3.1(a)), we observed a significant rearrangement (change in the
root-mean-squared deviation or RMSD of 3 Å) of the αC-helix position: see Figure
3.2(d). The shift in the C-helix position was accompanied by several changes in the
stabilizing network consistent with the predicted bond-patterns in Figures 3.2(a-c). In
particular, in the inactive conformation, the bonds between Y740-S744, L834-D813,
H846-R865, K851-R812 surrounding the activation loop and the αC-helix were severed.
Thus, already in the wildtype dimer, due to the re-configuration of the C-helix, the bond
pattern is found to be shifting significantly toward that observed in the active kinase. The
key bonds stabilizing the wildtype inactive ErbB1 kinase are the E738-K836 and E848R865 salt bridge interactions, as well as the L834-D813 hydrogen bond. In our dimer
simulations, the E738-K836 salt bridge has considerable weakened: the fraction of the
time this bond was present decreased from >90% in the monomer trajectory to ~60% in
the dimer trajectory; moreover this bond has undergone considerable stretching allowing
E738 to hydrogen bond to F832, which is one of the bonds seen in the active kinase. The
L834-D813 interaction is at the threshold of still being considered a stabilizing hydrogen
bond. The residue K851 is hydrogen bonded to E725, moving away from the inactive
bond K851-R812 and towards the active salt bridge K851-E734. The E848-R865 salt
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bridge is not perturbed significantly due to the formation of the asymmetric dimer
interface. Thus, we hypothesize that a few specific bonds act as gatekeepers for each step
of the conformational change, namely the E738-K836 salt guards against the C-helix
movement and the E848-R865 salt bridge guards against the activation loop
rearrangement. Our dimer simulations re-affirm our notion that the stabilizing network is
susceptible to perturbation in the inactive conformation of the kinase, and that formation
of the asymmetric dimer will have the effect of directly breaking the network of
interactions around the C-helix, thereby destabilizing the inactive state. The loss of
these interactions and the shift of the αC-helix conformation towards the active state will
provide the impetus for kinase domain activation. Intriguingly, several of the clinically
identified mutations that have been reported to constitutively activate the kinase also
directly perturb the stabilizing network by breaking key stabilizing bonds: these are
marked by the symbol M in Figure 3.2(c). In addition, the del L723-P729 ins S mutant reconfigures the C-helix in the inactive state to a conformation closer to the active state
(see Figure 3.2(d)). Thus, our delineation of the stabilizing hydrogen bond network
provides molecular-level insight into the possible mechanisms by which activating
mutations of ErbB1 kinase such as L834R and del L723-P729 ins S destabilize the
inactive conformation. This preferential destabilization of the inactive conformation
renders the receptor kinase constitutively active even as a monomer, producing high basal
activation levels of the kinase even in the absence of a growth-factor induced
dimerization.
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Considering that there is an excellent correlation between the stabilizing network of
interactions and the clinically identified activating mutations in ErbB1, our structural
studies on kinase activation are well poised to forecast the mutation landscape associated
with other ErbB members. We have extended the analysis we have presented for ErbB1
to ErbB2 and ErbB4 kinases in which we have identified similar networks of stabilizing
interactions. Based on the similarities between the stabilizing interactions between ErbB1
and ErbB4 kinase domains, we can predict the effect of analogous mutations in ErbB4 on
kinase activation: (1) based on the location of the mutations E690G, G700S, the mutants
are expected to be activating through directly impacting dimerization (similar to the
activating mutants E685G and G695S of ErbB1). (2) Del 728-G733 ins S and S749I are
poised to cause a conformation shift of the αC-helix of ErbB4 and hence are predicted to
be activating. (3) Mutations F740A, L839R and L842Q in ErbB4 are poised to perturb
the bond network of the inactive kinase and hence expected to be activating. We note that
in support of our predictions of ErbB4, the F740A and L839R have been tested
independently by Qiu et al. [297] and indeed found to be activating. Based on the subtle
differences we have noted in the stabilizing bond networks of ErbB1 and ErbB4, we are
also able to suggest new activating ErbB4 mutations (that do not have an obvious
counter-part in the ErbB1 system). In particular, R841 in ErbB4 is featured prominently
in the stabilizing network and mutating R841 to either alanine or aspartic acid is expected
to promote activation. Mutation of the two residues blocking the catalytic aspartate, E743
and G838, to residues with smaller side chains, alanine or glycine, is also expected to
promote activation.
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At the molecular level, considering that there is an excellent correlation between the
stabilizing network of interactions and the clinically identified activating mutations in
ErbB1, our structural studies on kinase activation are well poised to forecast the mutation
landscape associated with other ErbB members. Indeed based on our simulations of
ErbB2 and ErbB4, we have identified similar networks of stabilizing residues and are
already able to predict activating mutations in these receptors that have not yet been
reported clinically [unpublished results] which together with the extensions proposed
above can be valuable for evaluating the likely effect mutations on ErbB2 inhibition
efficacies in cancer, ErbB4 inhibition in cardiac development and schizophrenia [292].
How the constituent activity of the mutant ErbB kinases affects cell signaling, both as
phosphorylation of its C-terminal tail as well as the cell signaling pathways is crucial for
understanding how ErbB kinases can alter cell fates; the intersection of the atomic level
simulation with cell signaling models is considered in section 7.2
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Chapter 4.) Molecular Dynamics Analysis of Conserved Hydrophobic and
Hydrophilic Bond Interaction Networks in ErbB Family Kinases.

4.1) Introduction

This chapter is from work that has been submitted and is under review at Biochemical
Journal [298].

Receptor tyrosine kinases (RTKs) are transmembrane glycoproteins

important in intercellular communication and oncogenesis [299]; they comprise a large
ligand-binding extracellular domain, a single transmembrane α-helix, an intracellular
tyrosine kinase domain and a C-terminal tail that harbors regulatory tyrosine
autophosphorylation sites (reviewed in [1, 2]). The ErbB family consists of four
homologous RTKs: the epidermal growth factor receptor (EGFR/ErbB1/HER1), ErbB2
(HER2/Neu), ErbB3 (HER3), and ErbB4 (HER4). Binding of growth factors to the
extracellular ligand-binding domains of ErbB receptors promotes their homo and/or
heterodimerization, which in turn leads to activation of the cytoplasmic kinase domain.
This triggers a multi-layered signaling network of crucial pathways regulating cell
proliferation, differentiation, migration, etc [3]. Aberrant signaling by EGFR and ErbB2
is correlated with a variety of diseases, from psoriasis to cancer [300]. In particular,
clinically identified mutations in EGFR have been shown to increase the basal activity of
the EGFR kinase domain, and non-small-cell lung cancer (NSCLC) patients carrying
these mutations respond remarkably to the EGFR RTK inhibitor gefitinib [26, 27, 48].
ErbB2 is the target of the therapeutic Herceptin antibody, and its amplification and
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overexpression in breast cancer correlates with a poor prognosis [301, 302]. The loss of
ErbB4 signaling in mice has been shown to result in defective heart, nervous system, and
mammary gland function [303-305].

Figure 4.1: (A) Alignment of the four catalytic subdomains comprising the
active site in the ErbB kinases, with accompanying alignment scores for the
subdomains alone and for the entire kinase. (B-F) Comparison of the inactive
and active conformations of the ErbB kinases highlighting the conserved
features. (B) The C-loop is highlighted in red with the active conformation
shown in blue with the inactive in green. (C,D) The hydrophobic core is
shown in orange, (E,F) while the C-spine is shown in yellow and the R-spine
is in purple. (G) The residues comprising the C-spine and R-spine for EGFR,
ErbB2 and ErbB4 kinase. The residues highlighted in green are hydrophobic,
the residues in red are hydrophilic and those in white are neutral. (H) The
residues comprising the Hydrophobic core and the αC-β4 region for EGFR,
ErbB2 and ErbB4 kinase. Serine is shown in pink as it is slightly hydrophilic,
though it is still considered neutral.

In RTK signaling, the intracellular kinase domain catalyzes transfer of the -phosphate of
ATP to tyrosines on both the RTK itself and in other target substrates (reviewed in [1]).
Regulation of the RTK kinase domain is thought to involve contributions from several
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conserved subregions: the catalytic loop (C-loop), the activation loop (A-loop), the
glycine-rich nucleotide binding loop (P-loop), and the C-helix, which together define
the active site in the cleft between the  strand-rich N-lobe and the helical C-lobe. The
catalytic loop residues directly participate in phosphoryl transfer. The A-loop, P-loop and
C-helix (marked in Figure 4.1A) modulate the activity of the kinase domain by
regulating accessibility of the active site to binding and coordinating both ATP and the
substrate tyrosine. The ~20 amino acid A-loop in ErbB kinases contains one
phosphorylatable tyrosine (Y845 in EGFR, Y877 in ErbB2, Y850 in ErbB4). In many
kinases, e.g. the insulin receptor kinase (IRK), phosphorylation of this A-loop tyrosine
triggers conformational changes that allow substrate access to the active site. Thus, Aloop conformational changes constitute a key event in RTK regulation (Figure 4.1B).
The C-helix and P-loop must also be re-positioned to coordinate the ATP and the
substrate tyrosine for effective phosphoryl transfer. The four regulatory subdomains are
highly conserved across the ErbB family, with 88% sequence identity between EGFR and
ErbB2 and 77% sequence identity between EGFR and ErbB4 (Figure 4.1A). ErbB3 is
unique in the ErbB family as it lacks specific conserved residues considered to be
required for full kinase activity.

Recent structural studies have revealed highly conserved hydrophobic “spines” within
kinases that are considered important for defining their catalytic state [30, 31], shown in
Figure 4.1E,F. The regulatory spine (R-spine) consists of four hydrophobic side chains
(M742, L753, H811, F832 in EGFR) anchored by an aspartic acid in the αF-helix (D872
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in EGFR). The R-spine spans several key regulatory subdomains, and coordinates the
motion of the N- and C-lobes of the kinase [30]. The catalytic spine (C-spine) involves
eight hydrophobic side-chains (V702, A719, L774, V819, L820, V821, T879, L883 in
EGFR) that help support and coordinate the adenine ring of ATP in the active state [31].
Similarly, in the inactive state there is a small hydrophobic „core‟ formed between the
αC-helix and the A-loop, which maintains the kinase in the inactive conformation (Figure
4.1C-F). Disruption of this hydrophobic core by single point mutations has been shown
to activate EGFR [25-29].

EGFR stands out among RTKs in appearing not to require A-loop phosphorylation for its
activity [306]. Mutation of the EGFR A-loop tyrosine Y845 to phenylalanine does not
appear to change the level of receptor auto-phosphorylation in cells or in vitro [40], in
contrast to other kinases such as IRK (although Y845 is phosphorylated by Src in EGFR
signaling [307]). Crystal structures have confirmed that the EGFR and ErbB4 kinase
domains can adopt active-like conformations even without Y845 (Y850 in ErbB4)
phosphorylation [25, 42], and have revealed an allosteric mechanism for kinase domain
activation [40]. Activation of the EGFR TKD involves the formation of an asymmetric
„head-to-tail‟ dimer in which one kinase domain (the „receiver‟) becomes activated
through allosteric changes arising from contacts between its N-lobe and the C-lobe of its
neighbor (the „activator‟). The C-lobe of the activator kinase appears to play a cyclin-like
function in activating its dimerization partner (the receiver). The importance of the
asymmetric dimer interface was confirmed by mutational studies in EGFR and ErbB4
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[40, 42]. More recent studies have shown that the intracellular juxtamembrane region of
the receptor also contributes to formation of the asymmetric dimer interface, in a manner
that is necessary for maximal activation [43-45].

Considering the high degree of sequence similarity and structural homology across the
ErbB family members (Figure 4.1A,G,H), we sought to identify the degree to which
molecular mechanisms of activation are conserved across the ErbB family, and to
identify differences in overall function that arise from variability in primary structure.
Recently, we and others have hypothesized the existence of distinct networks of
intramolecular non-covalent bonds

that characterize the active

and inactive

conformations of kinases (for Lyn [308, 309], Abl [310], EGFR [152, 310, 311] and
ErbB2 [312]), with transitions between the states necessitating a shift in these bond
networks.

Here, we present bioinformatics and fluctuation analyses of molecular

dynamics trajectories of ErbB kinase domains and relate sequence similarities to
correspondence of specific bond-interaction networks and resemblances in collective
dynamical modes.

We investigate how the various stimuli/perturbations such as

dimerization, phosphorylation of the A-loop tyrosine, and mutations seen in cancer
patients impact both the active and inactive conformations of the ErbB family kinase
domains. The solvated systems of the truncated ErbB family kinases we present even
have a physiological relevance to cell studies. The protein tyrosine kinases, Src and Abl,
have a highly similar active structure to those in receptor tyrosine kinases [1, 313].
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Furthermore, ErbB4 is cleaved from the membrane into the s80 protein, a fully active
soluble form of the ErbB4 kinase domain [305].

4.2) Methods

Molecular Dynamics (MD) Simulations: Models for ErbB1 (EGFR) kinase were derived
from the 1M14 (active) and 2GS7 (inactive) structures [25, 40]. Models for ErbB4 were
derived from the structures of Qiu et al., PDB ID: 3BCE and 3BBW [42]. Structures for
ErbB2 were constructed using homology modeling following the procedure described in
[312]. Models for kinase dimers were constructed based on the asymmetric dimer
interface described in [40]. Each system was simulated as a fully atomistic, explicitly
solvated-system in NAMD [150], using the CHARMM 27 forcefield [141]. The missing
hydrogens in the protein were added using the hbuild plugin in the VMD algorithm [151].
To simulate a physiological pH of 7.0 the histidines were constructed with +1 protonation
state on the -nitrogen. The entire system consisted of the protein, water molecules
(TIP3P model [314]) and ions at 75 mM ionic strength to simulate physiological
conditions; the water molecules and ions were placed at locations of electrostatic extrema
(maxima for negative Cl- ions and minima for positive Na+ ions) as determined by a
Debye-Huckel potential using Solvate 1.0 [315]. The placement of the counter-ions was
also restricted to 8 Å away from any protein residue. The Rattle algorithm [316] was
employed to constrain the hydrogens to allow for a 2 fs timestep of integration. Periodic
boundaries were implemented in all three dimensions and long-ranged electrostatics
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interactions were accounted for using the Particle Mesh Ewald Algorithm [157]. A
conjugate gradient algorithm was employed for all energy minimizations. The solvated
system was energy minimized and the volume of each system subsequently equilibrated
with constant pressure and temperature (CPT) simulations. Both the temperature and
pressure were constrained using a Langevin algorithm [317]. The pressure Langevin
piston was set with a reference pressure of 1 atm, a mass of 2000 amu and a collision
frequency of 5 (1/ps), while the temperature Langevin piston was set with a reference
temperature of 300 K and a mass of 10000 kcal·ps2. Following volume equilibration, the
energy of the system was equilibrated using constant volume and temperature (NVT)
simulations. Each system was simulated for at least 10 ns. For the dimer systems
restraints of 1 kcal/Å2 were placed on each kinase to their initial state in the inactive
asymmetric dimers to maintain the equilibrated structures while removing steric clashes.
The kinase systems were equilibrated and then the restraints were reduced to 0.5 kcal/Å 2
and 0.1 kcal/Å2. Following this, the production simulations were performed.

Analyses of MD Simulations: Root-mean-squared deviation (RMSD) calculations were
performed using the RMSD tool plugin in VMD by first removing global translation and
rotation, and then computing the RMSD of the selected sub-regions (A-loop, C-loop, Ploop and C-helix) relative to a reference structure (the respective active or inactive
crystal structure). Principal component analysis (PCA) was performed using the software
Carma [318], by constructing the covariance matrix of atomic fluctuations  in Cartesian
space and then diagonalizing  to obtain the principal components (eigenvalues and
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eigenvectors). An analysis of hydrogen bond (H-bond) patterns in the production
simulations was performed using CHARMM in conjunction with VMD. The trajectories
were first analyzed in CHARMM with a hydrogen bond cutoff of 3.4 Å and a cutoff
angle of 150 degrees. CHARMM was used to generate a list of hydrogen bonds that
were present in at least 60% of the trajectory; we note that the threshold of 60% was
varied from 50-80% in our sensitivity analysis and the results were nor altered
significantly. These hydrogen bonds were then visualized in VMD and any bonds not
providing a consistent, sustained bond were removed to reveal the persistent H-bonds.
During the H-bond analysis, acidic and basic residues formed strong hydrogen bonds.
Such hydrogen bonds were considered salt bridges if they were between the side chain of
an acidic and basic residue, with a bond length less than 1.6 Å and present in the majority
(>60% of the trajectory) of the simulation. Statistical hydrogen bonding criteria was
chosen to highlight the contributions of specific residues within the protein regardless of
its surrounding energetic environment [319]. Solvent accessible surface area (SASA)
values were calculated in VMD using the measure SASA module using a probe radius of
1.4 Å larger than the van der Waals radius. The SASA was calculated for each step in the
trajectory from which the mean and standard deviation were computed. As an alternative
measure of hydrophobicity in heterogeneous environments, following Garde et al. [320,
321], normalized water density fluctuations were computed by recording the ratio of
VolN*(N2-N2)/N2, where VolN is the volume of interest, N2-N2 is the variance in
the fluctuation of water number in VolN, and N is mean associated with the number of
water molecules. We choose the region of interest to be within 5 Å of a specified
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hydrophobic sub-region in the EGFR monomer kinase. The results are then divided by
the water density fluctuations of bulk water for normalization. Although results are
presented for a cutoff of 5 Å, other cutoffs ranging from 3 Å-15 Å were investigated and
similar trends were recorded.

4.3) Results

Following molecular dynamics simulation of each active or inactive monomeric kinase
system for at least 10 ns, the time evolution of the RMSD was used to monitor
equilibration and to track any reorganization of the A-loop and C-helix conformations;
no conformational switching towards active or inactive states was observed (Figure 4A.1,
chapter 4A). Whereas the majority of the protein backbone, including the C-loop and the
P-loop, aligns closely between the inactive and active states, the A-loop and C-helix
conformations differ considerably. In transitioning from the inactive to the active
conformation, the C-helix rotates toward the C-lobe, with the rotating end shifting by
~9 Å toward the base of the cleft between the N- and C-lobes (Figure 4.1B). This helix is
also extended by 2 turns (involving residues 728-732 in EGFR) in the active
conformation compared with the inactive conformation. In the inactive kinase, the Aloop maintains a „closed‟ conformation (mainly through inter-region hydrogen bonds)
and partially blocks the catalytic site. By contrast, the A-loop appears „unfurled‟ in the
active kinase, and lies against the C-lobe (blue in Figure 4.1B).
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4.3.1) PCA reveals a tightly coordinated motion in all active ErbB members

Figure 4.2: Visualization of the first principal component for the four key
subdomains in the inactive and active conformation of the ErbB kinases. The
motions are overlaid sequentially where the large-amplitude motion in each
frame is highlighted in red and the low-amplitude motion is highlighted in
blue. For the two dimer systems, the activating dimer is shown in orange and
green. The inactive conformations exhibit large, localized motion while the
active conformations demonstrate smaller, coordinated motions.

Principal component analysis (PCA) revealed that motions occurring within the active
sites of the inactive and active EGFR monomers differ significantly, particularly in the Aloop (see Figure 4.2). The inactive EGFR monomer exhibits large-amplitude motion in
both the αC-helix and the A-loop (4.95 and 7.34 Å, respectively), with smaller
fluctuations in the P-loop and C-loop (4.17 and 3.65 Å, respectively). We attribute the
larger amplitudes to a more flexible protein segment; this is consistent with the
observation that part of the activation loop is unresolved in almost all the crystal
structures of ErbB kinases to date. Our previous work with the loop modeling program
MODELLER [172] discusses the sensitivity of the modeled region (which is absent in the
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crystallographic structures). In particular, several candidate structures do not show
significant differences in dynamics [312]. Moreover, alternate structures of ErbB4 also
using MODELLER are remarkably close to initial simulation structures (data not shown).
In contrast, the active EGFR monomer demonstrates a uniform level of motion across all
four subdomains of the active site with only low-amplitude fluctuations (2-3Å), and
shows no significant local deformations. This implies that the motions are more tightly
coordinated across the active site in the active conformation than in the inactive
conformation. The kinase monomers of the other ErbB family members (modeled ErbB2
and the ErbB4 structure) demonstrate similar motions, as shown in Figure 4.2. The
inactive ErbB4 kinase exhibits a dominant motion in the A-loop (6.46 Å), while the Ploop, C-loop, and the αC-helix undergo smaller lateral motions (4.45 Å, 2.64 Å, and 2.30
Å, respectively). In the active conformation, the ErbB4 kinase presents a fluctuation
profile similar to EGFR: the subdomains all have similar small-amplitude motions (2-3
Å) with no large local deformations. Thus, for the three homologous members of the
ErbB family, which have a high-degree of sequence similarity, not only are the principal
motions conserved across the systems, but the characteristic differences between the
inactive and active kinase conformations are maintained in character. This finding
suggests large (and possibly similar) differences in the internal network of bonds between
the two activity states of each kinase. Indeed, the identified bonding network (Table 4.1,
Table 4A.1) shows clear conservation across the members of the ErbB family, and also
reflects the differences in principal motions between the inactive and active
conformations. In general, the inactive conformations have significantly fewer persistent
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bonds in this network when compared to the active conformations, consistent with the
larger amplitude motion.

Table 4.1: Persistent H-bonds and salt bridges in the three homologous ErbB
kinase monomer systems. The salt bridges are in bold and homologous
bonds are aligned. The table presents the subdomains with key conserved
bonds across the ErbB family, see Table 4A.1 for an exhaustive list.

Activating bond-network: We find several bonds are conserved across all members of the
ErbB family in the active state (EGFR numbering is used in this discussion: see Table
4.1): two salt bridges: E734-K851 and E738-K721, three H-bonds: L834-R812, K836V810, and L838-R808, as well as the bond D813-R817 which is a salt bridge in EGFR
and ErbB4, but an H-bond in ErbB2. The E738-K721 salt bridge is highly conserved
across all active kinases and helps coordinate the α and β phosphates of ATP bound in the
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active site.

The E734-K851 salt bridge connects the A-loop and the αC-helix,

coordinating the movements of these two sub-domains and dampening larger
fluctuations.

Similarly, three conserved H-bonds link the A-loop and the C-loop,

coupling the motions of these two loops. These can be regarded as “fastening” H-bonds
that maintain the N-terminal side of the A-loop open in its active state – the alternative
(in the inactive state) being steric hindrance to the binding of ATP and peptide substrates.
A fourth H-bond is seen only in ErbB2: E876-R898 fastens the C-terminal side of the Aloop open [312]. Although there is no analogous bond in EGFR and ErbB4, the Y845Y867 bond in EGFR and the homologous Y850-F872 bond in ErbB4 serve a similar role.
The conserved D813-R817 bond positions the sidechain of the catalytic aspartate D813 in
the active site and thus likely facilitates the preorganization of the catalytic site in the
active kinase system.

Inactivating bond-network: In contrast with the case for the active configurations, few
intramolecular bonds in the inactive kinase conformation are conserved across the ErbB
family (Table 4.1 and Table 4A.1). In fact, only one such bond is conserved across
EGFR, ErbB2 and ErbB4: a hydrogen bond between M742-L753 that pins the C-terminal
end of the αC-helix in its location away from the active conformation. The inactive
kinases do share an autoinhibitory pattern in which key residues required for kinase
activation are sequestered. Similar to the situation described for Lck [308, 309], E738 of
EGFR is salt bridged to K836 in a manner that „sequesters‟ this glutamate and prevents it
from forming the highly conserved E738-K721 salt bridge [312] required for full
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activation. For ErbB2 and ErbB4, the homologous residue K836 is replaced with an
arginine.

In ErbB4, this arginine contacts additional residues (as well as the E738

equivalent), apparently dampening the fluctuations of the αC-helix.

In ErbB2 the

arginine that replaces the K836 equivalent has flipped away from the αC-helix, so cannot
sequester the E738 residue equivalent. In ErbB2 and ErbB4, the other half of the highly
conserved salt bridge is sequestered; namely, the homologous K721 interacts with the
D831 side chain, and this interaction in turn prevents K721 from forming the
coordinating salt bridge.

4.3.2) Activation in the asymmetric dimer occurs through disruption of the
inactivating bond-network

We also analyzed fluctuations in the EGFR kinase within the context of the asymmetric
dimer described by Kuriyan and colleagues [40]. The fluctuations recorded for active
EGFR in this context are very similar to those seen in the active EGFR monomer (Figure
4.2), with the conserved bonds described above being mostly preserved (Table 4A.2).
Slight variations in bond patterns in the active configuration include a shift from E734K851 and L838-R808 in the monomer to E734-K836 and A840-R808 in the dimer, but
dimerization has little overall effect on the activating bond network. In contrast, in the
inactive dimer the first principal component reveals substantial motion of the αC-helix
that is much greater than seen in the inactive monomer system (7.49Å shift in dimer
compared to 4.14 Å in the monomer, see Figure 4.2). Simulations of the symmetric
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dimer interface of the inactive kinase in the unphosphorylated and phosphorylated states
does not result in any conformational switching (see Figure 4A.2), each system is stable
in the inactive state. Furthermore, in previous simulations of ErbB2 [312] we used loop
modeling to reduce the effect of steric clashes with no significant differences in
dynamical motions. Therefore we attribute the motion of the αC-helix uniquely to the
introduction of the asymmetric dimer interface. Even in the short timescale of 30 ns of
the EGFR dimer trajectory, we observe a rearrangement of the αC-helix position towards
the active conformation. Consistent with the allosteric activation mechanism proposed
by Zhang et al. [40], several interactions in the inactivating bond network surrounding the
A-loop and the αC-helix are indeed disrupted in the dimer trajectory, including Y740S744, L834-D813, H846-R865, and K851-R812 interactions (Table 4A.2a&b). Some
bonds (e.g. E738-K836) are still present, although the population statistics indicate that
their survival percentage (fraction present in the trajectory) has decreased from >90% in
the inactive monomer trajectory to ~60% in the inactive dimer trajectory over 30ns.

When compared with their monomeric counterparts, the ErbB2 and ErbB4 inactive
dimers demonstrate a similar loss of bonds surrounding the αC-helix and the A-loop (see
Figure 4A.3, Table 4A.2a&b chapter 4A and [312]). For ErbB4, a list of bonds disrupted
upon dimerization includes: E739-R841, D742-R841, E743-R817, G838-R817, G855E730, and K856-E844. Similar to the E738-K836 salt bridge in EGFR, the E743-R841
salt bridge in ErbB4 shows a marked decrease in survival time from >90% in the
monomer trajectory to ~70% in the dimer trajectory. Moreover, two of the bonds broken
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(E739-R841 and D742-R841) involve the R841 residue, resulting in a significant
weakening of the bonds in the inactivating bond-network discussed above that sequester
key side-chains in the inactive state.

Figure 4.3: (Top) Comparison of the first principal component for the EGFR
inactive mutant dimer systems: del 723-729 ins S and L834R. (Bottom)
Mapping of the RMSD of the inactive EGFR dimers as a scatter plot with
RMSD from inactive on one axis and RMSD from active on the other. The
end structures are visualized with an active reference (orange) and an inactive
reference (purple). The conformational switching between active and
inactive for EGFR of the A-loop and αC-helix are separable.
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4.3.3) EGFR mutations activate the kinase by disrupting the inactivating bond
network

In light of the allosteric activation mechanism described in the context of the EGFR
dimer system, we examined the effect of EGFR-activating mutations clinically identified
in non-small cell lung cancer (NSCLC). The two mutants we examined are those most
commonly found in NSCLC: a small in-frame deletion in the αC-helix (del 723-729 ins
S) and a point mutation in the A-loop (L834R), see Figure 4.3. The deletion mutant
physically shifts the αC-helix, removing residues 723-729 and leading to the shortening
of a disordered segment that adjoins the αC-helix. This shifts the αC-helix toward the
active state. The shortening of the αC-helix also alters the overall movement of the αChelix, with a distinctly different motion from all other systems (Figure 4.3). The bond
patterns we recorded in the dimer of the deletion mutant are similar to those of the
wildtype (WT) inactive EGFR dimer (see Table 4A.2a&b).

The majority of the

differences between the two systems are seen in the αC-helix: the deletion mutant loses
two bonds seen in the WT inactive dimer between the αC-helix and the A-loop: E738F832 & E738-G833. The L834R mutation alters the conformation of the A-loop slightly;
however, our trajectory shows the mutant kinase is still in a distinctly inactive
conformation. The L834R mutant dimer system shares a similar bond pattern (Table
4A.2a&b) with the WT inactive EGFR dimer system with some exceptions: namely,
G833 has H-bonded with H811, similar to the N-terminal fastening bonds that couple the
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A-loop and C-loop in the active state. Moreover, R834 has H-bonded to R865,
representing a fastening bond to the C-lobe.

4.3.4) Hydrophobic interactions help differentiate active and inactive conformations

Figure 4.4: Normalized water density fluctuations and the Mean surface
accessible (exposed) surface area (SASA) values for functionally important
sub-regions, specifically: C-spine (panel A & B), and R-spine. For the
normalized water density fluctuations (panels A, C, E) a higher value is
correlated with a higher hydrophobicity, which would be expected to bury
more SASA. See also Figure 4.5.

To investigate the effect of hydrophobic interactions on the ErbB kinase conformations,
we analyzed the hydrophobicity as well as the solvent accessible surface area (SASA) of
relevant hydrophobic sub-regions, namely, the C-spine, R-spine, hydrophobic core, and
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the αC-β4 region (Figure 4.1). The four regions have a high percentage of hydrophobic
side chains; however, some minor differences between members of the ErbB family exist
(Figure 4.1), particularly in the αC-β4 region. The hydrophobicity of the sub-region is a
non-additive quantity, dependent not only upon the primary structure but also on the
surrounding environment. Garde et al. [320, 321] have recently proposed an approach for
quantifying the hydrophobicity of heterogeneous surfaces using normalized water density
fluctuations (see Methods), according to which increased normalized water density
fluctuations are used as a signature of a more hydrophobic surface. For an alternate
presentation of the hydrophobic interactions, see Appendix A.

The active conformations in the C-spine are noted by the elevated normalized water
density fluctuations with the exception of EGFR monomer (where the difference is
minor), see Figure 4.4A. The active conformations also consistently expose a mean
surface area of around 500 Å2 across the members of the ErbB family (represented as a
horizontal line), which is consistently less than the exposed surface area in the inactive
conformations (mean value of over 700Å2), see Figure 4.4B. Together, these trends
reflect a more hydrophobic C-spine region in the active compared to the inactive
conformations. The hydrophobicity of the R-spine is not significantly different between
the active and inactive conformations (Figure 4.4C). However, the R-spine analysis does
reveal that the active conformations have a lower mean SASA value than the inactive
conformations (Figure 4.4D); for some systems, the difference is not so clearly delineated
in part because it consists of just four residues, so SASA is subject to larger fluctuations.
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With similar levels of water density fluctuations between active and inactive
conformations, the decreased mean SASA values for the R-spines in the active
conformations imply a more stable hydrophobic context, consistent with the finding that
the well-formed spines are characteristic of the active kinase conformations.
Interestingly, all ErbB2 systems present a higher fluctuation in water density, which is
consistent with the notion that hydrophobicity is particularly important in the context of
ErbB2 owing to its interaction with Hsp90 known to be mediated by hydrophobic
contacts; see also the analysis surrounding the C-4 region, below. We also record a
decrease of the R-spine SASA for inactive EGFR in the dimeric form compared to the
monomeric form, with similar hydrophobicity (Figure 4.4C,D). The addition of the
dimer interface in inactive EGFR reduces the mean SASA for the R-spine from 140Å2 to
80Å2, implying that dimerization can provide additional stabilization due to hydrophobic
interactions in EGFR.

With respect to the water density fluctuations in the hydrophobic core, the inactive
conformation is more hydrophobic than the active conformation (with the exception of
ErbB2), see Figure 4.5A. This difference is consistent with the hydrophobic stabilization
of the inactive conformation, especially for EGFR and ErbB4 but not for ErbB2. Notably,
mutations of hydrophobic residues in the hydrophobic core are reported for EGFR and
ErbB4 in clinical studies, (see Discussion, section 4.4), whereas, for ErbB2, such
mutations are found surrounding the αC-β4 region. The analysis in Figure 4.5A also
implies that the difference in hydrophobicity between the inactive and active
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conformations is reduced in the dimer EGFR compared to monomer. This is consistent
with the allosteric activation mechanism, namely that dimerization significantly reduces
the hydrophobic advantage and provides a stimulus for activation. As for the SASA
results, the hydrophobic core does not show a clear separation between the active and
inactive conformations (Figure 4.5B). However, to describe the highly irregular nature of
the surface of the hydrophobic core, the water density analysis may be more suitable that
the SASA.

Figure 4.5: Normalized water density fluctuations and the Mean surface
accessible (exposed) surface area (SASA) values for functionally important
sub-regions, specifically: hydrophobic core (panel A & B), αC-β4 region
(panel C & D) and dimer interface (panel E & F). For the normalized water
density fluctuations (panels A, C, E) a higher value is correlated with a higher
hydrophobicity, which would be expected to bury more SASA.
The αC-β4 region is an unstructured span between the αC-helix and the β4 sheet in
RTKs. From a sequence perspective, only in ErbB2 is the αC-β4 region predominantly
hydrophobic (Figure 4.1, see primary sequence; G776 in ErbB2 corresponds to S744 and
S749 in EGFR and ErbB4, respectively; G778 in ErbB2 corresponds to D746 and D751
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in EGFR and ErbB4, respectively). The water density analysis clearly reflects this trend
by singling out the ErbB2 monomer systems are particularly hydrophobic (Figure 4.5C);
the mean SASA for the αC-β4 region in ErbB2 systems is also consistently lower than in
other members of the ErbB family (Figure 4.5D). As discussed in [312], this unique
feature of ErbB2 is thought to be responsible for its preferential association with the
molecular chaperone Hsp90.

The asymmetric dimer interface consists largely of hydrophobic side-chains in the N-lobe
of the receiver kinase (L680, I682, L736, L758, and V762) and the C-lobe of the
activator kinase (I917, Y920, M921, V924, and M928) [40]. With respect to water
density analysis, the dimer interface presents a similar hydrophobicity across all
members, with the ErbB2 monomers a little more hydrophobic, particularly in the active
conformation (Figure 4.5E). The monomeric systems record a mean SASA value of
approximately 350 Å2 for the dimer interface residues in the active conformations versus
200 Å2 in the inactive conformations (Figure 4.5F). This decrease for the inactive
monomers may imply a preference for the inactive state in the monomer context.
Notably, the dimeric systems record much lower SASA values of about 75 Å2, implying
that hydrophobic stabilization provides a dominant driving force for dimerization;
interestingly, for EGFR dimer, the SASA for the inactive state is greater than that for the
active case and hence the preference for the inactive conformation is not implied in the
context of the dimer. Thus, dimerization also provides a stimulus for activation.
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4.4) Discussion

The analysis described here identifies conserved intramolecular non-covalent bond
networks across the ErbB family kinases that emerge from sequence homology and lead
to conserved dynamic characteristics as well as function. The hydrophilic and
hydrophobic networks are cooperative interactions which help differentiate the active and
inactive conformations while modulating key loop fluctuations and bonds. Investigation
of the networks allows identification of network fragilities which can be exploited
through mutation to alter the basal kinase activity.

The bond-networks highlight key conserved residues and bonds that are characteristic to
each conformational state. Some of the bonds of been highlighted previously, the highly
conserved salt bridge E738-K721 [25] and the fastening bonds L834-R812, K836-V810
and L838-R808 [312]. We add to this another salt bridge coordinating the αC-helix and
the A-loop, E734-K851 salt bridge and the H-bond D813-R817 which facilitates the
placement of the D813 aspartate side-chain in a catalytically competent orientation.
Overall, the six conserved interactions tightly coordinate the N-lobe to the αC-helix, the
αC-helix to the A-loop, and the A-loop to the C-loop. The nature of this bond network
suggests that interactions among the nearest key subdomains in the ErbB family helps in
maintaining the proximity of important catalytic residues, and positioning them so they
can contribute directly to kinase activity. The conserved bond network in the inactive
conformations of the ErbB family kinases is less extensive (in EGFR, E738-K836 and
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D831-K721), but appears to serve a crucial role in sequestering key catalytic residues and
thus preventing activity.

Hydrophobic interactions appear to provide context-specific contributions to stability to
the active and inactive conformations of ErbB kinases (see Appendix A for an alternate
presentation of the hydrophobic interactions). Since a single amino acid change can alter
the hydrophobicity of a region, we considered the water fluctuation analysis in
conjunction with SASA to present the contributions from hydrophobicity for irregular
surfaces characteristic of sub-regions in the kinase. Both SASA and fluctuation analyses
of local water densities imply that the inactive monomer conformations of ErbB kinases
are preferentially stabilized through hydrophobic interactions associated with the dimer
interface. Moreover, consistent across the ErbB family, kinase domain dimerization
further reduces the SASA of the dimer interface residues, implying that hydrophobic
interactions provide a dominant impetus for dimerization.

The hydrophobic interactions with respect to the C-spine and R-spine regions are found
to benefit the active conformations, overall; in particular, the SASA analysis suggests the
active conformations benefit from a larger buried surface area). Interestingly, we found
ErbB2 to possess a greater hydrophobicity in the spine regions. Thus, the αC-β4 region as
well as the C-spine and R-spine are found to display uniquely hydrophobic character in
ErbB2 consistent with its association with Hsp90. Also, in the case of the ErbB2 dimer
interface, the active conformation is more hydrophobic than the inactive conformation,
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but also exposes more surface area, implying a destabilizing hydrophobic force in the
active conformation; considering that ErbB2 does not have a known ligand, this could
serve as an auto-inhibitory mechanism against activation. It is also intriguing to note that
in the hydrophobic core, there is a large differential between the inactive and active
conformations in the water fluctuations, consistent with preferential benefit for the
inactive conformation in EGFR and ErbB4, but not for ErbB2. Thus, the analyses for the
spine regions and the hydrophobic core collectively lead to the remarkable prediction that
while the αC-β4 region and the R-spine confer hydrophobic benefit to the inactive
conformation of ErbB2, the hydrophobic core has the same effect for EGFR and ErbB4.
Indeed, this correlates well with clinical studies, where activating point mutations in the
hydrophobic core have been found in EGFR and ErbB4 but those in the αC-β4 region are
found in ErbB2, suggesting that the hydrophobic analysis enables the context-specific
identification of fragile sub-regions.

The active kinase conformations have a greater number of conserved intramolecular
persistent bonds (hydrophilic specific interactions) than the inactive systems, whereas the
inactive kinase conformations appear to have a distinct hydrophobic advantage in the
dimer interface region. This observation is fully consistent with the view that, for ErbB
kinases, the dominant stimuli that activate them operate by modulating the dimer
interface (activation mechanism in the wildtype) and the hydrophobic core regions (mode
of activation in clinically identified mutation) to destabilize the inactive conformation,
which we discuss below.
81

For the wildtype systems, this finding provides strong support for the allosteric
mechanism associated with formation of the asymmetric dimer interface reported by
Zhang et al. [40] and Qiu et al. [42], and the recent studies of juxtamembrane domain
associations [43-45]. In this respect, the emerging view on allosteric EGFR regulation
posits that, rather than forcing the protein to a new conformation, the allosteric interface
guides the kinase domain to the active state through pre-existing conformational
ensembles [322]. Our results for the EGFR dimer simulations (Figures 4.2, 4.3) are
consistent with this view; namely, the allosteric dimer interface causes the αC-helix to
alter the conformational space it samples and thus biases it towards a more active
conformation. This leads to a metastable intermediate characterized by the αC-helix
adopting an active-like conformation, albeit still remaining partially molten.

We

therefore hypothesize a sequence of events that characterize the EGFR kinase activation
pathway (see section 4A.4): (1) Formation of the dimer interface triggers a shift of the
αC-helix conformation toward the active state. (2) Formation of the additional helical
turns in the αC-helix and the initiation of the A-loop movement, either happen
concurrently or sequentially, but the A-loop does not complete its conformational
switching until the αC-helix is fully formed. This sequence differs from the mapped
pathway of the Src kinase Hck [323-325]; in Hck, following A-loop tyrosine
phosphorylation the A-loop can adopt an open (active) conformation while the αC-helix
is still in the inactive conformation. In the EGFR the opposite is true, namely, upon
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dimerization the αC-helix moves towards the active conformation with the A-loop in the
closed (inactive) conformation (see section 4A.4).

Intriguingly, kinase activation in the two clinically identified EGFR activating mutants
studied here (L834R and del 723-729 ins S) also appears to be governed by the same
principles. The L834R mutation, apart from directly disrupting the hydrophobic core inlieu of the hydrophilic Arg, leads to additional coupling of the A-loop to the C-loop
(through the G833-H811 H-bond) and the A-loop to the C-lobe (through the R834-R865
interaction) not seen in other systems. The deletion mutation directly alters the αC-helix
to cause a shift toward its active conformation, although it also disrupts the normal
dynamics and potential extension of the αC-helix. In the functional studies of Choi et al.
[26], the deletion mutant showed an increase in basal phosphorylation, but a decrease in
the overall phosphorylation under EGF stimulation. By interfering with the key
interactions surrounding the helix, it can potentially stabilize the active conformation of
the monomer kinase. However, upon dimerization the active conformation is destabilized
because the deformation disrupts both the dimer interface due to its proximity and
because the αC-helix cannot fully form. This justifies the dual response of the deletion
mutant on kinase phosphorylation activity in the presence/absence of EGF stimulation.

The hydrophilic and hydrophobic bond networks we have identified also enable us to
propose a set of mechanisms that increase the basal level of kinase activity for the other
EGFR mutations in NSCLC [26, 27, 48]: E685S, G695S, S744I and L837Q, as well as a
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set of mutations in ErbB4 found in melanoma [60], namely, E836K, E872K and G936R.
Similar to L834R, in the L837Q mutation, replacing the hydrophobic leucine side-chain
with the hydrophilic glutamine side-chain is likely to cause it to rotate away from the
small hydrophobic core between the αC-helix and the A-loop, thereby disrupting the
hydrophobic core and inducing a local steric effect. This reconfiguration may also disrupt
the interaction of K836 with E738. The S744I mutation in NSCLC most likely disrupts
the M742-L753 bond, allowing transition of the αC-helix into its active position. E685G
and G695S are in the N-lobe, close to the asymmetric dimer interface, so mutations here
are likely to alter kinase activity either by increasing the dimerization affinity or by
reconfiguring the EGFR RTK monomer by partially mimicking the formation of the
asymmetric dimer interface. Two of the ErbB4 mutations seen in melanoma, E836K and
E872K, are situated around the small hydrophobic core and the change from a negatively
charged side chain to a positively charged chain is poised to disrupt the core‟s stability,
thereby providing an activating stimulus. The G936R mutant in ErbB4 is located close to
the asymmetric dimer interface in the C-lobe and potentially alters the dimerization
affinity. Analogous mutations in ErbB2 have not been reported. Instead, the activating
clinical mutations in ErbB2 are in αC-β4 region [55, 326], shown here to be uniquely
hydrophobic in the ErbB family. Disruption of the hydrophobicity of the αC-β4 region
would alter the binding to Hsp90 [124] and increase heterodimerization [123] and thus,
activity of ErbB2. Characterization of another set of mutations in ErbB4 found in
NSCLC, show two inactivating mutations G802dup and D861Y [125]. D861 is the start
of the highly conserved DFG motif in RTKs and mutation of it would reduce activity,
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while the G802dup is spatially located near the P-loop and likely affects ATP binding
affinity. Similarly in ErbB4, two of the point mutations are located near the active site:
E836 is located next to the C-loop, whereas E872 is situated in the A-loop and hence
owing to their proximity to the active site, the mutations are also poised to alter substrate
binding and phosphorylation; such mechanisms are discussed in a recent computational
study in the context of EGFR [327].

As mentioned in the Introduction, A-loop phosphorylation is thought not to be required
for ErbB family kinase activation [306]. Consistent with this notion, although we record
some context-specific structural changes between systems in which the A-loop is
phosphorylated versus unphosphorylated (see section 4A.1-3), our results indicate that
this phosphorylation does not provide a dominant activating effect. We reached a similar
conclusion in recent studies of ErbB2 using a free energy perturbation approach [312].

In conclusion, our results help to establish the molecular context governing the stability
and activation stimuli of ErbB kinases. Given that receptor tyrosine kinases are important
signaling elements in cells, and mutations within these kinases cause subtle changes in
molecular behavior that result in substantial alterations of downstream signaling [152],
this work helps establish the crucial link between molecular mechanisms of kinase
activation and the ensuing signaling response.
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Chapter 4A.) Appendix for 4: Molecular Dynamics Analysis of Conserved
Hydrophobic and Hydrophilic Bond Interaction Networks in ErbB Family Kinases
EGFR
ErbB2
active
active
aC-helix aC-helix bonds
––
P761,K765
K730,E734 K762,E766
A731,I735
A763,I767
N732,S728
N764,S760
N732,L736
N764,L768
––
––
K733,D737 K765,D769
E734,E738
E766,E770
I735,A739
I767,A771
L736,Y740
L768,Y772
D769,V773
E738,M742 E770,M774
––
A771,A775
Y740,S744
––
V741,V745 V773,V777
C-loop bonds
H811,D872 – –
R812,E848 – –
––
––
R812,D872 – –
R812,S875
––
––
––
A816,E882
––
N818,T830
N850,T862
A-loop A-loop bonds
––
––
––
––
––
––
––
––
––
––
––
D871,I872
––
D871,E874
––
––
––
––
––
––
––
––
––
––
Y845,E848
––
––
D880,G881
––
––

ErbB4
active

EGFR
inactive

ErbB2
inactive

ErbB4
inactive

––
––
A736,F740
N737,G733
N737,M741
––
V738,D742
E739,E743
F740,A744
––
D742,I746
E743,M747
––
L745,S749
I746,M750

––
––
––
––
––
––
K733,D737
E734,E738
I735,A739
L736,Y740
––
E738,M742
––
Y740,S744
––

––
K762,E766
A763,I767
N764,S760
––
K765,L768
––
––
I767,A771
––
––
E770,M774
––
Y772,G776
––

––
––
––
––
N737,M741
––
––
––
F740,A744
––
––
––
––
L745,S749
––

H816,D877
––
––
R817,D877
––
––
A821,E887
N823,T835

H811,D872
––
R812,K851
R812,D872
––
––
A816,E882
N818,T830

––
––
––
––
––
A848,L807
––
––

H816,D877
––
––
––
––
––
A821,E887
N823,T835

F837,A840
––
––
––
R841,E847
––
––
––
––
––
––
––
––
––
––

––
G833,K836
––
––
––
––
––
––
E841,K843
E841,E842
––
E844,Y845
––
E848,G849
––

––
––
G865,L869
L866,L870
––
––
––
––
––
––
––
––
––
––
E874,K883

––
––
––
––
––
––
––
E844,K856
––
––
E847,K848
––
––
––
––

Table 4A.1: Persistent H-bonds and salt bridges in the three homologous
ErbB kinase monomer systems. The salt bridges are in bold and homologous
bonds are aligned.
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EGFR
EGFR WT L834R
Active-U
Inactive-U
Dimer
Dimer
aC-helix interdimer bond
––
––
––
––
––
––
––
K730,E939
––
K733,D918
Y740,D918 – –
aC-helix A-loop bond

EGFR
deletion
Inactive-U
Dimer

EGFR WT
Inactive-U
Dimer

ErbB4 WT
Inactive-P
Dimer

––
––
––
––
K733,D918
––

––
––
P729,K925
K730,E939
K733,D918
––

K689,E912
E690,K910
––
––
––
––

––
––
––
––

––
––
E738,F832
E738,G833

––
E738,K836
aC-helix bonds

E738,K836

E738,K836

––
––
––
––
E743,
R841

––
––
N732,V762 – –
E738,K721 – –
––
M742,L753
––
A743,R752
A-loop C-loop bonds
––
––
––
G833,H811
L834,R812
––
––
––
K836,V810 – –
––
––
A-loop bonds
D831,K721 D831,K721
––
L834,R865
A840,R808 – –
E841,R808 – –
Y845,Y867 – –
A847,R865 – –
––
E848,R865
––
––
––
––

K730,F699
––
––
M742,L753
––

––
––
––
M742,L753
––

––
––
––
M747,L758
A748,R757

D831,N818
––
––
L834,D813
––
––

D831,N818
––
––
––
––
––

––
G838,H816
––
––
––
E847,R817

D831,K721
––
––
––
––
––
E848,R865
––
––

D831,K721
––
––
––
––
––
E848,R865
––
K851,E725

D836,K726
––
––
––
––
––
––
D853,R902
––

E734,K836
D737,K836
––
––

––
––
E738,F832
––

Table 4A.2A: Persistent H-bonds and salt bridges in the five ErbB kinase
dimer systems. The salt bridges are in bold and homologous bonds are
aligned. See also Table 4A.2B
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EGFR
EGFR WT L834R
Active-U
Inactive-U
Dimer
Dimer
aC-helix aC-helix bond
N732,S728
––
A731,I735
––
N732,L736 – –
K733,D737 K733,D737
––
––
––
E734,E738
I735,A739
I735,A739
L736,Y740 L736,Y740
––
D737,V741
E738,M742 E738,M742
A739,A743 A739,A743
Y740,S744
Y740,S744
V741,V745 V741,V745
A-loop A-loop bonds

EGFR
deletion
Inactive-U
Dimer

EGFR WT
Inactive-U
Dimer

ErbB4 WT
Inactive-P
Dimer

––
––
––
K733,D737
E734,E734
E734,E738
I735,A739
L736,Y740
––
E738,M742
––
Y740,S744
––

––
––
N732,L736
K733,D737
E734,E734
––
I735,A739
––
––
E738,M742
A739,A743
––
––

––
––
N737,M741
V738,D742
––
E739,E743
F740,A744
M741,L745
––
––
––
L745,S749
––

––
D831,K836
––
F832,K836
––
––
––
––
––
––
––
––
––
––
––
E841,K843
––
––
C-loop bonds
H811,D872 H811,D872
R812,D872 R812,D872
R812,S875
––
A816,E882 A816,E882
N818,T830 N818,T830
––
––
C-loop C-loop bonds
––
––
––
R812,D813
D813,R817 – –
––
A815,N818

––
––
––
––
A835,L837
––
––
E841,K843
––

D831,K836
––
G833,K836
––
––
G839,Y845
––
––
E848,G849

––
––
––
L839,L843
––
––
E844,K848
––
––

H811,D872
R812,D872
––
A816,E882
N818,T830
––

H811,D872
R812,D872
––
A816,E882
––
N818,D831

H816,D877
R817,D877
––
A821,E887
N823,T835
––

––
––
––
A815,N818

––
R812,D813
––
A815,N818

H816,R817
––
D818,R822
A820,N823

Table 4A.2B: Persistent H-bonds and salt bridges in the five ErbB kinase
dimer systems. The salt bridges are in bold and homologous bonds are
aligned.
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Figure 4A.1: The RMSD plots for the monomeric systems showing RMSD
from the active (red) and inactive (black) conformations.

Figure 4A.2: The RMSD plots for the EGFR symmetric dimer systems
showing RMSD from the active (red) and inactive (black) conformations.
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4A.1) A-loop phosphorylation in monomers promotes coordination of the catalytic
sub-domains

To simulate the phosphorylated systems, we used the phosphotyrosine patch from the
CHARMM27 forcefield on the A-loop tyrosines [328]. The systems were minimized,
equilibrated and simulated as described in the methods. There are two phosphorylated
systems created for the EGFR monomers: one in the active conformation and the other in
the inactive conformation.

Two similar monomer systems for ErbB2 have been

previously simulated [312].

Figure 4A.3: Visualization of the first principal component for the four key
sub-domains in the inactive and active phosphorylated ErbB systems. The
motions are overlaid sequentially, where the large-amplitude motion in each
frame is highlighted in red, and the low-amplitude motion is highlighted in
blue.
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The added charge from the phosphate tail to the A-loop tyrosine (Y845 in EGFR, Y877
in ErbB2) causes a minor reorganization of the residues in the A-loop (~2 Å), but does
not greatly alter the rest of the protein. Phosphorylation in the active systems keeps the
active site subdomains (A-loop, P-loop, αC-helix and C-loop) coordinated with
equivalent levels of fluctuations as the unphosphorylated systems (~3 Å). However, Aloop phosphorylation does not have a uniform effect upon the dominant modes of motion
in EGFR and ErbB2 (see Figure 4A.3). Compared to the unphosphorylated EGFR
system, the inactive has the same motions in the A-loop (~7.5 Å), but dampened
fluctuations in the other three loops (from ~4 Å to ~2 Å). In contrast, phosphorylation of
the ErbB2 systems does not greatly alter the magnitude of the fluctuations.

Activating Bond Network: The A-loop phosphorylated active systems mostly preserve the
conserved bonds seen in the unphosphorylated active systems (E738-K721, E734-K851
salt bridge; L834-R812, K836-V810, L838-R808, D813-R817 H-bonds), see Table 4A.3.
The ErbB2-P system loses the E734-K851 salt bridge, because the added charge from
phosphorylation causes the K851 residue to bind to the phosphate group (Y877-K883).
Both EGFR-P systems gain the D831-K721 bond, as a salt bridge in the active state and
as an H-bond in the inactive state. Since K721 is also salt bridged to E738, the D831K721 bond is a consequence of having all the catalytic residues close together. The
active phosphorylated systems also gain several more fastening bonds that maintain the
C-terminal side of the A-loop in the open conformation: the ErbB2 systems gain Y87791

EGFR-P
active

ErbB2-P
active
αC-helix bonds
––
––
––
A763,S760
N732,V762 – –
––
E766,R756
E738,K721 E770,K753
––
M774,L785
––
––
αC-helix A-loop bonds
––
––
K730,E848 – –
E734,K836 – –
E734,K851 – –
––
E770,F864
––
––
A-loop bonds
D831,K721 – –
––
––
––
––
L838,R808
L870,R840
––
E876,R898
––
––
Y845,Y867 Y877,F899
A847,R865 A879,R897
––
––
A-loop C-loop bonds
––
––
L834,R812
L866,R844
––
––
K836,
V810
R868,V842
Y845,R812 Y877,R844
C-loop bonds
H811,D872 – –
R812,D872 – –
A816,E882 – –
N818,T830 – –

EGFR-P
inactive

ErbB2-P
inactive

N732,A726
––
––
––
––
––
A743,R752

––
––
––
––
––
––
––

––
––
––
––
E738,F832
E738,K836

T759,E874
––
––
––
––
––

D831,K721
––
––
––
––
Y845,R865
––
––
E848,R865

D863,K753
G865,H843
R868,R840
––
––
Y877,R897
––
––
––

D831,N818
––
L834,D813

––
––
––

––
Y845,R812

––
Y877,R844

H811,D872
R812,D872
A816,D882
N818,T830

––
––
––
––

EGFR-P
ErbB2-P
active
active
C-loop C-loop bonds
––
––
––
––
D813,R817 D845,R849
––
D845,N850
A815,N818 A847,N850
––
A847,V851
––
––
––
––
αC-helix αC-helix bonds
––
P761,K765
––
K762,E766
A731,I735
A763,I767
––
N764,S760
N732,L736
N764,L768
K733,D737 K765,D769
E734,E738
E766,E770
I735,A739
I767,A771
L736,Y740
L768,Y772
D737,V741 D769,V773
E738,M742 E770,M774
A739,A743 A771,A775
––
––
––
V773,V777
A-loop A-loop bonds
––
D863,G865
––
––
––
––
––
––

EGFR-P
inactive

ErbB2-P
inactive

––
R812,D813
––
––
A815,N818
––
A816,V819
––

H843,N850
R844,D845
––
––
––
––
A848,V851
R849,N850

––
K730,E734
––
––
––
––
––
––
––
––
E738,M742
A739,A743
Y740,S744
V741,V745

––
––
––
––
N764,L768
K765,D769
E766,E770
I767,A771
––
––
––
A771,A775
Y772,G776
––

––
D831,K836
––
G833,K836

––
––
G865,L869
––

––
––
––
K843,E844
––
––
––

––
––
––
––
––
––
E848,K851

L866,L870
––
––
––
Y877,K883
––
––

––
R868,Y877
D871,E874
––
Y877,K883
D880,G881
D880,K883

Table 4A.3: Persistent H-bonds and salt bridges in the phosphorylated ErbB
kinase monomer systems. The salt bridges are in bold and homologous
bonds are aligned.
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F899, A879-R897 as seen in [312]; the EGFR phosphorylated systems have the
homologous fastening bonds in Y845-Y867 as well as A879-R865.

All of the

phosphorylated systems share a common bond in Y845-R812, which strengthens the
coordination between the A-loop and C-loop. The other fastening bonds in the active
conformation have an increased survival time and shorter bond length, further increasing
the coupling between the A-loop and C-loop.

Inactivating Bond Network: The inactivating bond network for the phosphorylated
systems does not present as many conserved bonds.

However, similar to the

unphosphorylated systems, there are bonds sequestering key catalytic residues. Half of
the highly conserved salt bridge E738-K721 [312] is salt bridged to K836 in EGFR while
the other half, residue K721, is salt bridged to D831 in ErbB2.

The inactive

phosphorylated systems have only one common bond not shared by any of the other
systems, Y845-R865, which maintains the closed A-loop conformation and thus serves a
role opposite of a fastening bond (see Table 4A.3). However, the conserved H-bond in
the unphosphorylated inactive systems M745-L753 is not present.

Phosphorylation of the A-loop tyrosine in the ErbB systems provides some alteration to
the bond patterns, strengthening the coordination between the loops. However, the shift
is not sufficient to cause a conformational change in the short time scales that we employ
here. The effects of phosphorylation are more subtle and likely involve more complex
protein-protein interactions to promote the full conformational change. To this effect we
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have also simulated several phosphorylated systems in the asymmetric dimer
configuration to examine whether dimerization and phosphorylation have a synergistic
effect as described below.

4A.2) Phosphorylation of the A-loop does not perturb the dimer-mediated allosteric
activation mechanism

Two A-loop phosphorylated dimer systems were examined to explore how
phosphorylation could affect the dimer-mediated allosteric activation mechanism. An
ErbB4 homodimer with the activator kinase in the active conformation and the receiver
kinase in the inactive conformation was created and simulated using the same
methodology as the monomers.

A similar ErbB2 heterodimer has previously been

simulated [312].

Addition of the asymmetric dimer interface causes a shift of the αC-helix toward the
active conformation, similar to the shift observed in the unphosphorylated systems. The
ErbB4 dimer exhibits a comparable motion and directionality in the A-loop and the αChelix to the EGFR dimer systems.

The A-loop-phosphorylated ErbB2 dimer

demonstrates slightly more motion than the unphosphorylated dimer, predominantly in
the αC-helix (2.56 Å vs. 1.14 Å). Phosphorylation of the A-loop tyrosine binds the Aloop and the αC-helix tightly, increasing the motions between the two subdomains. The
increased fluctuations are located near the N-terminal region of the helix (see Figure
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4A.3).

This region aligns with the molten region of the EGFR and ErbB4 dimer,

implying a larger motion allowed if the αC-helix of the ErbB2 dimer were also partially
molten.

4A.3) Hydrophobic interactions are not significantly affected by A-loop
phosphorylation

Phosphorylation of the A-loop tyrosine in the ErbB family does not significantly alter the
hydrophobic interactions of the five hydrophobic sub-regions: the asymmetric dimer
interface, the αC-β4 region, the C-spine, the R-spine and the hydrophobic core,
particularly in comparison to the unphosphorylated states. In the dimer interfaces, the
water fluctuation analysis shows a similar hydrophobicity in the phosphorylated systems
as the unphosphorylated systems (Figure 4A.4A). For the dimer interface residues, the
active conformations have the highest mean SASA value of ~360 Å2 with the inactive
conformations having a significantly lower value of ~220 Å2 (Figure 4A.4B). The dimer
system is the lowest of all the systems with a mean SASA value of ~75 Å2. Considering
that the αC-β4 region is predominantly hydrophobic only in ErbB2, it has the highest
overall hydrophobicity of all systems (Figure 4A.4C). Correlated with that, the SASA
values for the phosphorylated systems reveals that the ErbB2 systems have a lower mean
SASA value of ~220 Å2 with the non-ErbB2 systems having a higher mean SASA value
of ~315 Å2 (Figure 4A.4D).
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Figure 4A.4: Comparison of the normalized water density fluctuations with
the mean solvent accessible surface area for two functionally important subregions for the ErbB family in the A-loop phosphorylated systems: the dimer
interface (panels A & B) and the αC-β4 region (panels C & D). A higher
normalized density water fluctuation implies a greater hydrophobicity, which
would have less exposed surface area.
The C-spine in the active conformation presents a smaller mean SASA value than the
inactive kinase systems. The active conformations have a mean SASA value of 500 Å2
with the inactive conformations having greater variability, but a higher mean value of 680
Å2 (Figure 4A.5B). In the ErbB2 phosphorylated systems, the hydrophobicity shows a
similar trend implying a well formed spine (Figure 4A.5A). However, in the EGFR
systems the inactive has a higher exposed surface area with a higher water density
fluctuations and therefore higher hydrophobicity, implying a better formed spine in the
active conformation. The R-spine has a similar trend of a better formed spine in the active
conformation in all systems. The active conformations have a lower SASA value than
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the inactive conformations (Figure 4A.5D) with the inactive conformations having an
increase water density fluctuation (Figure 4A.5C). For the hydrophobic core (Figure
4A.5F), the active conformations have a higher mean SASA value (~500 Å2) than the
inactive conformations (~350 Å2). However, the inactive and active EGFR monomer
kinases have approximately equal SASA values, while the ErbB2 active kinase has a
higher mean SASA value than the inactive system. While the water density analysis
shows the inactive having a higher hydrophobicity than the active conformation in the
EGFR monomers, the gap has shrunk in comparison to the unphosphorylated systems
implying less of a network fragility in the phosphorylated systems (Figure 4A.5E).

Figure 4A.5: Comparison of the normalized water density fluctuations with
the solvent accessible surface area for three functionally important subregions for the ErbB family in the A-loop phosphorylated systems: the Cspine (panels A & B), the R-spine (panels C & D) and the hydrophobic core
(panels E & F). A higher normalized density water fluctuation implies a
greater hydrophobicity, which would have less exposed surface area.
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Overall the effect of A-loop phosphorylation in the ErbB family is not clear. Although
the phosphorylation of the A-loop tyrosine strengthens specific linkages between the Aloop and C-loop in the active state and promotes a subtle reorganization of the bond
network in the inactive state, the stimulus of the added charge is insufficient to cause a
conformational shift through hydrophilic bonds. The phosphorylated systems present a
similar profile to the unphosphorylated systems with regard to hydrophobic interactions.
We have previously performed an analysis on the ErbB2 monomer system with a F of
-1.1 ± 1.4 kcal/mol difference as a result of phosphorylation of the A-loop tyrosine, and a
F of 1.2 ± 1.5 kcal/mol difference for dephosphorylation [312].

4A.4) Targeted molecular dynamics studies reveal specific interactions associated
with the transition pathway

Targeted molecular dynamics (TMD) simulations were performed in CHARMM [329]
using the RMSD of the backbone atoms of the αC-helix and the A-loop as the reaction
coordinate (χi). The activation pathway is divided into 20 smaller windows and each
segment of the window is simulated individually to ensure adequate sampling. To
enhance the sampling of low probability events, a harmonic restraint of constant k=20
kcal/mol/(Å2) is applied along the reaction coordinate, χi.
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Figure 4A.6: Comparison of the first principal component of the EGFR
TMD monomer simulation (panel A) and the EGFR TMD dimer simulation
(panel C) vs. the active (Panel B) and inactive EGFR (Panel D) monomer
systems, with an active reference (orange) and inactive reference structure
(green). The activator kinase is shown in yellow in panel B. The motions are
overlaid sequentially, where the large-amplitude motion in each frame is
highlighted in red, and the low-amplitude motion is highlighted in blue.
TMD pathway for the EGFR monomer (panel E) and EGFR dimer (panel F).

The TMD study of EGFR captured the transition of the kinase from the inactive to the
active conformation. The PCA of the TMD trajectory is depicted in Figure 4A.6A.
Comparison of the PCA of the active and inactive EGFR unphosphorylated systems to
the TMD PCA reveals how each set of fluctuations progresses along the activation
pathway. The active unphosphorylated PCA fluctuates closely to the active state without
much motion, showing it is stable in the current energy well (see Figure 4A.6B).
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However, the inactive state shows some motion toward the active conformation, with
both the αC-helix and A-loop moving toward the active state in an indirect fashion (see
Figure 4A.6D).

The inactive EGFR unphosphorylated system exhibits comparable

motion to the TMD EGFR study (7.34 vs. 8.03 Å in the A-loop, 4.95 vs. 5.23 Å in the
αC-helix, respectively), though the motions are not sufficiently directed toward the active
state. The TMD study did not completely sample the activation pathway; similar to the
work of Athanasios et al. [311], we observed several significant molecular events: the
breaking of the E738-K836 salt bridge, the formation of the E738-K721 salt bridge and
the extension of the αC-helix (Figure 4A.6E). This is similar to what we observed in the
EGFR dimer TMD simulations (see Figure 4A.6C). However, the αC-helix extension
progresses through a different pathway than that of the monomer (see Figure 4A.6F).
The complete pathway has not been mapped, but the data we have collected strongly
suggests the αC-helix shifts before the A-loop contrary to the pathway mapped out for the
Src kinase Hck [324, 325].
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Chapter 5.) A multiscale modeling approach to investigate molecular mechanisms of
pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine
kinase signaling network

5.1) Introduction

This chapter is modified from work that has been submitted to Molecular Biosystems and
is currently under review [330]. Approximately 10%, or 48 of the 518 protein kinases
encoded by the human genome, lack at least one of three catalytic amino acid motifs in
the kinase domain, including the Val-Ala-Ile-Lys (VAIK) motif in subdomain II, in
which the lysine residue facilitates the positioning of the ATP molecule, the His-Arg-Asp
(HRD) motif in subdomain VIb, which contains the catalytic aspartic acid residue
responsible for deprotonating the substrate hydroxyl group, and the Asp-Phe-Gly (DFG)
motif in the A-loop, which contains the Mg2+-coordinating aspartic acid residue that
orients the β and γ phosphates of ATP [4, 331]. These kinases, termed „pseudokinases,‟
are therefore commonly regarded as catalytically inactive. However, not all kinase
domains that lack one or more of the conserved catalytic motifs are inactive. The kinase
WNK1 is catalytically active despite lacking the crucial lysine in its VAIK motif, as a
lysine residue in subdomain I performs the function of the missing amino acid [332]. In a
recent structural and biochemical study, Mukherjee et al. [333] resolved the crystal
structure of the pseudokinase domain of Ca2+/calmodulin-activated serine threonine
kinase (CASK), which lacks both of the canonical Mg2+-coordinating residues, and
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determined that CASK employs an unusual phosphorylation mechanism in which the
kinase preferentially binds unchelated nucleotides, and is hence capable of catalyzing
phosphotransfer despite lacking the conserved DFG motif. It is therefore plausible that
other pseudokinases are not truly inactive, but may employ alternative modes of ATP
binding and phosphoryl transfer.

In the ErbB family of receptor tyrosine kinases (RTKs), which includes epidermal growth
factor receptor (EGFR/ErbB1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4),
ligand binding followed by receptor homo- or heterodimerization performs a crucial role
in regulating critical cellular processes including migration, differentiation, and
proliferation [3, 334, 335]. EGFR, ErbB2, and ErbB4 all observe the canonical
mechanism of phosphate transfer. ErbB3, however, is the only member of the ErbB
family that has long been regarded as an inactive pseudokinase due to amino acid
substitutions in the conserved kinase domain. Until recently, ErbB3 activity has been
largely undermined, as it contains an asparagine residue (N815) in place of the catalytic
aspartic acid residue that is responsible for deprotonating the substrate hydroxyl group
[336]. In addition, a crucial glutamate residue in the αC helix, which indirectly
participates in ATP-binding, is replaced by a histidine (H740) in ErbB3. Hence it has
been widely believed that ErbB3 is dependent on interactions with the other active ErbB
receptors for its biological activity.
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However, it was recently demonstrated that ErbB3 does, in fact, exhibit robust residual
kinase activity that may be crucial for ErbB signaling. Two recent studies by Jura et al.
[43] and Shi et al. [337] resolved the crystal structure of the ErbB3 kinase domain,
revealing an inactive-like conformation. In addition, Shi et al. [337] demonstrated that,
when clustered at a membrane surface, the purified ErbB3 intracellular domain is capable
of robust autophosphorylation, albeit at a level 1000-fold weaker than the active EGFR
kinase, and that the kinase domain binds ATP with an affinity similar to that of other
active kinases. In the same study [337], our quantum mechanics/molecular mechanics
(QM/MM) simulations suggested that ErbB3 may catalyze phosphoryl transfer from its
inactive-like kinase conformation via an alternative pathway, which explains the 1000fold slower rate of phosphoryl transfer in ErbB3 compared to EGFR: the alternative
pathway involves the migration of the substrate tyrosyl –OH proton directly to the O1γ
oxygen of ATP, hence obviating the requirement for the catalytic aspartate residue. Our
study suggests the intriguing possibility that therapeutic targeting of the robust activity of
ErbB3, rather than the routinely-targeted EGFR and ErbB2 kinases, may provide a more
effective treatment strategy for certain ErbB-driven cancers. However, a major question
arising from our work is: what is the physiological relevance, if any, of weak ErbB3
activity to ErbB signaling in the cell?

This question is clinically pertinent as over-expression and activating mutations of the
ErbB kinases are implicated in cellular transformation and clinical malignancies
including lung and breast cancers [49, 338-342]. Recent studies have demonstrated that
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mechanisms of resistance to tyrosine kinase inhibition (TKI) of EGFR and possibly
ErbB2 in the treatment of certain human malignancies are mediated by ErbB3 [343-346].
In this scenario, it is hypothesized that incomplete inhibition of ErbB2 catalytic activity
restores phosphorylation of ErbB3 in the context of ErbB2/3 heterodimers. As ErbB3
contains six PI3K-binding sites in its C-tail, leaky ErbB3 phosphorylation induces
proliferative signaling through the PI3K-AKT pathway [343]. However, the detailed
molecular mechanism of this process remains an open question. Indeed, it is possible that
ErbB3 catalytic activity is involved in the TKI resistance mechanism.

To explore the implications of ErbB3 activity for ErbB signaling and TKI resistance, a
multiscale modeling approach is advantageous. Multiscale computational modeling has
been applied to a variety of biological systems [347-351] to help quantify the complexity
inherent in intracellular signaling networks. As the biochemical processes within a cell
occur on multiple spatial and temporal scales, a multiscale modeling approach is
necessary to represent a hierarchy of interactions ranging from the molecular (nm, ns) to
cellular signaling (μm, ms) length and time scales. Multiscale modeling provides a
powerful and quantitative methodology for studying the effect of molecular
perturbations, in our case, ErbB3 catalytic activity, on downstream signaling events, i.e.,
the ErbB signaling network and development of TKI resistance.

In light of the implication of ErbB3 in TKI resistance mechanisms, the recent interest in
catalytic mechanisms of pseudokinases and particularly in the potential for ErbB3
104

activity demonstrated by Shi et al. [337], we pursue a multiscale modeling study of the
ErbB3 kinase system at the molecular and cellular levels. A variety of modeling
techniques, ranging from atomic-level molecular dynamics (MD) simulations to systemslevel modeling, are applied to investigate the non-canonical catalytic mechanism
employed by the ErbB3 kinase and the physiological relevance of this activity to
mechanisms of drug resistance in an ErbB-driven tumor cell in silico. Here we discuss
the results of our MD simulations which suggest that the assembly of the catalytic site in
ErbB3 is achieved through a unique network of hydrophobic interactions, in contrast to
the extensive set of hydrogen bonds present in the active sites of the other ErbB kinases,
and thus the ErbB kinases may have evolved two different modes of achieving the shared
goal of prearranging the catalytic machinery for phosphoryl transfer.

For how the

homology modeling techniques feed into MD simulations as well as the investigation of
the molecular level simulation affecting the cell signaling networks, see sections 7.1 and
7.3, respectively.

5.2) Results

5.2.1) PCA reveals that the sub-domain motions of ErbB3 diverge from those of an
inactive ErbB kinase

To determine whether the ErbB3 kinase behaves similarly to its ErbB family members at
the atomic level, we performed 10 ns molecular dynamics (MD) simulations of the ErbB3
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crystal structure (PDB code 3LMG) [337]. The ErbB3 structure was stable for the
duration of the simulation, as indicated by the time-course plots of the RMSD of the
backbone atoms (Fig. 5.1). Principal component analysis (PCA) was applied to the 10 ns
trajectory to characterize the most significant global motions of the ErbB3 kinase. The
PCA calculation is based on the diagonalization of the variance-covariance matrix of the
atomic fluctuations along the MD trajectory to yield the set of eigenvectors (PCs) and
associated eigenvalues. The eigenvectors represent the independent modes of atomic
motion, and the eigenvalues reflect the contribution of the corresponding eigenvectors to
the global fluctuation of the protein.

Figure 5.1. Molecular dynamics time course plots of the RMSD for (A) the
backbone atoms of the ErbB3 kinase, (B) the backbone atoms of the A-loop
and (C) the backbone atoms of the αC helix. The RMSD is plotted in
reference to the initial (unsimulated) structure (red) as well as the active
EGFR structure (black), for reference.
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Figure 5.2: Motion along the first principal component of the MD trajectory
is illustrated for the complete ErbB3 kinase and compared to the active and
inactive conformations of EGFR, ErbB2 and ErbB4. The structures are colorcoded according to the RMSD, where red regions indicate large-amplitude
fluctuations and blue regions indicate small-amplitude fluctuations. The Aloop and αC helix are highlighted in green for structural reference. Overall,
the global motions are conserved across the ErbB family members.

Motion along the first eigenmode for the complete ErbB3 kinase was compared to PCA
trajectories for the inactive and active conformations of EGFR, ErbB2 and ErbB4 that
had been previously simulated by us [348, 352] (Fig. 5.2); overall the global motions of
the kinases were conserved across the ErbB family members. To determine whether the
PCA pattern was also conserved in ErbB3‟s unique active site region, we applied PCA to
an active site region which included the A-, C-, and N-loops and the αC helix. Figure 5.3
illustrates that motion along the first eigenmode in the inactive EGFR, ErbB2 and ErbB4
systems is dominated by A-loop movement, with smaller fluctuations in the other
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catalytic sub-domains, whereas the active ErbB systems exhibit a uniform level of motion
across the sub-domains, with lower-amplitude fluctuations. Despite the crystallization of
the ErbB3 kinase in an inactive-like conformation, the PCA pattern in ErbB3 appears to
diverge from that of the other inactive ErbB kinases and instead resembles that of the
active ErbB kinases, in terms of its concerted and low-amplitude sub-domain
fluctuations. We reason that the interactions among the A-, C-, and N-loops and the αC
helix in the active ErbB systems (i.e., active EGFR, ErbB2 and ErbB4, and weakly-active
ErbB3) are crucial for alignment of the key sub-domains for catalysis. Consistent with
this view, our PCA demonstrates that at the atomic level, the sub-domain motions of the
ErbB3 system deviate from those of an inactive ErbB kinase.

Figure 5.3. Motion along the first principal component of the MD trajectory
is illustrated for ErbB3 and compared to the active and inactive
conformations of EGFR, ErbB2 and ErbB4 focused on the active site. The
structures are color-coded according to the RMSD, where red regions
indicate large-amplitude fluctuations and blue regions indicate smallamplitude fluctuations. Despite the crystallization of the ErbB3 kinase in an
inactive-like conformation, the ErbB3 PCA pattern resembles that of the
active ErbB kinases, in terms of the concerted and low-amplitude fluctuations
of its catalytic sub-domains.
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5.2.2) Hydrogen bonding analysis indicates a lack of conserved hydrophilic
interactions in the ErbB3 catalytic site

To identify specific interactions that could be contributing to the distinct pattern of global
motion in the ErbB3 kinase in the inactive-like conformation, individual salt bridges and
hydrogen bonds were tabulated for the ErbB3 system through a hydrogen-bonding
analysis of the 10 ns MD trajectory (Table 5.1a&b) and compared to the bonds present in
the other ErbB systems [348, 352]. The major difference that we observed between the
inactive and active ErbB systems is a significantly greater number of bonds that couple
the catalytic sub-domains of the kinases in the active systems compared to the inactive
systems. Table 5.1a&b highlights several of these bonds (EGFR numbering will be used
here): E734-K851 is a key salt bridge which couples the A-loop and αC helix and is
conserved across the active conformations of EGFR, ErbB2 and ErbB4, and the L834R812 and K836-V810 bonds bridge the A-loop and C-loop to maintain the A-loop in its
extended, active conformation. We hypothesize that the tight coupling of the subdomains in the active ErbB systems may help to correctly position the catalytic residues
during assembly of the active site for phosphoryl transfer [352].

By contrast, the bonding pattern in ErbB3 is distinct from the active and inactive states of
its ErbB family members in its scarcity of hydrogen bonds (Table 5.1a&b). ErbB3 lacks
many of the bonds present in the other ErbB kinases due to substitutions in its amino acid
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EGFR
active

ErbB2
active

ErbB4
active

EGFR
inactive

ErbB2
inactive

ErbB3
Inactive

ErbB4
inactive

aC-helix A-loop bonds
––

––

––

––

––

––

E739,R841

E734,K851

E766,K883

E739,K856

––

––

––

––

D737,K836

D769,R868

––

––

––

––

D742,R841

E738,F832

––

E743,F837

––

––

––

––

––

––

––

E738,K836

––

––

E743,R841

––

––

––

––

E743,R817

aC-helix C-loop bonds
––
––
A-loop C-loop bonds
––

––

––

––

G865,V842

––

––

––

––

––

––

––

––

G838,R817

L834,R812

L866,R844

L839,R817

––

––

––

––

––

––

––

L834,D813

––

––

––

K836,V810

R868,V842

R841,V815

––

––

––

––

––

––

––

––

––

––

––

––

D838,R814
––

––

––
E848,R812
––
––
C-loop C-loop bonds

––

K851,R812

––

––

––

––

––

H843,D845

––

––

––

H813,N815

––

––

––

––

R812,D813

R844,D845

––

––

D813,R817

D845,R849

D818,R822

––

––

––

––

D813,N818

––

––

––

––

N815,N820

––

A815,N818

A847,N850

A820,N823

A815,N818

A847,N850

A817,N820

––

––

A848,V851

––

––

––

––

––

Table 5.1a: Hydrogen bonding analysis of the ErbB3 MD trajectory and
comparison to the active and inactive conformations of EGFR, ErbB2 and
ErbB4. ErbB3 lacks many of the conserved bonds present in the active
EGFR, ErbB2 and ErbB4 structures. The characteristic active bonds are
highlighted in green and the sequestering bonds are highlighted in yellow.
See also Table 5.1b
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EGFR
ErbB2
active
active
A-loop bonds

ErbB4
active

EGFR
inactive

ErbB2
inactive

ErbB3
Inactive

ErbB4
inactive

––

––

D836,K726

––

D863,K753

D833,K723

D836,K726

––

––

D836,T835

––

––

––

––

L838,R808

L870,R840

L843,R813

––

––

––

––

––

D871,R840

––

––

––

––

––

A840,G672

––

––

––

––

––

––

––

––

––

––

D873,R897

––

––

––

––

––

––

––

––

K848,T873

––

––

D844,K853
––

––

––
K843,D932
––

––

K848,D937

––

––

––

––

E876,R898

––

––

––

––

––

––

––

E849,K871

––

––

––

––

Y845,Y867

––

Y850,F872

––

––

––

––

––

––

––

H846,R865

––

––

––

––

––

––

––

––

K845,E851

––

––

––

A852,R870

––

––

––

––

––

D853,R870
––

E848,R865
––

D880,R897
––

––

––

D880,R897
––

––

D853,R870
G855,E730

––

––

––

––

K883,E757

––

––

––

––

––

––

––

––

K856,E844

––

A763,S760

––

––

––

––

––

––

E766,R756

––

––

––

––

––

E738,K721

E770,K753

E743,K726

––

––

––

––

––

––

––

M742,L753

M774,L785

––

M747,L758

A743,L679

––

A748,Q684

––

––

––

––

––

––

––

––

––

––

A748,R757

––

aC-helix bonds

Table 5.1b: Hydrogen bonding analysis of the ErbB3 MD trajectory and
comparison to the active and inactive conformations of EGFR, ErbB2 and
ErbB4. ErbB3 lacks many of the conserved bonds present in the active
EGFR, ErbB2 and ErbB4 structures. The characteristic active bonds are
highlighted in green and the sequestering bonds are highlighted in yellow.
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sequence: E738 (EGFR numbering), which coordinates the α and β phosphates of ATP
by forming a salt bridge with K721 in the αC helix, is mutated to a His in ErbB3. In
addition, E734, which couples the A-loop and αC helix by bonding to K851, is an Ala in
ErbB3. The few bonds that are present in ErbB3 help to maintain its distinctive active
site: the D838-R814 bond, which bridges the 310 helix and the C-loop in ErbB3, does not
appear in the other ErbB kinases. ErbB3‟s unique hydrogen bonding network (or lack
thereof) suggests that the molecular mechanism of catalysis in ErbB3 is distinct from that
operating in EGFR, ErbB2 and ErbB4.

5.2.3) Hydrophobic analysis of the ErbB kinases identifies a perturbation-sensitive
region in ErbB3

In the active conformation, EGFR, ErbB2 and ErbB4 rely on an extensive network of
hydrophilic interactions to maintain their active sites in a catalytically competent state,
whereas the inactive conformations exhibit characteristic hydrophobic interactions, a
feature that helps to differentiate the inactive and active states. In ErbB-mediated
signaling, the introduction of the ErbB dimer interface alters the hydrophobicity of the
region and, in conjunction with allosteric effects, perturbs the conformational sampling
space of the protein to induce a shift toward the active conformation [297, 353, 354].

To quantify these hydrophobic interactions, we computed the solvent accessible surface
area (SASA) and water density fluctuations (see Methods, section 5.4) for the ErbB3 MD
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trajectory and compared the results to the EGFR, ErbB2 and ErbB4 trajectories
previously simulated by us [354]. In particular, we focused on several highly conserved
hydrophobic regions which are considered to be important for defining the catalytic state
of the ErbB kinases [30, 31]: the catalytic spine (C-spine), regulatory spine (R-spine),
hydrophobic core, and β3-αC loop. Figure 5.4 displays the correlation between the mean
SASA and the normalized water density fluctuations for each hydrophobic region in the
inactive and active conformations of each ErbB kinase. The SASA analysis is a reliable
measure of hydrophobicity for smooth hydrophobic interfaces but does not always
correlate perfectly with free energies of solvation of hydrophobic groups near irregular
hydrophobic surfaces, which are often found in proteins. The normalized water density
fluctuation calculation, which quantifies the hydrophobicity of heterogeneous surfaces,
provides an alternative to the SASA analysis and proposes that increased normalized
water density fluctuations signify a more hydrophobic region, where a normalized value
of 1 indicates a neutral surface [320, 321]. Thus the correlation between the SASA and
water density fluctuations produces additional insights into region hydrophobicity that are
not revealed by either analysis independently. Specifically, we have designated four
„quadrants‟ in each correlation subplot (Fig. 5.4A): quadrant II represents a
hydrophilically favorable region, quadrant IV defines a hydrophobically favorable region,
and quadrant I, which is characterized by high SASA (more hydrophilic) and large water
density fluctuations, represents a fragile or perturbation-sensitive region. The quadrants
facilitate the identification of key patterns that may emerge from a comparison of the
hydrophobic interactions in the ErbB systems.
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Figure 5.4: Correlation between the solvent accessible surface area (SASA)
and water density fluctuations in the key hydrophobic regions of the ErbB
kinases: (A) hydrophobic core, (B) β3-αC loop, (C) C-spine and (D) R-spine.
Dark and light markers represent the active and inactive ErbB systems,
respectively. The ErbB kinase systems are represented as follows: EGFR
(square), ErbB2 (circle), ErbB3 (diamond), and ErbB4 (triangle). Quadrant I
represents a perturbation-sensitive region, quadrant II defines a
hydrophilically favorable region, and quadrant IV represents a
hydrophobically favorable region.

The ErbB2 system, in general, lies within the hydrophobically favorable region (quadrant
IV), which may be rationalized in terms of ErbB2‟s unique ability to bind the molecular
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chaperone Hsp90 through a hydrophobic interface, a point that is elaborated in our
previous studies [352, 354]. In the hydrophobic core, which includes segments of the αC
helix and the A-loop and helps to maintain the ErbB kinases in the inactive conformation
[30, 31], ErbB3 demonstrates characteristic hydrophobic interactions that are similar to
the inactive EGFR and ErbB4 systems. Fig. 5.4A illustrates that ErbB3, as well as the
inactive EGFR and ErbB4 systems, lies within the „perturbation-sensitive‟ quadrant,
indicating that the hydrophobic core is a potential fragile point of the protein, in which
single point mutants would be expected to disrupt the local interactions. Indeed, it has
been reported that mutations in the hydrophobic core of EGFR and ErbB4 result in
activation of the kinase, due to destabilization of the inactive state [337]. By contrast, an
analogous mutation in ErbB3 abolishes ATP-binding and phosphorylation activity [337],
indicating that hydrophobic interactions in the core promote ErbB3 activity, rather than
maintain an autoinhibited state as they do in EGFR and ErbB4. Furthermore, the β3-αC
loop, which is uniquely extended in ErbB3 and lies proximal to the hydrophobic core,
represents a perturbation-sensitive node in ErbB3 (Fig. 5.4B). Thus mutations in this
region would also be expected to inactivate the ErbB3 kinase. Our results support the
conclusion that ErbB3 critically depends on a coordinated set of hydrophobic interactions
for its weak yet robust activity from the inactive-like conformation, whereas EGFR and
ErbB4 employ similar interactions to maintain their autoinhibited status from the
inactive-like conformation. We propose that these hydrophobic contacts, including the
interactions in the β3-αC loop, account for the tightly coordinated sub-domain motions
observed in our PCA analysis of the ErbB3 system, in contrast to the hydrogen bond115

mediated mechanism underlying the coordinated sub-domain motion in the active ErbB
systems.

The hydrophobicity of the C-spine and R-spine, whose function is to coordinate the
motions of the N- and C-lobes of the EGFR and ErbB4 kinases in the active
conformation [30, 31], was also quantified (Fig. 5.4C, D). In the C-spine and R-spine
hydrophobicity plots, the inactive and active conformations of EGFR and ErbB4 are
clearly delineated with respect to the SASA, with the active systems exhibiting a
preferential hydrophobic stabilization (low SASA). The SASA of the ErbB3 C-spine falls
within range of the inactive EGFR and ErbB4 systems, reflecting that, despite its weak
activity, there is no corresponding „fully-active‟ state for ErbB3 as for the other ErbB
kinases. This inability to „fully‟ activate can be attributed to the lack of the crucial
hydrogen bonding network identified earlier, which is required to stabilize the active-like
kinase conformation. The SASA of the ErbB3 R-spine deviates from the values for the
inactive EGFR and ErbB4 systems, and instead demonstrates low SASA (high
hydrophobicity). This result can be rationalized by the increased hydrophobicity of the Rspine, which includes segments of the truncated αC helix in ErbB3, hence positioning the
ErbB3 system in the hydrophobically-favorable quadrant of the R-spine hydrophobicity
plot (Fig. 5.4D).

5.3) Discussion
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In this work we applied a molecular modeling approach to investigate the non-canonical
catalytic mechanism employed by the ErbB kinase ErbB3, a RTK formerly categorized
as an inactive pseudokinase, and the physiological relevance of this activity to
mechanisms of drug resistance in an ErbB-driven tumor cell in silico. At the molecular
level, our results suggest that the prearrangement of the catalytic site in ErbB3 is
achieved through a unique network of hydrophobic interactions, in contrast to the
extensive set of hydrogen bonds present in the active sites of the other ErbB kinases. For
the implications of a weakly active ErbB3 kinase at the cellular level, please see section
7.3.

At the atomic level, our molecular dynamics simulations and PCA analysis of the ErbB3
kinase crystal structure revealed that the ErbB3 system exhibits tightly coordinated
fluctuations of its catalytic sub-domains, which may facilitate the alignment of key
catalytic residues involved in phosphoryl transfer. Despite sharing a pattern of concerted
sub-domain motion with its fully-active ErbB family members, the ErbB3 system
appeared to achieve this state through a unique mechanism, namely, a tightly coordinated
set of hydrophobic contacts. By contrast, an extensive network of hydrophilic interactions
is employed by EGFR, ErbB2 and ErbB4. The hydrogen bonding analysis and
hydrophobicity calculations demonstrated that the conserved hydrophilic contacts present
in the active sites of EGFR, ErbB2 and ErbB4 are replaced in ErbB3 by a unique
hydrophobic interface formed by the extended β3-αC loop, the molten αC helix and the
310 helix in the A-loop [355]. Thus our atomic-level simulations suggest that the ErbB
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kinases may have evolved two different modes of achieving the shared goal of
prearranging the catalytic machinery for phosphoryl transfer. For the implications of the
weakly active ErbB3 kinase domains upon the cell signaling networks, especially the Akt
pathway, and its potential role as a TKI resistance mechanism, see section 7.3.

5.4) Methods

Molecular dynamics (MD) simulations: The HER3 kinase crystal structure solved in our
previous study (PDB code 3LMG) [356] was prepared for molecular dynamics
simulation according to the procedure outlined in [348, 352]. Briefly, the structure was
explicitly solvated using the TIP3P model for water [357] and with the buffering distance
set to 15 Å. Sodium (Na+) and chloride (Cl-) ions were added to achieve net
electroneutrality of the system and an ionic strength of 75 mM. The ions were positioned
at points of electrostatic extrema using a Debye-Huckel potential calculated within the
program Solvate 1.0 [358]. All simulations were performed with NAMD [359] using
CHARMM27 force-field parameters. To prepare the system for MD simulation, the
solvated structure was energy-minimized using a conjugate gradient algorithm to remove
unfavorable contacts. The system was then heated to 300 K using the temperature
reassignment method in NAMD. Constant pressure and temperature (NPT) simulations
were performed at 300 K and 1 atm to equilibrate the volume of the solvation box.
Temperature and pressure were maintained using a Langevin piston coupling algorithm
[360]. Following the NPT simulations, constant volume and temperature (NVT)
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simulations were performed in NAMD. Finally, a 10 ns production run was completed
using the same parameters as in the NVT simulations.

Hydrogen bonding analysis: CHARMM was used to analyze the hydrogen bonds present
in the 10 ns trajectory for each system according to the procedure outlined in our
previous studies [348, 352]. Hydrogen bonds were defined by a bond length cutoff of 3.4
Å and an angle cutoff of 150º. Bonds that fulfilled these criteria and were present in at
least 60% of the trajectory were tabulated in CHARMM. Salt bridges were defined as
hydrogen bonds occurring between an acidic and a basic residue and satisfying a bond
length cutoff of 1.6 Å. All hydrogen bonds and salt bridges were also visualized in VMD
[361] for the duration of the 10 ns simulation.

Principal component analysis: A principal component analysis (PCA) was applied to the
10 ns trajectory to identify the main eigenvectors (3N directions) along which the
majority of the complex motion is defined. The calculation is based on the
diagonalization of the variance-covariance matrix of the atomic fluctuations along each
MD trajectory to yield the set of eigenvectors (PCs) and associated eigenvalues. The
eigenvectors represent the independent modes of atomic motion, and the eigenvalues
reflect the contribution of the corresponding eigenvectors to the global fluctuation of the
protein. PCA computes the covariance matrix as

 ij  ( xi   xi )( x j   x j  )
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where (i,j=1,…,3N), and N is the total number of atoms with positions given by Cartesian
coordinates x. The resulting matrix is diagonalized to compute the 3N independent
(uncorrelated) eigenvectors, {ξi}, and the eigenvalues, {λi}, sorted in descending order.
The angle brackets denote the time average over the entire trajectory. PCA was
performed on the entire protein backbone (i.e. all C atoms), and also an active site
region that comprises all catalytic sub-domains, including the A-, C-, and N-loops and the
αC helix. The program CARMA [362] was used to project the atomic fluctuations along
the MD trajectory.

Solvent accessible surface area (SASA) and water density fluctuation analysis: SASA
values were calculated in VMD [361] using the measure SASA module with a probe
radius 1.4 Å larger than the van der Waals radius. The SASA was calculated for each step
in the trajectory, from which the mean and standard deviation were computed. As an
alternative measure of hydrophobicity in heterogeneous environments, following the
procedure established in [320, 321], normalized water density fluctuations were
computed by recording the ratio of σN/N, where σN and N are the standard deviation
and mean associated with the number of water molecules within 5 Å of a specified
hydrophobic sub-region in the HER3 kinase. Although results are presented for a cutoff
of 5 Å, other cutoffs ranging from 3-15 Å were investigated and similar trends in σN/N
were recorded.
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Chapter 6.) Future Work

RTKs are pieces of molecular machinery important in normal cell function and the
disregulation of which leads to disease states, particularly cancer. Understanding the
activation mechanisms allows a better regulation of the RTKs and in turn offers better
therapeutic options.

Computational methods provide a unique perspective in

understanding activation at the atomic level by allowing us to construct, visualize and
analyze multiple proteins as they move in a physiologically relevant environment. Also
by constructing the proteins in different conformations as well as using directed
simulation techniques it is possible to observe the proteins as they function, offering a
wealth of information into their molecular mechanisms. In this thesis we have examined
how hydrophilic and hydrophobic interaction networks help the activation mechanisms of
the ErbB family kinases using molecular dynamics simulation techniques. Still, there is
much to learn about the ErbB kinases, not to mention the rest of the RTKs. Future work
presented here is either wide-spread application of the techniques used here across the
entire kinase domain and full-length RTK, improving the techniques used here to allow
easier translation of the results to different scales or methodological improvements to
capture rare events.

We have presented a method to examine hydrophilic/hydrophobic interaction networks
and shown their importance in kinase activation by comparing the results across
homologous proteins. To reduce the computational burden and ensure validated results,
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we focused on subregions shown previously to be biologically relevant. The active
kinase domains are highly conserved structurally, so by expanding the scope of the
analysis to the entire intracellular kinase domain, it would be possible to highlight
hydrophilically and hydrophobically important residues and regions not explicitly
observed through experiments. The hydrophobic interaction analysis can be automated
especially with the normalized water density fluctuations in conjunction with the Solvent
Accessible Surface Area to provide regions that are hydrophobically sensitive, giving
potential mutational hotspots. Similarly, the hydrophilic interaction analysis with a wider
focus would provide a larger list of bonds and by comparing the lists across the ErbB
family a characteristic network of bonds through the entire kinase can be highlighted.

Refinement of the interaction network analysis gives a better picture of the atomic level
characteristics of each protein.

The hydrophilic interaction analysis can be refined

beyond mean survival time and mean bond length to observe the bond characteristics
fitted to a statistical distribution. The hypothesis here is the characteristic bonds defining
a conformation would be stronger and therefore have a shifted distribution in comparison
to those that are transient. Since we have already identified sets of bonds important in
each conformation they would serve as a control for the refinement. Characterizing the
hydrophobic stability of a system is difficult and is its own field of research within
computational chemistry.

The normalized water density fluctuation analysis is one

current technique that correlates with hydration free energy. To provide a better analysis
using standard molecular dynamics forcefields, collaborations with groups like the Garde
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group [320, 321] would be necessary so as to not reinvent the wheel. However, once the
method is refined, it would facilitate identifying important subregions significantly easier.

Even though we have employed modern molecular dynamics simulation techniques, there
are still time and length scale limitations in the microseconds and micrometers regime
respectively. Since most of the biological processes exist on milliseconds to minutes to
even longer, simulating for hundreds of years using the same technology would not
breach even the millisecond threshold. However the techniques are constantly improving
and there are two techniques that would offer enormous improvement into both length
and timescales: coarse graining and specialized hardware. Coarse graining groups atoms
together into a functional group and simulates them as one single “atom”. By grouping
atoms, the length scale is enhanced and the smallest vibrational frequency (hydrogen
vibration) is removed so the minimum time step is increased by orders of magnitude.
The currently accepted coarse grain force-field is MARTINI [363] offering simulation
times into microseconds as the norm, with improvements to come. There are also sets of
specialized computer hardware that is designed and tuned to provide a similar speed up
for molecular dynamics simulation while maintaining the same accuracy, particularly
MDGRAPE-3 [158, 159] and ANTON [160, 161]. Extending the simulations would give
access to a wider range of conformational space mapped out and give better ensemble
data as well as allowing us to explicitly capture and analyze rarer events.
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An alternate technique to sample rare events is biased or directed sampling simulations,
which apply a potential to the protein in simulation to transition it to the desired
conformation, usually down the activation pathway (see section 2.2.5). Some of the
techniques reviewed are more complex to explore pathways if the final structure is not
known. However, since there are beginning and ending crystal structures for the EGFR
kinase domain, free energy simulations are a better option (see section 2.2.3). Umbrella
sampling simulations not only transition the protein but also measure the free energy
change necessary for the conformation change. Here we present preliminary results on
Targeted Molecular Dynamics (TMD) simulations performed on monomer and dimer
trajectories of the EGFR kinase domain mapping out the activation pathway in
preparation for umbrella sampling simulations.

6.1) The Asymmetric Dimer Interface achieves Activation through Allosteric Means,
Hydrophilic Interactions and Hydrophobic Shielding

The EGFR kinase is a member of the EGFR/ErbB/HER family of kinases which contain
four homologous Receptor Tyrosine Kinases (RTKs) that are important regulatory
elements in key signaling pathways. RTKs are transmembrane proteins important in
translating extracellular signals (ligands) into intracellular nuclear responses leading to
cell proliferation, differentiation, migration and the cell cycle (reviewed in [1, 2, 18]).
They consist of a large ligand-binding extracellular domain, a single transmembrane αhelix, a juxtamembrane domain, an intracellular tyrosine kinase domain and a C-terminal
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tail that contains several phosphorylatable tyrosines [1, 2]. Considering the cell signaling
pathways it regulates, understanding how the EGFR kinase domain activates is crucial.
Clinically identified activating mutations in the EGFR kinase domain found in NonSmall Cell Lung Cancer (NSCLC) patients have been shown increase the basal activity of
the EGFR kinase domain [26, 27, 48] and respond to the EGFR RTK inhibitor gefitinib
with efficacy rivaling that of chemotherapy [130, 131].

The intracellular kinase domain of RTKs transfers the -phosphate of ATP to tyrosines on
both the RTK itself as well as other target substrates [1]. The active conformations of
kinases are all remarkably similar, with two separate lobes, the  strand-rich N-lobe plus
the α-helix rich C-lobe and the active site situated in the cleft between N-lobe and C-lobe.
There are also several conserved subregions in the RTK kinase domain thought to be
important in regulation of kinase activity: the catalytic loop (C-loop), the activation loop
(A-loop), the glycine-rich nucleotide binding loop (P-loop), and the C-helix.

The

catalytic loop contains the conserved HRD motif, with the aspartate directly participating
in the phosphoryl transfer. The A-loop defined at the start by the DFG motif and the Chelix modulate the activity of the kinase domain by regulating accessibility of the active
site to binding and coordinating both ATP and the substrate tyrosine. The A-loop consists
of approximately 20 amino acids and in the EGFR kinase contains one phosphorylatable
tyrosine (Y845 in EGFR, note: there are two numbering schemes for the EGFR where
Y845 is equivalent to Y869). The C-helix and P-loop must be positioned correctly to
coordinate the ATP and the substrate tyrosine for effective phosphoryl transfer.
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Beyond the structural similarities, recent studies upon the spatial location of nonsequential residues in the kinases have revealed highly conserved hydrophobic “spines”
that are thought to help coordinate the motions of key domains during activity [30, 31].
The regulatory spine (R-spine: M742, L753, H811, F832 in EGFR) helps maintain the
motion of the N- and C-lobes of the kinase [30]. The catalytic spine (C-spine: V702,
A719, L774, V819, L820, V821, T879, L883 in EGFR) helps coordinate the adenine ring
of ATP [31]. In the inactive state there is a small hydrophobic „core‟ formed between the
αC-helix and the A-loop, which when disrupted by single point mutations have been
shown to activate EGFR [25-29].

There have been activation pathway studies done upon the Abl kinase [161] and Src
family kinase Hck [323, 325], but our previous studies on the ErbB family show a
fundamentally different pathway of activation [364].

The Abl kinase inactive

conformation compares well to the active conformation, with a well formed active site
and many of the conserved kinase bonds in place [365]. However the sidechain of the
coordinating aspartate (D381, the D in the conserved DFG motif) is in an “out” position
pointing away from the active site. In the active conformation D381 has flipped into an
“in” position pointing towards the N-lobe, and forms a salt bridge. In the transition
between the two states the αC-helix rotates away from the active site, creating a
hydrophobic pocket at the base of the N-lobe and F382 slips into this pocket causing the
flip of D381. The final step is for the αC-helix to rotate back into its original position.
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The Src family kinase Hck is inactivated by autoinhibitory interactions in the
unphosphorylated A-loop causing steric hindrances to the active site. In addition, there
are SH3 and SH2 domain interactions in the Hck kinase fairly distal to the active site that
result in outwards rotation of the αC-helix and disrupt some conserved active kinase
bonds (reviewed in [366]). Phosphorylation of these regions release their autoinhibitory
interactions allowing full activation of the kinase [233], where the A-loop moves towards
the active state before the αC-helix rotates into its active state [323].

In terms of inactive states, the EGFR kinase domain is more similar to Hck kinase or to
the intermediate state of the Abl kinase, where the αC-helix is rotated out in comparison
to the active state, preventing key bonds from forming. The activation mechanism
though, is not from phosphorylation; the ErbB family is not dependent on
phosphorylation on the A-loop or any part of the intracellular kinase domain for
activation.

Instead, an asymmetric dimer interface similar to that seen in cyclin

dependent kinases serves as the allosteric activation mechanism [41]. In the ErbB family,
the dimer interface is asymmetric; the C-lobe of one kinase, the “activator”, contacts the
N-lobe of the other kinase, the “receiver,” with the asymmetric dimer contacts causing a
conformational change towards the active state through allosteric methods. Our previous
simulations of the asymmetric dimer have shown that introduction of the interface causes
a rearrangement of the αC-helix towards the active state before any motion of the A-loop
[364]. Here we present an analysis of the hydrophilic and hydrophobic interaction
networks of catalytically important subdomains as the EGFR kinase progresses through
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the activation pathway in both the monomer and dimer states to elucidate the precise
mechanisms of the allosteric, activating asymmetric dimer interface.

6.2) Preliminary Results

6.2.1) RMSD Analysis Reveals the Activation Pathway of the Dimer is Distinct from
the Monomer

Figure 6.1: RMSD plots tracking the progression of the targeted molecular
dynamics of the dimer (green squares) and the monomer (blue circles)
simulation down the activation pathway for the (A) combined A-loop and
αC-helix as well as the (B) A-loop alone and (C) the αC-helix alone.

The RMSD calculation of the TMD trajectory in both the monomer and dimer shows a
complete capture of the pathway between the inactive and active conformations (Figure
6.1). The predominant motions involved in the reorganization of the active site involved
the αC-helix and A-loop without much motion in the P-loop of C-loop, so we focused
upon the motions of the αC-helix and A-loop as the reaction coordinates.
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In the

monomer TMD dynamics, the simulations run through a fairly linear pathway from the
inactive to the active states in the A-loop and αC-helix, with the A-loop transitioning
from a closed conformation over the C-loop to laying open within the N-lobe and C-lobe
as well as the αC-helix rotating in and extending the helical conformation. There is a
small section at the end of the simulation for the αC-helix (Figure 6.1C), starting at 6Å
from the inactive and 2Å from the active, that deviates from this path, which is associated
with the extension of the αC-helix. The dimer TMD simulations also follow a fairly linear
path mapping from inactive to active and seem to align remarkably well with monomer
simulations, but without the small non-linearity at the end of the simulation seen in the
monomer for the αC-helix. However the reference structures for the dimer TMD are the
equilibrated dimer conformations. Marked on Figure 6.1 are black X‟s as the starting
point of the dimer simulations using the equilibrated monomer structures and red X‟s as
the end point of the dimer simulations using the same structures. Although the pathways
in the monomer and dimer are very similar, there is shift in the pathway because of the
introduction of the asymmetric dimer interface, particularly in the αC-helix (Figure
6.1C).

6.2.2) Interkinase Salt Bridges Alter the Conformation of the αC-helix and Promote
Partial Extension

We have previously identified several bonds that are conserved across the canonical
kinase members of the ErbB family in the active state: two salt bridges: E734-K851
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(E734-K836 in the dimer) and E738-K721, three H-bonds: L834-R812, K836-V810, and
L838-R808 and the bond D813-R817 [298, 364]. The D813-R817 bond helps position
the aspartate side chain in proper orientation for phosphotransfer. The E738-K721 salt
bridge is highly conserved across all active kinases and helps coordinate the phosphates
in ATP. The E734-K851 salt bridge connects the A-loop and the αC-helix, coordinating
the movements of these two sub-domains and dampening larger fluctuations. Similarly,
the three conserved H-bonds link the A-loop and the C-loop, coupling the motions of
these two loops. These can be regarded as “fastening” H-bonds that maintain the Nterminal side of the A-loop open in its active state. The inactive bond network is less
extensive and not well conserved, but in EGFR the E738-K836 salt bridge sequesters
residues in the key E738-K721 salt bridge thereby preventing activation by keeping the
salt bridge from forming.

The transition between the E738-K836 salt bridge and the formation of the E738-K721
salt bridge is a crucial one for activity of the kinase. However previous TMD studies of
EGFR have seen the two events happen almost simultaneously [311, 364]. To better
resolve the pathway and the interaction networks of the monomer and dimer simulations,
we broke up each TMD pathway simulation into smaller windows of 10 ns a piece (5
windows for the monomer and 6 windows for the dimer) and performed the interaction
network analysis on each window independently.

The hydrophilic bond networks

between the monomer and the dimer simulations are fairly similar (Table 6.1a&b and
Appendix B).
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EGFR
Dimer
Inactive
Window 1
aC-helix A-loop bond
––

––

Window 2

Window 3

Window 4

Window 5

Window 6

EGFR
Dimer
Active

––

––

––

––

E734,K836

E734,K836

––

––

––

––

––

––

––

D737,K836

E738,F832

E738,F832

E738,F832

E738,F832

E738,F832

E738,F832

E738,F832

––

E738,G833

E738,G833

E738,G833

E738,G833

––

E738,G833

––

––

E738,K836 E738,K836
aC-helix bonds

E738,K836

E738,K836

E738,K836

E738,K836

––

––

––

––

––

––

––

N732,V762

––

––

––

––

––

––

––

––

E738,K721

E738,K721

M742,L753

M742,L753

M742,L753

M742,L753

––

––

––

––

––

A743,R752

A743,R752

––

––

––

––

––
T830,N818

A-loop C-loop bonds
––

T830,N818

T830,N818

T830,N818

T830,N818

T830,N818

––

D831,N818

D831,N818

D831,N818

D831,N818

D831,N818

D831,N818

––

––

––

––

––

––

––

––

––

L834,R812

––

L834,D813

L834,D813

––

L834,D813

L834,D813

L834,D813

––

––

––

––

––

––

––

K836,V810

K836,V810

––

––

––

––

––

––

––

––

––

––

––

––

––

––

––

––

D831,K721

D831,K721

D831,K721

D831,K721

––

––

––

D831,K721

––

––

––

––

––

––

––

L838,R808

A-loop bonds

Table 6.1a: Persistent H-bonds and salt bridges in the EGFR kinase dimer
system as it progresses from inactive to active with the salt bridges in bold,
and bonds consistently present but not considered persistent in grey.
Characteristic inactive bonds are boxed in orange while characteristic active
bonds are boxed in green. The common bonds between the monomer and
dimer break and form in a similar timeframe; see Table 6.1b.

In the monomer and dimer the sequestering salt bridge E738-K836 breaks in a similar
position in the pathway, the E738-K836 is weakened severely in window 4 in the
monomer and broken between window 4 and window 5, while in the dimer the salt bridge
is broken between window 5 and window 6. After the E738-K836 salt bridge is broken
we see the beginning of formation of the characteristic active kinase salt bridge E738131

K721 weakly in the penultimate window in both the monomer and the dimer which
finalizes once the kinase completes its transition to active. All of the fastening bonds
seen in the ErbB active kinases do not appear in the monomer or the dimer simulations
until the active conformation is fully achieved, except for K836-V810 that appears in
window 6 in the dimer.

EGFR
Monomer
Inactive

Window 1

Window 2

Window 3

Window 4

Window 5

EGFR
Monomer
Active

aC-helix A-loop bonds
––

––

––

––

––

E734,K851

E734,K851

––

––

––

––

––

D737,K836

D737,K836

––

––

––

––

––

E738,F832

E738,F832

––

––

––

––

––

E738,G833

––

E738,K836

E738,K836

E738,K836

E738,K836

E738,K836

––

––

––

––

––

––

––

––

aC-helix bonds
––
––

––

––

––

––

E738,K721

E738,K721

M742,L753

M742,L753

M742,L753

M742,L753

M742,L753

M742,L753

––

––
A743,R752
A-loop C-loop bonds

A743,R752

A743,R752

A743,R752

––

A743,L679

T830,N818

T830,N818

T830,N818

T830,N818

T830,N818

––

T830,N818

––

––

––

D831,N818

D831,N818

D831,N818

––

––

––

––

––

––

––

L834,R812

L834,D813

L834,D813

L834,D813

L834,D813

––

––

––

––

––

––

––

––

––

K836,V810

––

––

––

––

––

––

E848,R812

––

––

K851,R812

K851,R812

––

––

––

D831,K721

D831,K721

––

––

––

––

––

––

––

––

––

––

L838,R808

K851,R812
A-loop bonds

Table 6.1b: Persistent H-bonds and salt bridges in the EGFR kinase
monomer system as it progresses from inactive to active with the salt bridges
in bold and bonds consistently present but not considered persistent in grey.
Characteristic inactive bonds are boxed in blue while characteristic active
bonds are boxed in red. The common bonds between the monomer and
dimer break and form in a similar timeframe.
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EGFR
Dimer
Inactive
Window 1
A-loop Interdimer bonds
––

––

EGFR
Dimer
Active

Window 2

Window 3

Window 4

Window 5

Window 6

––

––

E841,R949

E841,R949

––

––

––

––

––

––

––

––

––

––

––
––

aC-helix interdimer bond
P729,K925

P729,K925

K730,E939

K730,E939

K730,E939

K730,E939

K730,E939

K733,D918

K733,D918

––

K733,D918

K733,D918

––

––

––

––

––

––

––

K733,E943

––

––

––

––

––

––

––

––

––

Y740,D918

Table 6.2: Persistent H-bonds and salt bridges between kinase domains in the
EGFR kinase dimer systems as it progresses from inactive to active. The salt
bridges are in bold and bonds consistently present but not considered
persistent in grey. Important salt bridges are boxed in purple.

The main differences in the hydrophilic bond networks between the monomer and dimer
simulations are those formed between the two kinase molecules which can only be
present in the dimer simulations and not in the monomer simulations (Table 6.2). In the
inactive dimer, we see the formation of three inter dimer bonds, the P729-K925 H-bond
plus the K730-E939 and the K733-D918 salt bridges. All of these residues are at the tip
of the αC-helix and help alter the conformation of the helix in the dimer into a partial
extension as the simulation progresses (Figure 6.2C). These bonds are all broken by the
fifth window and only one H-bond Y740-D918 is present in the active conformation,
which is near the end of the αC-helix. Between the inactive and active conformations
(window 4 and window 5) we see the formation of two transient bonds which are not
present in either the inactive and active conformations: the salt bridge E841-R949 and the
H-bond K733-E943. The E841 residue is in the middle of the A-loop and forms a salt
bridge E841-K843 which makes a small curl within the A-loop in the inactive kinase
simulations (Appendix B) of both the monomer and the dimer systems and the K733
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bond is at the tip of the αC-helix. There is overlap in the salt bridges in the αC-helix and
the A-loop opening salt bridge in window 4, which may indicate a potential intermediate
state.

Figure 6.2: Order of events as they occur for the dimer simulations with
enhanced views of the active site; the αC-helix is in green, A-loop is in
orange, and the C-loop is in red. (A) The inactive monomer alone (B)
introduction of the asymmetric dimer and formation of the K730-E939 and
K733-E939 salt bridges (C) partial extension of the αC-helix in dimer (green)
not present in monomer (blue) (D) formation of the E841-R949 salt bridge
keeping the A-loop partially open and presents a potential “active”
intermediate state (E) full extension of the αC-helix.

6.2.3) The Dimer Interface Shields the “Receiver” Kinase from Hydrophobic Effects
during the Transition to Active
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To investigate the effect of hydrophobic interactions as the EGFR kinase transitions
between the monomer and dimer, we analyzed the water density fluctuations as well as
the solvent accessible surface area (SASA). The hydrophobicity of a sub-region is a nonadditive quantity, where the primary structure and the surrounding environment both
affect the overall hydrophobicity. Recent studies by Garde et al. [320, 321] have shown
quantifying the hydrophobicity of heterogeneous surfaces using water density
fluctuations correlates with hydration free energy: increased water density fluctuations
are signature of a more hydrophobic surface. We have normalized the water density
fluctuations so that a neutral surface is at a value of one. Plotting the normalized water
density fluctuations versus SASA allows us to divide the plot into four quadrants labeled
on Figure 6.3A. Quadrant I represents a hydrophilically favorable region with low
hydrophobicity and high SASA, quadrant IV represents a hydrophobically favorable
region with high hydrophobicity and low SASA and quadrant II represents a fragile or
perturbation sensitive region with high hydrophobicity but also with a high SASA.

We analyzed the effects of hydrophobic interactions of relevant hydrophobic sub-regions,
namely the dimer interface (Figure 6.3A) the hydrophobic core (Figure 6.3B) the R-spine
(Figure 6.3C) and the C-spine (Figure 6.3D) for each simulation: dimer (green border)
and monomer (black border) progress from the inactive (white filled squares) to active
(black filled squares); each window is connected sequentially with dotted lines on Figure
6.3. The asymmetric dimer helps shields the effects of hydrophobicity by minimizing the
SASA in comparison to the monomer in particular to the dimer interface (mean 96.4 Å2
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Figure 6.3: Hydrophobic plots of the solvent accessible surface area (SASA)
versus normalized water density fluctuations in the key hydrophobic regions
of the ErbB kinases: (A) Dimer Interface (B) Hydrophobic Core (C) R-spine
and (D) C-spine. The edge colors represent monomer (black) and dimer
(green) systems. The shape internal color represents active (black) and
inactive (white), with the gradient between the two a progressive step.
in the dimer vs. mean 277.8 Å2 in the monomer), but also the hydrophobic core (mean
481.6 Å2 in the dimer vs. mean 540.7 Å2 in the monomer) and the R-spine (mean 108.3
Å2 in the dimer vs. mean 155.7 Å2 in the monomer). The C-spine is more exposed (722.4
Å2 in the dimer vs. 611.9 Å2 in the monomer) in the dimer during the transition, but the
C-spine is thought to help coordinate ATP by providing a hydrophobic environment for
the adenine ring that is not present in the simulation.

The monomer simulations‟

hydrophobic path progresses through the perturbation sensitive regions whereas the dimer
path tends to sit in the hydrophobically stable regions, excepting the C-spine, indicating
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the dimer helps shield from any negative hydrophobic interactions, to ease the transition
to active. We present the idea of the path length of the normalized water density with
SASA as a measure of the rearrangement (protein and environmental) necessary for the
change in hydrophobicity, with a lower path length representing an easier transition. The
SASA was normalized so that the SASA and normalized water density each had equal
contribution to the path lengths. The dimer simulations had a lower mean path length for
the hydrophobic core (0.5703 in the dimer vs. 1.2954 in the monomer) dimer interface
(0.2773 in the dimer vs. 0.3842 in the monomer) and the R-spine (0.2773 in the dimer vs.
0.3842 in the monomer). The C-spine had roughly equal mean path length in the dimer
(0.5051) and the monomer (0.4873). The dimer interface then not only reduces the
amount of SASA and time spend in perturbation sensitive regions, but also reduces the
amount of reorganization necessary for the change in hydrophobic interactions.

6.3) Discussion

The fastening bonds do not appear until the active conformation is fully formed and well
defined. This is indicative of the hypothesis that they help maintain a well formed active
site, keeping key loops close together while dampening large fluctuations, and are
necessary for activity but they themselves are not an activating stimulus. The hydrophilic
bond network also helps keep the kinase inactive by sequestering key residues from
forming bonds necessary for kinase activity, the key one being E738-K836 in EGFR.
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The allosteric activation mechanism shown by Zhang et al. [41] moves the αC-helix into
a more active like conformation, and also causing the αC-helix of the dimer to move
down a different pathway in comparison to the monomer in our simulations. The dimer
interface helps promote the active conformations not only allosterically, but also through
hydrophilic and hydrophobic interaction networks. Introduction of the dimer interface
hydrophobically shields the “receiver” kinase in its transition to active while reducing the
amount of reorganization during the transition and promotes several bonds not seen in the
monomer.

As the EGFR kinase transitions between inactive and active because of the dimer
interface, we propose several events occur in a specific order (Figure 6.2): (1) the
introduction of the dimer interface shifts the αC-helix and causes the formation of the
K730-E939 and the K733-D918 salt bridges that help maintain the αC-helix in a partially
“in” conformation (2) the flexible A-loop moves freely until it forms the E841-R949 salt
bridge reducing its motions and keeping the A-loop partially open; which we hypothesize
is an “active” intermediate (3) the E738-K836 salt bridge is broken thereby freeing E738
from sequestration (4) the formation of the conserved active E738-K721 salt bridge (5)
extension of the αC-helix places the αC-helix in the active conformation and allows the
fastening bonds to form, making a well formed and coordinated active site.

We hypothesize the combined effect of the allosteric mechanism as well as the added
hydrophilic bonds from the dimer interface promotes a partially active state, while the
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active kinase needs the formation of the fastening bonds for full activity. These two
states in the pathway fits well into the “three phases” of autophosphorylation in kinase
proposed by Lemmon and Schlessinger [18]. The partially active conformation of the
EGFR dimer represents the “first phase” steps of autophosphorylation in kinase activity
enhancement following a ligand-binding event, where it creates the local increase in
kinase activity. The “first phase” of autophosphorylation in FGFR correlates with a 1050 times increase in kinase activity [367]. A study by Shi et al. showed the ErbB3
kinase, which is missing crucial residues, previously thought to be a dead kinase is still
competent to bind ATP and phosphorylate tyrosines, though at a greatly reduced kinase
activity [337]. Since EGFR is a fully competent kinase, the opening of the active site and
partial alignment of αC-helix potentially increases the kinase activity 10-50 times.

The “second phase” is trans-phosphorylation of its kinase partner‟s tyrosines, in the Cterminal tail as well as in the A-loop to create phosphotyrosine binding sites to recruit
downstream signaling molecular containing Src homology-2 SH2 domains and
phosphotyrosine binding domain PTB containing proteins. Considering the arrangement
of the EGFR asymmetric dimer, the “activator” kinase is in position for phosphorylation
of its C-terminal tail. Recent studies have shown that the FGFR kinase domains also
arrange into an asymmetric dimer, not as an activating stimulus but to phosphorylate
specific tyrosine residues [368]. The “third phase” of autophosphorylation follows the
phosphorylation of the C-terminal tail and increases the kinase activity to 500-1000 times
the basal activity of the kinase. There is evidence that the C-terminal tail in EGFR forms
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autoinhibitory interactions keeping the kinase domain in the inactive conformation [43,
369] with two residues in the start of the C-terminal tail, D960 and E961, forming an
auto-inhibitory interaction with the S787 in the kinase domain [370]. Since the D960 and
E961 are both negatively charged, the added negative charge from phosphorylation of Cterminal tail tyrosines could break the inhibitory interaction in the “activator” kinase and
allowing another increase in kinase activity. The transition into the active conformation
of both kinase domains in the dimer pair, including the formation of the well coordinated
active site through the set of fastening bonds (L834-R812, K836-V810, and L838-R808)
and coordinating bonds (E734-K851/K836, E738-K721 and D813-R817) could represent
the “third phase” activation into a fully active kinase.

In conclusion, our results presented here have helped establish the molecular context the
asymmetric dimer interface has upon the EGFR kinase.

Furthermore, through the

timeline of specific events of activation we have evidence of the formation of a partially
active intermediate that fits in well with the current thoughts of kinase activation via
autophosphorylation. Since ErbB4 and ALK kinase domains have a similar inactive
crystal structures to EGFR, expansion of this methodology to the ErbB4 kinase as well as
the ALK kinase domain and contrasting the results from the EGFR TMD studies would
be interesting to elucidate differences in primary structure and crystal structures affecting
the activation mechanism of each kinase.
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6.4) Methods

Simulation techniques: Models for EGFR kinase monomer and dimer systems in the
inactive conformation were constructed, minimized and equilibrated [364]. Targeted
molecular dynamics (TMD) simulations were performed in NAMD using the RMSD of
the heavy atoms of the αC-helix and the A-loop as the reaction coordinate (χi). The
activation pathway is divided into 5 smaller windows for the monomer and 6 windows
for the dimer. Each window is simulated individually for 10 ns to ensure adequate
sampling. To enhance the sampling of low probability events, a harmonic restraint of
constant k=20 kcal/mol/(Å2) is applied along the reaction coordinate, χi.

Analyses of MD Simulations: Root-mean-squared deviation (RMSD) calculations were
performed using the RMSD tool plugin in VMD by first removing global translation and
rotation, and then computing the RMSD of the selected reaction coordinate (A-loop and
C-helix) relative to a reference structure (the respective active or inactive crystal
structure). An analysis of hydrogen bond (H-bond) patterns in the TMD simulations was
performed using CHARMM in conjunction with VMD similar to previous studies [152,
298, 312, 330]. Solvent accessible surface area (SASA) values and normalized water
density fluctuations were used to measure the hydrophobicity as performed previously
[298, 330]
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Chapter 7.) Perspectives

The molecular dynamics strategies we have presented in this thesis so far have been
exceptionally useful in examining atomic level protein characteristics. While there has
been a lot of controversy on the accuracy of molecular dynamics simulations, the
phenomena we are examining (side chain motions, hydration dynamics and loop and
collective motions) are all within the timescales (nanoseconds) we are simulating (Table
7.1).
Time Scales
short femto to pico
10-15 s – 10-12 s

Length Scales

Event

0.001 Å – 0.1 Å

 bond stretching, angle bending
 constraint dihedral motion

0.1 Å – 10 Å

 surface side chain motion
 loop motion, collective motion
 hydration dynamics

1 Å – 100 Å

 folding in small peptides
 helix coil transition

medium pico to nano
-12

10

-9

s – 10 s

long nano to micro
10-9 s – 10-6 s

very long micro to second
 protein folding
 cellular processes
Table 7.1: Time scales and length scales of common phenomena associated
with protein dynamics.

10-6 s – 1 s+

10 Å – 100 Å

The results we show have a striking correlation in highlighting perturbation sensitive
regions with the regions mutated in clinically identified oncogenic kinase mutations: the
hydrophobic core in the EGFR and ErbB4 kinase domains as well as the αC-β4 region in
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ErbB2 kinase domain. We also have preliminary results resolving the sequence of events
in the activation of the EGFR kinase domain. However, the start of molecular dynamics
simulations is a high resolution crystal structure.

When a crystal structure is not

available, then homology modeling techniques can create a crystal structure with which
to allow simulation as well as providing insights into similarities in primary structure
affecting the crystal structure. Furthermore, by linking together the atomic level protein
fluctuation data we can see the effects of the kinase activity upon the cell signaling
networks. Such a multi-scale model then can not only link kinase domain fluctuations
with signaling effects to help contextualize mutations found in oncogenic cell lines, but
refine therapeutic strategies to target key perturbation sensitive regions of kinase
signaling, at the molecular level as well as the cellular level. Here in this chapter we
review methods and results performed by others in the Radhakrishnan lab that helps link
the MD simulations with the multi-scale model (for an example see Figure 3.1). The
ErbB3 homology (section 7.1) and signaling models (section 7.3) were done by Shannon
Telesco which was submitted to Molecular Biosystems and is under review [330], while
the EGFR signaling models (section 7.2) were performed by Jeremy Purvis and the work
is published in Molecular Biosystems [282].

7.1) Homology modeling of the ErbB3 kinase domain

Given the recently-resolved crystal structure of the ErbB3 kinase domain [337] (as well
as the structure by Jura et al. [43]), we chose to use this structure in our MD simulations.
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However, as the ErbB3 kinase domain shares a relatively high level of sequence identity
with its family members (54%, 55% and 63% identity with EGFR, ErbB2, and ErbB4,
respectively) (Fig. 7.1), we first constructed several homology models of the ErbB3
kinase based on the other ErbB kinase structures and validated them with respect to the
ErbB3 crystal structure, as a verification of our homology modeling method and also as a
means of deriving insights into a structural comparison of the ErbB kinase active sites.
As the crystal structures of the EGFR and ErbB4 kinase domains have been determined
[25, 297, 353], we selected EGFR (PDB code 2GS7) [353] and ErbB4 (PDB code 3BBT)
[297] as templates for homology modeling of the ErbB3 kinase in the inactive-like
conformation. In addition, we applied the multiple templates (MT) algorithm in
MODELLER to generate a ErbB3 kinase model based on a combination of the EGFR and
ErbB4 crystal structures. To verify that EGFR and ErbB4 were the most suitable
templates available for modeling ErbB3, a search was performed in MODELLER‟s
internal database for other proteins that might have high sequence identity with ErbB3.
The ErbB receptor kinases were confirmed to be the most homologous structures for
modeling of the ErbB3 kinase domain.

The protein sequence selected for alignment of the kinase domains included residues 678957 (EGFR) and 683-962 (ErbB4); we opted to exclude the flexible C-tail from the
alignment, as its sequence is highly variable among the ErbB kinases. A total of 50
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Figure 7.1: Multiple sequence alignment of the kinase domains of the ErbB
RTK family members. Residues highlighted in gray are conserved among all
four ErbB kinases, whereas residues highlighted in yellow are unique to
ErbB3. The ErbB3 kinase shares a relatively high level of sequence identity
with its family members (54%, 55% and 63% identity with EGFR, ErbB2,
and ErbB4, respectively). The key catalytic sub-domains (A-loop, C-loop, Nloop, αC-helix, and β3-αC loop) are labeled.
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Figure 7.2. The top 10 refined A-loops for the best ErbB3 models
constructed from each ErbB template. The top structures are shown for the
ErbB3 models based on (A) the EGFR template, (B) the ErbB4 template, (C)
Multiple templates and (D) the loop-modeled ErbB3 crystal structure. The
structures are colored-coded according to the RMSD, where red regions
indicate large RMSD values and blue regions represent small RMSD values.
The original unrefined model for each ErbB3 structure is shown in yellow.
The top structures form a dominant cluster of conformations in each ErbB3
model, indicating a pronounced energy minimum and a higher level of
accuracy in the best structural prediction.

models were generated from each of the templates (EGFR, ErbB4, and multiple
templates) by satisfying a set of static and dynamic spatial restraints in MODELLER. The
stereochemical quality of each model was evaluated using the Discrete Optimized Protein
Energy (DOPE) method [371], which is an atomic distance-dependent statistical potential
optimized for model assessment in MODELLER. A combination of stereochemical
parameters and DOPE energies were considered in order to determine the most
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energetically favorable ErbB3 models derived from each template. Furthermore, the
RMSD among the top model A-loops was computed, as minimal variation among the low
energy conformations correlates with a more pronounced free energy minimum and a
higher level of accuracy in the best structural prediction [179]. The superposition of the
top 10 models from each template resulted in a dominant cluster of conformations,
increasing our confidence in the reliability of the top structures (Fig. 7.2). The top 10 MT
models exhibited the smallest RMSD, or minimal variation.

A comparison of the most energetically favorable models derived from each template
revealed several similarities in structure and in DOPE energies: overall, the C-lobes of
the kinase models are similar, as are the DOPE profiles, although the DOPE scores in the
A-loop region are lowest for the ErbB4- and MT-based models (Fig. 7.3b). However, in
comparing the top homology-modeled structures to our ErbB3 crystal structure, we
observed several conformational differences, which can be better understood by first
describing the major structural features that distinguish the ErbB3 crystal structure from
the EGFR and ErbB4 structures. A unique feature of the catalytic site in the ErbB3
crystal structure is the truncated N-terminus of the αC helix (Fig. 7.3a); in the EGFR and
ErbB4 kinase crystal structures, the helix is fully formed. The molten terminus of the
ErbB3 αC helix forms a loop, referred to as the β3-αC loop, which interacts with specific
sub-regions of the catalytic site, including the short 310 helix in the A-loop, to form a
hydrophobic interface that maintains the weakly-active conformation of ErbB3 and is not
observed in EGFR or ErbB4 [355]. F734, which is located in the β3-αC loop and
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corresponds to an Asn in EGFR and ErbB4, appears to nucleate the hydrophobic interface
(Fig. 7.3a) [355], and V836, L839 and L840, which are located in the 310 helix, form
hydrophobic contacts with the truncated αC helix. The extensive set of residues
stabilizing the hydrophobic interface and the 310 helix are unique to ErbB3 and function
to maintain the distinctive catalytic site conformation resolved in the ErbB3 crystal
structure.

Figure 7.3. (A) Superposition of the top ErbB3 models constructed from the
ErbB templates: EGFR (blue), ErbB4 (yellow) and multiple templates
(brown) as well as the ErbB3 crystal structure (red) (PDB code 3LMG). Key
residues contributing to the hydrophobic interface in ErbB3 are highlighted.
(B) DOPE energy plots for the top ErbB3 models based on each ErbB
template after A-loop refinement. The ErbB4- and MT-based models exhibit
lower DOPE energies in certain regions, including the sequence spanning
residues 775-800. The DOPE energy plot for the ErbB3 crystal structure
(PDB code 3LMG) is illustrated for reference.
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In comparing our top homology-modeled structures to the ErbB3 crystal structure, we
focused on the unique set of interactions in the β3-αC loop, αC helix and 310 helix (Fig.
7.3a). The side-chain conformations of the aliphatic residues in the 310 helix, including
V836, L839, and L840, were correctly predicted in the models derived from EGFR,
ErbB4, and MT. This result is not entirely surprising, as the inactive EGFR and ErbB4
templates also contain the 310 helix in the A-loop. However, F734, which serves to
nucleate the hydrophobic interface in the ErbB3 crystal structure, points away from the
hydrophobic pocket in the homology models. The reason for the altered F734
conformation is depicted in Fig. 3a, which illustrates that the homology models contain a
fully formed αC helix in place of the truncated helix and extended β3-αC loop (which
contains F734) in the ErbB3 crystal structure. In addition, the H740 ring in the αC helix,
which stabilizes homology models. The D838-R814 bond, which bridges the 310 helix
and the C-loop in the ErbB3 crystal structure, is conserved in the ErbB4- and MT-based
models, whereas the residues are unbonded in the EGFR-based model. Furthermore, the
ErbB4-based model more closely mimics the extended β3-αC loop in the ErbB3 crystal
structure, as the apex of the loop projects away from the catalytic site.

Although none of the homology models correctly predict the molten αC helix, several
features of the ErbB4- and MT-based models, including the D838-R814 bond,
approximate the ErbB3 crystal structure more closely than does the model derived from
the EGFR template. Additionally, the DOPE plots for the top structures (Fig. 7.3b) reveal
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smaller (more favorable) DOPE energies for the ErbB4- and MT-based models,
especially for residues 775-800, which exhibit an energy peak in the EGFR-based model,
and residues 840-860 in the A-loop. These results may be attributed to the closer
evolutionary ties between ErbB3 and ErbB4, as ErbB3 and ErbB4 are thought to have
emerged from a gene duplication event separate from the one that led to EGFR and
ErbB2 [372]. Indeed, Jura et al. [43] postulate that the N-lobe dimer observed in their
resolved ErbB3 and ErbB4 crystal structures but not in their EGFR structure may be a
consequence of the evolutionary homology between ErbB3 and ErbB4. Our results
emphasize the importance of selecting the best available template for homology modeling
of even highly related proteins, and indicate that the application of multiple templates in
the sequence alignment may improve the quality of homology models in certain cases
[373]. Furthermore, the homology modeling analysis provides a framework for
comparing the ErbB kinase active sites and identifying the molecular features that
contribute to ErbB3‟s unique catalytic conformation.

7.2) Clinical Implications of Oncogenic EGFR mutations from a Multiscale Model of
ErbB Receptor Signaling

Previously in this thesis, we have extensively explored atomic level characterization of
the ErbB family kinase domains. Here in this section as well as section 7.3 we link those
molecular results to cell signaling models into a multiscale model.

For cellular

homeostasis, pro-survival signals are balanced by pro-apoptotic signals, with both being
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triggered and balanced by a variety of interacting intracellular pathways. Using a
simplified model (Figure 7.4) for the effect of AKT activation on cell response, we
showed that preferential AKT activation is conducive for the cell to rely on and be
addicted to [126, 374]) for generation of pro-survival signals [282]. Our simplified model
illustrates a mechanism by which inhibition of the dominant source of pro-survival
signals shifts the cellular state to one devoid of pro-survival signals, representing a
perturbation sensitive point in the cellular signaling network which can account for a
remarkable inhibitor sensitivity [375].

Figure 7.4: Schematic diagram of the EGFR signaling model used as well as
the ErbB3 signaling model used. The differential ligands (EGF and NRG-1β)
causes differential heterodimerization between members of the ErbB family
triggering their respective cell signaling pathways.

We hypothesized the mechanisms that lead to inhibitor hypersensitivity (Gefitinib for
EGFR) attack these perturbation sensitive points of network hypersensitivity and
fragility. Since preferential AKT activation is a hall mark of the hyper-sensitive mutants
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as well as the efficacy of the inhibitors, we determined, through a global sensitivity
analysis [375, 376], the combinations of model parameter perturbations that drive
enhanced production of pAKT and pERK (Table 7.2B).

The top components that

produce maximum sensitivity in terms of changes to the pAKT and pERK levels were
PI3K, Ras, Gab-1, MEK, Raf which have all been observed in several human cancers
[377-381]. Moreover, it has been established in screened breast and colorectal cancer
patients that the GAB-1, MEK, and Ras mutations are non-random and likely arise from
selective evolutionary pressures that give the cancer cells a survival advantage [381].

Wildtype

L834R

Del

kf :Y1068; kf : Y1173

ERK-(p) in nM for normal ErbB1 expression
-EGF/+EGF

0.2/5.0

1.0/1.0

8.0/8.0

1.0/15.0

13.0/13.0

20.0/20.0

3.0/3.0

5.0/5.0

1.0/1.0

20.0/20.0

22.0/22.0

[Pase3] phosphatase for ERK-(p)
[Pase4] phosphatase for Akt-(p)

Akt-(p) in nM for ErbB1 over-expression
-EGF/+EGF

Initial Concentrations
[Raf●Ras●GTP]

ERK-(p) in nM for ErbB1 over-expression
-EGF/+EGF

Ki: Inhibitor; KM: ATP●RTK
KM : GAB-1●ErbB1-(p)

Akt-(p) in nM for normal ErbB1 expression
-EGF/+EGF

Rate & Binding Constants

19.0/19.0

[MEK-(p)]

Cellular EC50 in nM for inhibition of ERK-(p) and Akt-(p)
for normal ErbB1 expression/ErbB1 over-expression

[PI3K inactive]

ERK-(p)
Akt-(p)

[ErbB1●Shc●Grb2●SOS●RasGTP]

700/4000
100/1000
1200/500000 300/50000

-/-/-

[MEK●Raf active]
[inhibitor]

Table 7.2: (A, left) Comparison of signaling and inhibition characteristics
predicted by our network simulations for wildtype and mutant systems under
different conditions; Del stands for the deletion mutant del L723-P729 ins S.
(B, right) Parameter variations constituting the top three principal
components for network hyper-sensitivity calculated through global
sensitivity analysis: kf, turnover for phosphorylation; (●) denotes bound
complex; the square brackets represent concentrations.
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With reference to the clinically identified EGFR mutants found in non-small cell lung
cancer patients, mainly L834R and del L723-P729 ins S, we found the mutations had
altered affinities for phosphorylation of specific tyrosines in the C-terminal tail: Y1068
and Y1173. The preferential binding characteristics of different cytosolic substrates to
different phospho-tyrosine locations of the ErbB family kinases has been reported [382].
Thus, differences in the phosphorylation kinetics associated the different tyrosine sites of
the cytoplasmic C-terminal tail of the EGFR kinase can induce differential patterns of
downstream signaling leading to differences in the activation of cell signaling networks.
The effect of altered affinities of the Y1068 and Y1173 sites to the catalytic domain of
the EGFR is that the L834R under normal EGFR expression sees a ~5-fold decrease in
ERK activation and a smaller ~15% decrease in AKT activation (Table 7.2A). The del
L723-P729 ins S mutant however, shows sustained ERK as well as AKT activation
relative to wildtype. For EGFR over-expressed cells, both ERK and AKT activation
characteristics show relative insensitivity to EGFR as a result of signal saturation.
Furthermore, the mutants can continue to signal even in the absence of the growth factor.
In addition, the mutant signaling can be different due to changes in the ATP affinity.
However, both these factors do not introduce any differential characteristics (in terms of
preferring Y1068 to Y1173) and cause a differential in overall activation levels of ERK
and AKT.

The perturbation of the phosphotyrosine kinetics of Y1068 and Y1173 through mutations
(L834R and del L723-P729 ins S) is directly responsible for the differential signaling
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leading to preferential AKT activation [282]. The restoration of signaling has also been
reported through a double mutation of L834R/T766M [133, 383]. This double mutant
increases receptor phosphorylation (Y1068 and Y1173) kinetics 100-fold [384] while
simultaneously decreasing inhibitor affinity [383]. Another drug resistance mechanism
related to Y1068 kinetics that circumvents Y1068 has been identified. In the presence of
ErbB3, a branch of signaling analogous to that through Y1068 becomes available through
ErbB hetero-dimerization, directly resulting in PI3K recruitment on ErbB3 and
subsequent AKT activation, which is discussed below.

7.3) Systems model of ErbB signaling defines a mechanism for ErbB3-mediated TKI
resistance

Previous experimental studies have demonstrated that ErbB3 is a key mediator of
resistance to various tyrosine kinase inhibitors (TKIs) currently in use [343, 344, 385387]. Some postulated mechanisms include leaky ErbB2-catalyzed phosphorylation of
ErbB3, e.g., incomplete inhibition of ErbB2 catalytic activity by the TKI [343, 386, 388].
Indeed,

previous

experimental studies

have demonstrated that

leaky

ErbB2

phosphorylation of ErbB3 in TKI-bound ErbB2/3 heterodimers is amplified by additional
resistance mechanisms, such as inhibition of cellular phosphatases by TKI-mediated
production of reactive oxygen species (ROS), and increased expression of ErbB3 at the
plasma membrane [343, 345, 389]. However, Shi et al. [337] have recently shown the
assumed inactive ErbB3 pseudokinase is, in fact, a weakly active kinase with ~1000 fold
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weaker phosphorylation than the canonical kinase members of the ErbB family [337].
Therefore, though the ErbB2 kinase is a viable route of resistance, here we consider
ErbB3 catalytic activity in the ErbB signaling network as a potential TKI resistance
mechanism [330].

To translate our observations of the weak, yet robust, activity of the ErbB3 kinase into a
physiologically relevant context and investigate the implications of ErbB3 activation for
ErbB signaling dynamics, we constructed a systems-level model for ErbB3 based on that
of Schoeberl et al. [390], with added ErbB3 phosphorylation rate constants derived from
experiments [337] (Figure 7.4). We simulated stimulation of the ErbB signaling network
through NRG-1β, which signals through the ErbB2/ErbB3/ErbB4 kinases (though ErbB4
kinase is omitted from the model since ErbB4 signaling is weak or absent in many cancer
cell lines).

A parameter sensitivity analysis identified the key proteins that direct signaling in our
model of the ErbB network with respect to AKT activation via stimulation of NRG-1β.
ErbB3 and NRG-1β represent the most sensitive species in the signaling network,
followed by ErbB2 concentration (Figure 7.5A). EGFR is not a strong determinant of the
extent of AKT phosphorylation, as expected from the weak ability of NRG-1β to elicit
EGFR dimers. PTEN (the PIP3 phosphatase) and the ErbB phosphatase exhibited a
negative sensitivity in the analysis, as these phosphatases negatively regulate the
signaling network through dephosphorylation of key molecular species.
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Figure 7.5 Parameter sensitivity analysis of the ErbB3 signaling model. The
normalized, time-integrated sensitivity of pAKT to key molecular species
was computed in response to NRG1-β=25 nM by making a 0.1% change in
each species concentration for (A) the model representing weak ErbB3
activity, and (B) the model representing weak ErbB3 activity in the presence
of the EGFR/ErbB2 inhibitor lapatinib. Sensitivity to certain species,
including ErbB3, ErbB2 and the ErbB phosphatase, changed upon addition of
lapatinib.

Upon incorporation of the TKI lapatinib, which inhibits EGFR and ErbB2 catalytic
activity, into our model of ErbB3, the ErbB signaling network relies more heavily upon
ErbB3 activity for AKT induction (Figure 7.5B). With completely inhibited EGFR and
ErbB2 signaling via introduction of lapatinib into the model, ErbB3 and AKT signals still
persist at maximal inhibition by lapatinib. The results of pAKT sensitivity analysis of the
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lapatinib-treated model to those of the inhibitor-free model show that sensitivity to ErbB3
and NRG-1β increases, whereas sensitivity to EGFR and ErbB2 decreases, as lapatinib
sequesters EGFR and ErbB2 molecules. The negative normalized sensitivity to the ErbB
phosphatase also increases, as the pool of ErbB dimers has diminished due to
sequestration of EGFR and ErbB2 by lapatinib. Thus a single alteration to the signaling
model (in this case, addition of lapatinib) significantly redefines the most perturbationsensitive nodes in the network.

Although the pAKT signal induced by ErbB3 phosphorylation in our in silico lapatinibtreated cell is relatively weak, in an actual physiological context, a tumor cell may
employ several resistance mechanisms at once [343, 386, 391, 392]. One of the sensitive
nodes of NRG-1β-driven ErbB signaling is ErbB phosphatase levels, and simulations
showed decreased activity of phosphatases resulted in an amplification of the level of
AKT signaling induced by ErbB3. It has been demonstrated that in certain cases of TKI
resistance, the tumor cell responds to the reduction in pAKT levels by upregulating
vesicular transport of ErbB3 from the cytoplasm to the plasma membrane [343, 389].
Our results show for a 2-fold increase in surface ErbB3 level, AKT signaling is similarly
amplified. For 25 nM NRG-1β, the pAKT signal is restored to nearly 60% of its noinhibitor control level, and pAKT levels are nearly 100% regained for 100 nM NRG-1β,
effectively recreating drug resistance in silico.

157

Our data parallels the experimental studies performed by Sergina and colleagues [343],
which describe ErbB3-mediated resistance and pAKT signaling in various TKI-treated
tumor cell lines. Thus our model demonstrates that even a weak level of ErbB3 signaling,
as suggested by our previous results [337], are physiologically relevant in the context of
an ErbB-driven tumor cell, and illustrates several routes through which ErbB3 signaling
may be compounded by other previously postulated resistance mechanisms to generate
TKI resistance.

7.4) Conclusions

As multi-scale modeling techniques become more sophisticated, the application of
simulations will become more widespread necessitating a stronger link between
experiments and simulations. This thesis has aimed to present a thorough exploration of
the ErbB kinase activation at the atomic level, highlighting hydrophilic and hydrophobic
interaction networks that help differentiate the active and inactive state. We have also
highlighted perturbation sensitive regions which correlate well with clinically identified
activating mutations in cancer as well as hypothesized the mechanism and the sequence
of events that occur from the activating asymmetric dimer interface. Furthermore, by
linking the atomic level data with cell signaling networks we can also highlight
perturbation sensitive regions at the network level from altered signaling characteristics
of the mutants and thereby predict potential therapeutic targets. Therefore, use of a
multiscale model can investigate biological systems at multiple timescales and length
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scales, providing detailed and predictive information purely in silico. Hopefully this
work has shown the interesting and complex biological problems that can be addressed
through computational methods.
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Appendix A: Hydrophobic interactions help identify perturbation sensitive regions
for the ErbB kinases

Figure A1: Hydrophobic plots of the solvent accessible surface area (SASA)
versus normalized water density fluctuations in the key hydrophobic regions
of the ErbB kinases: (A) C-spine (B) R-spine (C) Hydrophobic Core (D)
Dimer Interface and (E) αC-β4 loop. The edge colors represent monomer
(black) and dimer (green) systems. The shape internal color represents active
(black) and inactive (white). The shape itself represents a different member
of the ErbB family EGFR (square), ErbB2 (circle) and ErbB4 (triangle). The
quadrants represent different hydrophobic interaction regions (I)
hydrophilically favorable region, (II) perturbation-sensitive region and (IV)
hydrophobically favorable region.
Hydrophobic interactions appear to provide context-specific contributions to stability to
the active and inactive conformations of ErbB kinases. To investigate the effect of
hydrophobic interactions on the ErbB kinase conformations, we analyzed the
hydrophobicity as well as the solvent accessible surface area (SASA) of relevant
hydrophobic sub-regions, namely, the C-spine, R-spine, hydrophobic core, and the αC-β4
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region. The four regions have a high percentage of hydrophobic side chains; however,
some minor differences between members of the ErbB family exist, particularly in the
αC-β4 region.

Garde et al. [320, 321] have recently proposed an approach for

quantifying the hydrophobicity of heterogeneous surfaces using water density
fluctuations, according to which increased normalized water density fluctuations are used
as a signature of a more hydrophobic surface. We have normalized the water density
fluctuations so that 1 is indicative of a neutral region and plotted it against the SASA. By
splitting the graph into four quadrants (Figure A1.A) we can see quadrant I represents a
hydrophilically favorable region with low hydrophobicity and high SASA, while
quadrant IV represents a hydrophobically favorable region with high hydrophobicity and
low SASA. Quadrant II represents a fragile or perturbation sensitive region with high
hydrophobicity but also with a high SASA.

The active conformations in the C-spine show a clear delineation between the active and
inactive conformations regardless of dimer or mutational state (Figure A1.A). The active
conformations minimize the SASA (mean of 500Å2) in comparison to the inactive (mean
value of 700Å2). In addition, in the transition between the inactive to active, the active
conformations increase in hydrophobicity and settle into the hydrophobically favorable
region, implying the active conformations have a better formed C-spine correlating with
the observation that the C-spine helps in coordinating the loops in the active
conformation. The SASA of the ErbB3 C-spine falls within range of the inactive EGFR
and HER4 systems, reflecting that, despite its weak activity, there is no corresponding
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„fully-active‟ state for HER3 as for the other ErbB kinases. This inability to „fully‟
activate can be attributed to the lack of the crucial hydrogen bonding network identified
earlier, which is required to stabilize the active-like kinase conformation.

The

hydrophobicity plots of the R-spine show a similar difference between the active and
inactive conformations but not as drastically as the C-spine (Figure A1.B). For each
system the active systems expose less surface area than the inactive systems, but only for
each system locally (dotted lines on Figure A1). The SASA of the ErbB3 R-spine
deviates from the values for the inactive EGFR and ErbB4 systems, and instead
demonstrates low SASA (high hydrophobicity). This result can be rationalized by the
increased hydrophobicity of the R-spine, which includes segments of the truncated αC
helix in ErbB3.

With respect to the hydrophobicity plots of the hydrophobic core, the monomer EGFR
and ErbB4 inactive systems are situated within the perturbation sensitive region with
their respective active conformations out of the perturbation sensitive region (Figure
A1.C). For ErbB2 the reverse is true which is consistent with sensitivity of the inactive
conformation to hydrophobic perturbation, especially for EGFR and ErbB4 but not for
ErbB2. Therefore single point mutations would be expected to disrupt local
conformations contributing to hydrophobicity.

Notably, mutations of hydrophobic

residues in the hydrophobic core are reported for EGFR and ErbB4 in clinical studies
[27-29], whereas, for ErbB2, such mutations are found surrounding the αC-β4 region [56,
57].

By contrast, an analogous mutation in ErbB3 abolishes ATP-binding and
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phosphorylation activity [337], indicating that hydrophobic interactions in the core
promote ErbB3 activity, rather than maintain an autoinhibited state as they do in EGFR
and ErbB4.

So far all the hydrophobic plots have shown preferential hydrophobic interactions in the
active systems versus the inactive systems. However, examination of the asymmetric
dimer interface reveals a clear delineation in hydrophobicity in preference for the inactive
systems as well as dimerization reducing this hydrophobic benefit implying an activating
stimulus (Figure A1.D). The asymmetric dimer interface consists largely of hydrophobic
side-chains in the N-lobe of the receiver kinase (L680, I682, L736, L758, and V762) and
the C-lobe of the activator kinase (I917, Y920, M921, V924, and M928) [40]. The active
monomer systems trend to the perturbation sensitive quadrant, while the inactive
monomer systems show a reduced SASA in comparison to the active removing them
from the perturbation sensitive quadrant. This decrease for the inactive monomers may
imply a preference for the inactive state in the monomer context. Notably, the dimeric
systems record much lower SASA, pushing all the dimer systems into the
hydrophobically favorable quadrant, implying that hydrophobic interactions provides a
dominant driving force for dimerization; interestingly, for EGFR dimer, the inactive state
is very similar to the active and hence the preference for the inactive conformation is not
implied in the context of the dimer. Thus, dimerization also provides a stimulus for
activation.
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Interestingly, all ErbB2 monomer systems present a very high hydrophobicity (black
bordered circles on Figure A1) across all of the hydrophobic subregions while the ErbB2
dimer as a reduced hydrophobicity in comparison to the monomers (green circles on
Figure A1).

This is consistent with the notion that hydrophobicity is particularly

important in the context of ErbB2 owing to its interaction with Hsp90 known to be
mediated by hydrophobic contacts, particularly the αC-β4 region which is an unstructured
span between the αC-helix and the β4 sheet in RTKs. From a sequence perspective, only
in ErbB2 is the αC-β4 region predominantly hydrophobic and exceptionally so. Both the
inactive and active conformations of the ErbB2 monomer systems reflect the trend by
singling out the ErbB2 monomer systems are particularly hydrophobic for the αC-β4
region (Figure A1.E). The mean SASA for the αC-β4 region in ErbB2 systems is also
consistently lower than in other members of the ErbB family. As discussed in [312], this
unique feature of ErbB2 is thought to be responsible for its preferential association with
the molecular chaperone Hsp90.

Thus, the analyses for the spine regions and the hydrophobic core collectively lead to the
remarkable prediction that while the αC-β4 region is perturbation sensitive for the
inactive conformation of ErbB2, the hydrophobic core has the same effect for EGFR and
ErbB4. Indeed, this correlates well with clinical studies, where activating point mutations
in the hydrophobic core have been found in EGFR and ErbB4 but those in the αC-β4
region are found in ErbB2, suggesting that the hydrophobic analysis enables the contextspecific identification of fragile sub-regions.
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Appendix B: Exhaustive Persistent Bond Tables for EGFR TMD simulations
EGFR
Dimer
Inactive
Window 1
aC-helix aC-helix bond
––
––
––
––
––
––
N732,L736 N732,L736
K733,D737 K733,D737
––
––
I735,A739
I735,A739
––
L736,Y740
E738,M742 E738,M742
A739,A743 A739,A743
––
––
––
––
A-loop bonds
––
––
––
––
––
––
E848,R865 E848,R865
––
––
K851,E725
––
C-loop bonds
H811,D872 H811,D872
R812,D872 R812,D872
––
––
A816,E882 A816,E882
C-loop C-loop bonds
R812,D813 R812,D813
––
––
––
––
––
––
A815,N818 A815,N818
––
––
A-loop A-loop bonds
D831,K836 D831,K836
G833,K836 G833,K836
G839,Y845
––
––
E841,K843
––
––
––
––
E848,G849 E848,G849
––
––
––
––

Window 2

Window 3

Window 4

Window 5

Window 6

EGFR
Dimer
Active

––
––
––
N732,L736
K733,D737
E734,E738
I735,A739
L736,Y740
E738,M742
A739,A743
Y740,S744
––

––
––
––
N732,L736
K733,D737
E734,E738
I735,A739
L736,Y740
E738,M742
A739,A743
Y740,S744
––

––
––
––
––
K733,D737
E734,E738
I735,A739
L736,Y740
E738,M742
A739,A743
Y740,S744
V741,V745

K730,E734
––
––
––
K733,D737
E734,E738
I735,A739
L736,Y740
E738,M742
A739,A743
Y740,S744
V741,V745

K730,E734
––
––
N732,L736
K733,D737
E734,E738
I735,A739
L736,Y740
E738,M742
A739,A743
Y740,S744
V741,S744

––
A731,I735
N732,S728
N732,L736
K733,D737
––
I735,A739
L736,Y740
E738,M742
A739,A743
Y740,S744
V741,V745

––
––
––
E848,R865
––
––

––
––
––
E848,R865
––
––

––
––
––
E848,R865
E848,Y867
––

––
––
––
E848,R865
E848,Y867
––

––
––
––
E848,R865
––
––

E841,R808
Y845,Y867
A847,R865
––
––
––

H811,D872
R812,D872
––
A816,E882

H811,D872
R812,D872
––
A816,E882

H811,D872
R812,D872
––
A816,E882

H811,D872
R812,D872
––
A816,E882

H811,D872
R812,D872
––
––

H811,D872
R812,D872
R812,S875
A816,E882

R812,D813
R812,L814
––
––
A815,N818
A816,V819

R812,D813
R812,L814
––
––
A815,N818
A816,V819

R812,D813
R812,L814
––
––
A815,N818
A816,V819

R812,D813
––
––
D813,N818
A815,N818
A816,V819

R812,D813
R812,L814
––
D813,N818
A815,N818
––

––
––
D813,R817
––
––
––

D831,K836
G833,K836
––
E841,K843
––
––
E848,G849
E848,K851
––

D831,K836
G833,K836
––
E841,K843
––
––
E848,G849
E848,K851
––

D831,K836
G833,K836
––
––
K843,E844
––
E848,G849
––
––

D831,K836
G833,K836
––
––
––
H846,E848
––
––
––

––
G833,K836
––
––
––
––
E848,G849
––
G850,V852

––
––
––
––
––
––
––
––
––

Table B1: Exhaustive list of persistent H-bonds and salt bridges in EGFR
kinases in an asymmetric dimer formation as it progresses from inactive to
active. The salt bridges are in bold and identical bonds are aligned. Weaker
bonds are in grey, to track the progression of bonds.
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EGFR
Monomer
Inactive
Window 1
aC-helix aC-helix bonds
––
––
––
––
––
N732,S728
––
N732,L736
K733,D737 K733,D737
E734,E738 E734,E738
I735,A739
I735,A739
L736,Y740 L736,Y740
––
D737,V741
E738,M742 E738,M742
––
A739,A743
Y740,S744 Y740,S744
––
––
A-loop bonds
––
––
––
––
––
––
––
––
––
––
E848,R865 E848,R865
––
––
C-loop bonds
H811,D872 H811,D872
––
––
R812,K851
––
R812,D872 R812,D872
––
––
––
––
––
A816,L775
A816,E882
––
––
R817,D776
C-loop C-loop bonds
R812,D813 R812,D813
––
––
––
––
A815,N818 A815,N818
A-loop A-loop bonds
G833,K836 G833,K836
E841,E842 E841,E842
E841,K843 E841,K843
––
––
E844,Y845
––
––
––
E848,G849 E848,G849
––
––

Window 2

Window 3

Window 4

Window 5

EGFR
Monomer
Active

––
––
N732,S728
N732,L736
K733,D737
E734,E738
I735,A739
L736,Y740
––
E738,M742
A739,A743
––
V741,V745

––
––
N732,S728
N732,L736
K733,D737
E734,E738
I735,A739
L736,Y740
––
E738,M742
A739,A743
––
V741,V745

––
––
N732,S728
N732,L736
K733,D737
E734,E738
I735,A739
L736,Y740
D737,V741
E738,M742
A739,A743
Y740,S744
––

––
A731,I735
––
N732,L736
K733,D737
E734,E738
I735,A739
L736,Y740
D737,V741
E738,M742
A739,A743
Y740,S744
––

K730,E734
A731,I735
N732,S728
N732,L736
K733,D737
E734,E738
I735,A739
L736,Y740
––
E738,M742
––
Y740,S744
V741,V745

––
––
––
––
––
E848,R865
––

––
––
––
––
––
E848,R865
––

––
E841,R808
––
––
––
E848,R865
––

––
––
––
Y845,Y867
H846,R865
E848,R865
E848,Y867

A840,G672
––
K843,D932
Y845,Y867
––
––
––

H811,D872
––
––
R812,D872
––
––
A816,L775
––
R817,D776

H811,D872
––
R812,K851
R812,D872
––
––
A816,L775
––
R817,D776

H811,D872
––
R812,K851
R812,D872
––
A816,V819
––
A816,E882
R817,D776

H811,D872
––
––
R812,D872
––
––
A816,L775
A816,E882
––

H811,D872
R812,E848
––
R812,D872
R812,S875
––
––
A816,E882
––

R812,D813
––
––
A815,N818

R812,D813
––
––
A815,N818

R812,D813
––
––
A815,N818

R812,D813
––
––
A815,N818

––
D813,R817
D813,N818
A815,N818

G833,K836
––
––
E841,Y845
––
––
––
––

G833,K836
––
––
––
––
––
––
––

––
––
––
––
––
––
––
––

––
––
––
––
––
––
E848,G849
E848,G850

––
––
––
––
––
Y845,E848
––
––

Table B2: Exhaustive list of persistent H-bonds and salt bridges in the EGFR
kinase monomer as it progresses from inactive to active. The salt bridges are
in bold and identical bonds are aligned. Weaker bonds are in grey, to track
the progression of bonds.
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